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Apoptosis –  
the end of an individual cell, at the same time a martyrdom in favor of the organism 
as a whole. A well-ordered process, genetically determined, also called “programmed 
cell death” what sounds somewhat artificial. However, apoptosis is as natural as the 
falling of leaves from a tree in autumn. 
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Summary 
 
Starting point for this thesis was the application of a genetic screening procedure for the identification 
of dominant apoptosis-inducing genes. Apoptosis is a form of programmed cell death by which cells 
of a multicellular organism die in a well-ordered and genetically determined sequence of morphologic 
and molecular events. Since apoptosis plays major roles during development and homeostasis, it is 
highly regulated by the action of a multitude of proteins that either promote or suppress the activation 
of the cell death program. Although a plethora of pro- or antiapoptotic proteins have already been 
described, many more, yet unidentified protein factors are expected to be involved in the induction, 
mediation and regulation of apoptosis. In this context, the main objective of this thesis was to identify 
and characterize proteins as novel regulatory factors of apoptosis pathways. To this end, a genetic 
screen was applied that aimed on the isolation and identification of cDNA clones which upon 
overexpression induce the typical morphological features of apoptosis in the chosen 293T cell system. 
Selected cDNA clones identified in this way, were subsequently characterized for their proapoptotic 
activity. 
 
Two projects are described within the scope of this thesis (Fig. S1). The first project characterizes the 
ubiquitin-specific protease UBP41 as a protein which upon overexpression causes apoptosis induction 
in several mammalian cancer cell lines. The second project investigates a possible involvement of the 
lysosomal cysteine proteases cathepsin-L and cathepsin-B in apoptosis pathways induced by distinct 
death stimuli, in particular by the tumor necrosis factor α (TNF-α). Therefore, both projects examine a 
possible regulation of apoptosis induction by proteases that are part of one of the two major systems of 
protein degradation. UBP41 as a protease with deubiquitylating activity is expected to play a role in 
the ubiquitin/proteasome system which is the major proteolytic apparatus for the degradation of 
cytosolic proteins. Cathepsins, on the other hand, are lysosomal proteases that participate in the 
breakdown of membrane-associated proteins and of extracellular proteins that are taken up by 
endocytosis. Both, the ubiquitin/proteasome system as well as lysosomal proteases have been 
previously implicated in the regulation and mediation of apoptosis, and it therefore appeared 
particularly attractive to further study the effect of UBP41 and cathepsins on cell death signalling in 
more detail. 
 
Project 1:  
Identification and characterization of UBP41 as a dominant apoptosis-inducing factor 
The mouse cDNA of the ubiquitin-specific protease UBP41 was one of the positive clones that 
induced cell death when overexpressed in 293T cells. Overexpression of the human UBP41 orthologue  
Summary 
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(hUBP41) also led to the induction of apoptosis with all its typical morphological and biochemical 
features. hUBP41-induced cell death was further characterized in human 293T and HeLa cells. An 
enzymatic inactive mutant form of hUBP41 did not induce significant cell death in 293T cells, 
indicating that the deubiquitinating activity of hUBP41 is necessary for its apoptosis-inducing effect. 
Indeed, overexpression of hUBP41 in 293T and HeLa cells resulted in a dramatic decrease of overall 
protein ubiquitination, suggesting that it is the interference with the ubiquitination system that causes 
cell death induction. The turnover of most cytoplasmic proteins is regulated by the 
ubiquitin/proteasome system. In a temporally and locally regulated process, specific proteins are 
covalently attached to the small ubiquitin protein and by this are targeted for recognition by the 
proteasome, a multi-subunit complex for the proteolysis of proteins. The untimely and inappropriate 
deubiquitination of proteins by hUBP41 might correspond to their rescue from proteasomal 
degradation, to an extension of their half life and therefore to an accumulation of proteins within the 
cell that normally are regulated by the ubiquitin/proteasome system. However, of several endogenous 
proteins tested, none was found to be stabilized by hUBP41 overexpression. Moreover, the 
proapoptotic effect of hUBP41 overexpression was clearly different from a general inhibition of 
Two major systems of
protein degradation
Ubiquitin/Proteasome System
Tightly regulated degradation
of the majority of cytoplasmic 
Proteins.
ubiquitin-specific protease
UBP41
Project 1 Project 2
Apoptosis
Lysosomes
Non-specific breakdown of mostly 
membrane-associated and extra-
cellular proteins; Autophagy.
??
lysosomal cysteine proteases  
Cathepsins
Fig. S1 
The two projects of this thesis. This thesis comprises two projects which both describe a
possible interplay between components of the two major systems of protein degradation and 
apoptosis. The ubiquitin-specific protease UBP41 is part of the ubiquitin/proteasome system and
induces apoptosis upon its overexpression, whereas cathepsins are part of the hydrolytic content
of lysosomes and might contribute to proapoptotic signalling. Since UBP41 as well as the 
cathepsins-B and -L are cysteine proteases, both projects investigate the influence of non-
caspase cysteine proteases on apoptosis pathways, a topic that recently gained increasing
recognition. 
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proteasomal protein degradation as provoked by the drug proteasome inhibitor MG132 which 
primarily leads to cell cycle arrest and only subsequently to moderate apoptosis induction. I found 
additional experimental evidence that hUBP41 in principle can rescue ubiquitylated proteins from 
degradation, leaving open the possibility that distinct short-lived substrates are stabilized by hUBP41. 
The accumulation of proteins with proapoptotic activity therefore might be responsible for apoptosis 
induction triggered by UBP41 overexpression. 
According to the unified nomenclature for ubiquitin-specific proteases, UBP41 belongs to the family 
of USP2 splice isoforms whose gene is localized to chromosome 11q23.3. Deletions within this 
chromosomal region have been previously reported in cases of  lymphoma, melanoma and cervical 
cancer. Results of northern hybridization experiments using a commercial tumor/normal profiling 
array indicate that the hUSP2 mRNA message might be specifically downregulated in tumor samples 
of the kidney when compared to normal tissue. Those observations tempt to speculate that UBP41 as a 
protein with proapoptotic regulatory functions might be considered a candidate tumor-suppressor.  
The results of this project were published in Cancer Research [Gewies, 2003b]. 
 
Project 2:  
Investigation of a possible role for cathepsin-L and cathepsin-B in proapoptotic signalling 
Another cDNA clone selected from the screen was identified to encode mouse cathepsin-L. When 
murine or human cathepsin-L was overexpressed in 293T or HeLa cells, a minor fraction of cells 
displayed a small and round phenotype resembling apoptosis. It became apparent that the observed 
effect of cathepsin-L was too weak for being detected unequivocally by the available apoptosis 
standard assays such as DNA fragmentation or caspase activity assays. Therefore, studying the 
possible proapoptotic activity of cathepsin-L overexpression on its own was not feasible. Instead, it 
was further investigated whether enhanced human cathepsin expression levels might sensitize tumor 
cell lines, such as HeLa cells, to distinct apoptosis-inducing stimuli. Investigating this question was of 
special relevance because recent publications presented an accumulating body of evidence that 
cathepsins might be involved in the mediation of apoptosis. In many cases, cathepsin inhibitors were 
reported to render cells more resistant to the treatment with apoptosis inducers, e.g. TNF-α. 
Importantly, elevated cathepsin expression is frequently observed in various types of cancer and 
traditionally is regarded to be a tumor marker correlated with poor prognosis because cathepsins are 
believed to contribute to the degradation of the extracellular matrix, thereby promoting invasion and 
metastasis. Considering a possible proapoptotic activity of cathepsins, it has been hypothesized that 
cathepsin-B-like proteases, despite their implication as “bad prognosis” factors in the promotion of 
cancer progression, may prove useful in selectively targeting tumor cells for apoptosis-induction. Up 
to now there are no reports in the literature directly investigating the possible correlation between 
cathepsin expression levels and sensitivity to apoptosis. 
In this context, I first of all studied the effect of various cathepsin inhibitors on TNF-α-induced cell 
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death. Treatment of HeLa cells with TNF-α resulted in DNA fragmentation that was significantly 
reduced in the presence of cathepsin-inhibitors, suggesting a possible role for cathepsins, such as 
cathepsin-B or –L, in this type of cell death. As a next step, it was examined whether sensitivity to 
TNF-α-mediated cell death might be influenced by increased cathepsin expression levels. Transient 
transfection of HeLa cells with cathepsin-B or -L resulted in strongly increased expression levels 
comparable to those found in many tumors but did not sensitize the cells to TNF-α-mediated 
apoptosis. As could be expected from previous reports, TNF-α caused a partial release of lysosomal 
content into the cytosol as was observed by anti-cathepsin-L immunocytochemical staining. In 
comparison, lysosomal integrity was efficiently disturbed during the treatment of HeLa cells with the 
lysosomotropic detergent N-dodecyl-imidazole-HCl (NDI-HCl), consequently resulting in cell death 
induction. Importantly, cell death induced by NDI-HCl also was not increased as a consequence of 
elevated cathepsin-B or –L expression levels.  
Therefore, the data presented in this study suggest that cathepsin enzymatic activity contributes to 
certain aspects of TNF-α-mediated apoptosis, such as DNA fragmentation, but overexpression 
experiments do not support the hypothesis that the high cathepsin-B or -L expression levels frequently 
detected in tumor cells can be exploited to selectively target those tumors to an enhanced cell-death 
effect induced by e.g. TNF-α or lysosomotropic agents. The results of this projects were published in 
the British Journal of Cancer [Gewies, 2003a]. 
 
Conclusion:  
The two projects presented in this thesis are a contribution to currently intensely studied fields of 
apoptosis research. The finding, that the ubiquitin-specific protease UBP41 might play a role as a 
proapoptotic regulatory factor adds to the growing body of evidence that there is intense crosstalk 
between apoptosis signalling pathways and the ubiquitin/proteasome system. In particular, the 
characterization of UBP41 as a dominant apoptosis-inducing protein suggests an important influence 
of deubiquitinating enzymes on the regulation of cell death, further supporting recently published 
observations. The second project tested the interesting hypothesis whether elevated cathepsin 
expression levels of tumor cells might be exploited to selectively target those tumor cells to cell death 
induction. My observation that high level overexpression of cathepsin-B and -L does not have any 
detectable impact on the sensitivity of HeLa cells to apoptosis induction does not support this 
hypothesis and stimulates further investigations of this kind in order to clarify the controversely 
debated role of cathepsins as proapoptotic signalling molecules. Since UBP41 as well as the 
cathepsins-B and -L are cysteine proteases, the here presented results additionally contribute to the 
growing knowledge about the influence of non-caspase cysteine proteases on the initiation, mediation, 
execution and regulation of apoptosis. 
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1  Introduction 
 
1.1  Apoptosis 
 
1.1.1  The development of the term apoptosis 
 
Already since the mid-nineteenth century, many observations have indicated that cell death plays a 
considerable role during physiological processes of multicellular organisms, particularly during 
embryogenesis and metamorphosis [Gluecksmann, 1951; Lockshin, 2001]. The term programmed cell 
death was introduced in 1964, proposing that cell death during development is not of accidential 
nature but follows a sequence of controlled steps leading to locally and temporally defined self-
destruction [Lockshin, 1964]. 
 
Eventually, the term apoptosis had been coined in order to describe the morphological processes 
leading to controlled cellular self-destruction and was first introduced in a publication by Kerr, Wyllie 
and Currie [Kerr, 1972]. Apoptosis is of greek origin, having the meaning "falling off or dropping off", 
in analogy to leaves falling off trees or petals dropping off flowers. This analogy emphasizes that the 
death of living matter is an integral and necessary part of the life cycle of organisms. The apoptotic 
mode of cell death is an active and defined process which plays an important role in the development 
of multicellular organisms and in the regulation and maintenance of the cell populations in tissues 
upon physiological and pathological conditions. It should be stressed that apoptosis is a well-defined 
and possibly the most frequent form of programmed cell death, but that other, non-apoptotic types of 
cell death also might be of biological significance [Leist, 2001a]. 
 
1.1.2  The significance of apoptosis 
 
The development and maintenance of multicellular biological systems depends on a sophisticated 
interplay between the cells forming the organism, it sometimes even seems to involve an altruistic 
behaviour of individual cells in favour of the organism as a whole. During development many cells are 
produced in excess which eventually undergo programmed cell death and thereby contribute to 
sculpturing many organs and tissues [see Box 1.1 and Meier, 2000].  
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BOX 1.1  Examples of physiological cell death  
A particularly instructive example for the implication of programmed cell death in animal 
development is the formation of free and independent digits by massive cell death in the interdigital 
mesenchymal tissue [Zuzarte-Luis, 2002]. Other examples are the development of the brain, during 
which half of the neurons that are initially created will die in later stages when the adult brain is 
formed [Hutchins, 1998] and the development of the reproductive organs [Meier, 2000]. Also cells of 
an adult organism constantly undergo physiological cell death which must be balanced with 
proliferation in order to maintain homeostasis in terms of constant cell numbers. The majority of the 
developing lymphocytes die either during genetic rearrangement events in the formation of the antigen 
receptor, during negative selection or in the periphery, thereby tightly controlling the pool of highly 
efficient and functional but not self-reactive immune cells and at the same time keeping lymphocyte 
numbers relatively constant [Rathmell, 2002].  
 
Taken together, apoptotic processes are of widespread biological significance, being involved in e.g. 
development, differentiation, proliferation/homoeostasis, regulation and function of the immune 
system and in the removal of defect and therefore harmful cells. Thus, dysfunction or dysregulation of 
the apoptotic program is implicated in a variety of pathological conditions. Defects in apoptosis can 
result in cancer, autoimmune diseases and spreading of viral infections, while neurodegenerative 
disorders, AIDS and ischaemic diseases are caused or enhanced by excessive apoptosis [Fadeel, 
1999a]. 
Development and Morphogenesis:
- 131 of the 1,090 somatic cells die during C.elegans development
- during limb formation separate digits evolve by death of interdigital mesenchymal tissue (a)
- ablation of cells no longer needed such as the amphibian tadpole tail during metamorphosis (b)
- demise of cells allows sculpturing of hollow structures (c)
- formation of reproductive organs (d)
(Müllerian duct uterus, deleted in males;Wolffian duct male organs, deleted in females)
- massive cell death occurs during early development of the nervous system (> 50 percent of
all neurons die)
In the human body about 100,000 cells are produced every second by mitosis 
and a similar number die by apoptosis (Vaux and Korsmeyer, 1999, Cell) ! 
Homeostasis:
- a paradigm for the involvement of apoptosis in homeostasis is the immune system: several
millions of B and T cells are generated every day and the majority (> 95 percent) of those die
during maturation (death by neglect, negative selection) or by AICD of peripheral immune cells) 
Deletion of damaged and dangerous cells:
- Cells with severely damaged DNA that cannot be repaired appropriately usually are
removed by apoptosis
- Inappropriate mitogenic signalling that is in conflict with the environmental or cellular
status of the cell usually results in cell cycle arrest or apoptosis
- Autoreactive cells of the immune system are deleted by apoptosis
- Elimination of infected cells
(a)
(b)
(c)
(d)
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Due to its importance in such various biological processes, programmed cell death is a widespread 
phenomenon, occuring in all kinds of metazoans [Tittel, 2000] such as in mammals, insects 
[Richardson, 2002], nematodes [Liu, 1999b], and cnidaria [Cikala, 1999]. Moreover, programmed cell 
death also might play a role in plant biology [Solomon, 1999], and apoptosis-like cell death 
mechanisms even have been observed and used as a model system in yeast [Frohlich, 2000; 
Skulachev, 2002]. Fascinating insights into the origin and evolution of programmed cell death might 
possibly be given by the fact, that programmed cell death is also an integral part of the life cycle of 
other unicellular eukaryotes (such as the kinetoplastid parasite Trypanosoma brucei brucei, the ciliate 
Tetrahymena thermophila, and the slime mold Dictyostelium discoideum) and that even prokaryotes 
(such as Bacillus subtilis, Streptomyces and Myxobacteria) sometimes undergo regulated cell death 
[Ameisen, 2002]. 
 
1.1.3  Morphological features of apoptosis 
 
Apoptotic cells can be recognized by stereotypical morphological changes: the cell shrinks, shows 
deformation and looses contact to its neighbouring cells. Its chromatin condenses and marginates at 
the nuclear membrane, the plasma membrane is blebbing or budding, and finally the cell is fragmented 
into compact membrane-enclosed structures, called 'apoptotic bodies' which contain cytosol, the 
condensed chromatin, and organelles (Fig. 1.1). The apoptotic bodies are engulfed by macrophages 
and thus are removed from the tissue without causing an inflammatory response. Those morphological 
changes are a consequence of characteristic molecular and biochemical events occurring in an 
apoptotic cell, most notably the activation of proteolytic enzymes which eventually mediate the 
cleavage of DNA into oligonucleosomal fragments as well as the cleavage of a multitude of specific 
protein substrates which usually determine the integrity and shape of the cytoplasm or organelles  
[Saraste, 2000]. Apoptosis is in contrast to the necrotic mode of cell-death in which case the cells 
suffer a major insult, resulting in a loss of membrane integrity, swelling and disrupture of the cells. 
During necrosis, the cellular contents are released uncontrolled into the cell's environment which 
results in damage of surrounding cells and a strong inflammatory response in the corresponding tissue 
[Leist, 2001a]. 
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1.1.4  Molecular mechanisms of apoptosis signalling pathways 
 
This paragraph is meant to provide a general overview of basic apoptotic signalling pathways and of 
the molecular machinery responsible for the induction and execution of apoptosis. The most important 
signalling molecules and cellular structures will be discussed in context of their function and of the 
mechanisms in which they are involved in the initiation, mediation, execution, and regulation of 
apoptosis. This chapter should give an impression of the sophisticated interplay between factors that 
promote or suppress apoptosis, resulting in a complicated regulatory network which determines the 
fate of an individual cell as part of its multicellular environment (Fig. 1.5). 
 
1.1.4.1  Various death signals activate common signalling pathways 
 
Apoptosis is a tightly regulated and at the same time highly efficient cell death program which 
requires the interplay of a multitude of factors. The components of the apoptotic signalling network 
are genetically encoded and are considered to be usually in place in a nucleated cell  ready to be 
activated by a death-inducing stimulus [Ishizaki, 1995; Weil, 1996]. 
Fig. 1.1  
Hallmarks of the apoptotic and necrotic cell death process. Apoptosis includes cellular
shrinking, chromatin condensation and margination at the nuclear periphery with the eventual
formation of membrane-bound apoptotic bodies that contain organelles, cytosol and nuclear
fragments and are phagocytosed without triggering inflammatory processes.The necrotic cell swells,
becomes leaky and finally is disrupted and releases its contents into the surrounding tissue resulting
in inflammation. Modified from [Van Cruchten, 2002]. 
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Apoptosis can be triggered by various stimuli from outside or inside the cell, e.g. by ligation of cell 
surface receptors, by DNA damage as a cause of defects in DNA repair mechanisms, treatment with 
cytotoxic drugs or irradiation, by a lack of survival signals, contradictory cell cycle signalling or by 
developmental death signals. Death signals of such diverse origin nevertheless appear to eventually 
activate a common cell death machinery leading to the characteristic features of apoptotic cell death.  
 
Much of the understanding of cell death has come from genetic studies in the nematode C. elegans by 
which several genes have been identified that function in the apoptotic killing and elimination of 131 
of the initially 1090 somatic cells that are generated druing hermaphrodite development [Hengartner, 
1999]. The proximal cause of apoptosis in C. elegans is the activation of the cysteine protease ced-3, 
which is mediated by its oligomerization at the activator protein ced-4. Activity of the ced-3/ced-4 
complex is regulated by the apoptosis inhibitor ced-9 and the apoptosis inducer egl-1 (Fig. 1.2). 
Subsequent studies in mammals and in the fly, D. melanogaster, have identidied counterparts for these 
C. elegans genes, demonstrating that the core components of the cell death machinery are conserved 
through evolution [Richardson, 2002]. Accordingly, ced-3 is the single C. elegans member of a family 
of cysteine proteases, the caspases, whereas ced-4 corresponds to the mammalian apoptotic protease 
activating factor 1, Apaf-1, which is the core of a caspase-activating signalling complex, the 
apoptosome. Egl-1 and ced-9 are members of the Bcl-2 family of pro- or antiapoptotic proteins, 
respectively, which play an important role in the mediation and regulation of apoptotic signalling 
pathways. All of those central components will be discussed within the following paragraphs.  
 
 
Fig. 1.2 
C. elegans as a model system contains basic components of the cell death machinery. Apoptosis
regulation in C.elegans relies on a simple basic network of factors for which corresponding analogous
components also can be found in higher organisms as given within brackets. Thus egl-1 is the worm
representative for mammalian proapoptotic BH3-only proteins, ced-9 belongs to the antiapoptotic Bcl-2
family, ced-3 is the only worm caspase, and ced-4 is homologous to mammalian Apaf-1 (according to
[Cecconi, 1999]). 
egl-1 ced-9 ced-3ced-4 Cell Death
(pro-apoptotic
Bcl-2 members)
(anti-apoptotic
Bcl-2 members)
(caspases,
Apaf-1)
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1.1.4.2  Caspases are central initiators and executioners of apoptosis 
 
The caspases, cysteine proteases homologous to C. elegans ced-3, are of central importance in the 
apoptotic signalling network which are activated in most cases of apoptotic cell death [Bratton, 2000]. 
Actually, strictly defined, cell death only can be classified to follow a classical apoptotic mode if 
execution of cell death is dependent on caspase activity [Leist, 2001a].  
The term caspases is derived from cysteine-dependent aspartate-specific proteases: their catalytical 
activity depends on a critical cysteine-residue within a highly conserved active-site pentapeptide 
QACRG, and the caspases specifically cleave their substrates after Asp residues. So far, 7 different 
caspases have been identified in Drosophila, and 14 different members of the caspase-family have 
been described in mammals, with caspase-11 and caspase–12 only identified in the mouse [Denault, 
2002; Richardson, 2002]. According to a unified nomenclature, the caspases are referred to in the 
order of their publication: caspase-1 is ICE (Interleukin-1ß-Converting Enzyme), the first mammalian 
caspase described to be a homologue of Ced-3 [Creagh, 2001; Miura, 1993]. Caspase-1 as well as 
caspases-4, -5, -11, and –12 appear to be mainly involved in the proteolytic maturation of pro-
inflammatory cytokines such as pro-IL-1ß and pro-IL-18 and their contribution to the execution of 
apoptosis remains questionable [Denault, 2002]. Indeed, mice deficient for caspase-1 or caspase-11 
develop normally and cells from those knockout mice remain sensitive to various death stimuli [Li, 
1995; Wang, 1998]. In contrast, gene knockout experiments targeting caspase-3 and caspase-9 resulted 
in perinatal mortality as a result of severe defects in brain development [Kuida, 1998; Kuida, 1996], 
whereas caspase-8 deficient embryos died after day 12 [Varfolomeev, 1998]. This and the observation 
that cell lines derived from those knockout experiments are resistant to distinct apoptosis stimuli 
underlines the importance of caspases as proapoptotic mediators. Indeed, caspase-3, caspase-9, 
caspase-8, and additionally caspases-2, -6, -7, and –10 have been recognized to play an important role 
in the apoptotic signalling machinery [Earnshaw, 1999].  
 
In the cell, caspases are synthesized as inactive zymogens, the so called procaspases, which at their N-
terminus carry a prodomain followed by a large and a small subunit which sometimes are separated by 
a linker peptide. Upon maturation, the procaspases are proteolytically processed between the large and 
small subunit, resulting in a small and a large subunit. The prodomain is also frequently but not 
necessarily removed during the activation process. A heterotetramer consisting of each two small and 
two large subunits then forms an active caspase. The proapoptotic caspases can be divided into the 
group of initiator caspases including procaspases-2, -8, -9 and –10, and into the group of executioner 
caspases including procaspases-3, -6, and –7. Whereas the executioner caspases possess only short 
prodomains, the initiator caspases possess long prodomains, containing death effector domains (DED) 
in the case of procaspases-8 and –10 or caspase recruitment domains (CARD) as in the case of 
procaspase-9 and procaspase-2.  
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Via their prodomains, the initiator caspases are recruited to and activated at death inducing signalling 
complexes either in response to the ligation of cell surface death receptors (extrinsic apoptosis 
pathways) or in response to signals originating from inside the cell (intrinsic apoptosis pathways).  
 
In extrinsic apoptosis pathways (Fig. 1.3), e.g. procaspase-8 is recruited by its DEDs to the death 
inducing signalling complex (DISC), a membrane receptor complex formed following to the ligation 
of a member of the tumor necrosis factor receptor (TNFR) family [Sartorius, 2001]. When bound to 
the DISC, several procaspase-8 molecules are in close proximity to each other and therefore are 
assumed to activate each other by autoproteolysis [Denault, 2002].  
 
 
Ligand
(FasL, TNF-α, TRAIL)
Death Receptor
(Fas, TNFR1, DR5, ...)
Adaptors
(FADD, TRADD)
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D
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D
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D
D
ED
D
D
D
ED
D
ED
Procaspase-8
D
ED
D
ED
active Caspase-8
Activation of 
Caspases-3, -6, -7 APOPTOSIS
Fig. 1.3   
Receptor-mediated caspase activation at the DISC. Upon ligation by its cognate ligand, the
trimeric death receptor recruits adaptor molecules via its cytoplasmic death domains (DD). Besides
possessing DDs, the adaptors additionally contain death effector domains (DED) which recruit
procaspase-8 to the receptor complex which now is called the death-inducing signalling complex
(DISC). Procaspase-8 is activated by autoproteolytic cleavage and forms the active caspase-8
which is a heterotetramer of  two small and two large subunits. The initiatior caspase-8 cleaves and
thereby activates effector caspases for the execution of apoptosis. 
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Intrinsic apoptosis pathways (Fig. 1.4) involve procaspase-9 which is activated downstream of 
mitochondrial proapoptotic events at the so called apoptosome, a cytosolic death signalling protein 
complex that is formed upon release of cytochrome c from the mitochondria [Salvesen, 2002b]. In this 
case it is the dimerization of procaspase-9 molecules at the Apaf-1 scaffold that is responsible for 
caspase-9 activation [Denault, 2002]. Once the initiator caspases have been activated, they can 
proteolytically activate the effector procaspases-3, -6, and -7 which subsequently cleave a specific set 
of protein substrates, including procaspases themselves, resulting in the mediation and amplification of 
the death signal and eventually in the execution of cell death with all the morphological and 
biochemical features usually observed [Earnshaw, 1999]. 
 
Fig. 1.4   
Mitochondria-mediated caspase activation at the apoptosome.  A. Apoptotic stimuli trigger the
release of apoptogenic factors from the mitochondrial intermembrane space to the cytosol, such
as cytochrome c which induces the formation of the apoptosome and the activation of procaspase-
9. B. By the action of cytochrome c (Cyto C) and dATP the Apaf-1 protein adopts a conformation
that allows the formation of a heptameric, wheel-like structure, the apoptosome. Procaspase-9
molecules can bind to the inner “hub” region of the apoptosome and are activated by dimer
formation. Active caspase-9 dimers further mediate activation of effector caspases [Acehan,
2002]. 
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1.1.4.3  Extrinsic apoptosis pathways of type I and type II 
 
Extrinsic apoptosis signalling is mediated by the activation of so called “death receptors” which are 
cell surface receptors that transmit apoptotic signals after ligation with specific ligands. Death 
receptors belong to the tumor necrosis factor receptor (TNFR) gene superfamily, including TNFR-1,  
Fas/CD95, and the TRAIL receptors DR-4 and DR-5 [Ashkenazi, 2002]. All members of the TNFR 
family consist of cysteine rich extracellular subdomains which allow them to recognize their ligands 
with specificity, resulting in the trimerization and activation of the respective death receptor 
[Naismith, 1998]. Subsequent signalling is mediated by the cytoplasmic part of the death receptor 
which contains a conserved sequence termed the death domain (DD). Adapter molecules like FADD 
or TRADD themselves possess their own DDs by which they are recruited to the DDs of the activated 
death receptor, thereby forming the so-called death inducing signalling complex (DISC). In addition to 
its DD, the adaptor FADD also contains a death effector domain (DED) which through homotypic 
DED-DED interaction sequesters procaspase-8 to the DISC (Fig. 1.3). As described above (1.1.4.2, 
page 8), the local concentration of several procaspase-8 molecules at the DISC leads to their 
autocatalytic activation and release of active caspase-8. Active caspase-8 then processes downstream 
effector caspases which subsequently cleave specific substrates resulting in cell death. Cells harboring 
the capacity to induce such direct and mainly caspase-dependent apoptosis pathways were classified to 
belong to the so called type I cells [Scaffidi, 1998]. 
 
In type II cells, the signal coming from the activated receptor does not generate a caspase signalling 
cascade strong enough for execution of cell death on its own. In this case, the signal needs to be 
amplified via mitochondria-dependent apoptotic pathways. The link between the caspase signalling 
cascade and the mitochondria is provided by the Bcl-2 family member Bid. Bid is cleaved by caspase-
8 and in its truncated form (tBID) translocates to the mitochondria where it acts in concert with the 
proapoptotic Bcl-2 family members Bax and Bak to induce the release of cytochrome c and other 
mitochondrial proapoptotic factors into the cytosol (see Fig. 1.5 and [Luo, 1998]). Cytosolic 
cytochrome c is binding to monomeric Apaf-1 which then, in a dATP-dependent conformational 
change, oligomerizes to assemble the apoptosome, a complex of wheel-like structure with 7-fold 
symmetry, that triggers the activation of the initiator procaspase-9 (see Fig. 1.4 and [Acehan, 2002]). 
Activated caspase-9 subsequently initiates a caspase cascade involving downstream effector caspases 
such as caspase-3, caspase-7, and caspase-6, ultimately resulting in cell death [Slee, 1999]. 
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Fig. 1.5 
Schematic representation of some major apoptotic signalling pathways. Apoptosis can be
induced in response to various signals from inside and outside the cell, e.g. by ligation of so called
death receptors or by cellular stress triggered by oncogenes, irradiation or drugs. Signals emanating
from death receptors initially activate the Death Inducing Signalling Complex (DISC) which mediates
activation of the initiator caspase-8. Activated caspase-8 initiates a caspase cascade by processing
the effector caspases-3, -6, and – 7 which in turn cleave a number of protein substrates. Cleavage of
caspase substrates eventually leads to the characteristic morphological and biochemical features of
apoptosis. In some cell systems, this direct caspase cascade is sufficient to elicit apoptosis on its own
(type 1 signalling), whereas in other cases the signal coming from the DISC must be amplified by the
proteolytic activation of the BH3-only protein Bid by caspase-8 with subsequent induction of apoptotic
events at the mitochondria (type 2 signalling). Mitochondrial apoptotic signalling includes the release
of  cytochrome c from the mitochondrial intermembrane space to the cytosol where it contributes to the
formation of the apoptosome which consists of cytochrome c, Apaf-1 and dATP. The apoptosome
activates caspase-9 which is another initiator caspase and thus is able to mediate the caspase
cascade by activating caspase-3. Another mitochondrial proapoptotic factor is Smac which acts by
inhibiting the IAPs from blocking caspase activity. IAPs are a family of proteins with antiapoptotic
activity by directly inhibiting caspases. IAP expression can be upregulated in response to survival
signals such as those coming from growth factor receptors, e.g. by activation of the transcription factor
NF-kB, therefore providing a means to suppress apoptosis signalling. Of central importance are the
antiapoptotic Bcl-2 family members such as Bcl-2 and Bcl-XL which counteract the action of BH3-only
proteins such as Bid but also of proapoptotic Bax and Bak and thus can inhibit mitochondrial
proapoptotic events. Apoptotic signals coming from the inside of the cell frequently have their origin
within the nucleus, being a consequence of DNA damage induced by irradiation, drugs or other sort of
stress. DNA damage in most cases eventually results in the activation of the p53 transcription factor
which promotes expression of proapoptotic Bcl-2 members and suppresses antiapoptotic Bcl-2 and
Bcl-XL. Other organelles besides mitochondria and the nucleus, such as the ER and lysosomes also
have been implicated in apoptotic signalling pathways, and it should be kept in mind that presumably
hundreds of proteins are part of an extremely fine-tuned regulatory network consisting of pro- and
antiapoptotic factors. 
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1.1.4.4  Mitochondria as central regulators of intrinsic apoptosis pathways 
 
Besides amplifying and mediating extrinsic apoptotic pathways, mitochondria also play a central role 
in the integration and propagation of death signals originating from inside the cell such as DNA 
damage, oxidative stress, starvation, as well as those induced by chemotherapeutic drugs [Kaufmann, 
2000; Wang, 2001]. Most apoptosis-inducing conditions involve the disruption of the mitochondrial 
inner transmembrane potential (∆ψ) as well as the so called permeability transition (PT), a sudden 
increase of the inner mitochondrial membrane permeability to solutes with a molecular mass below 
approximately 1.5 kDa. Concomitantly, osmotic mitochondrial swelling has been observed by influx 
of water into the matrix with eventual rupture of the outer mitochondrial membrane, resulting in the 
release of proapoptotic proteins from the mitochondrial intermembrane space into the cytoplasm 
[Bernardi, 1999; Loeffler, 2000]. Released proteins include cytochrome c, which activates the 
apoptosome and therefore the caspase cascade, but also other factors such as the apoptosis-inducing 
factor AIF [Susin, 1999], the endonuclease endoG [Li, 2001a], Smac/Diablo [Verhagen, 2000], and 
Htr/Omi [Verhagen, 2002]. Interestingly, PT is always followed by ∆ψ, but ∆ψ is not always caused 
by PT, and cytochrome c release has been observed even in absence of ∆ψ [Bernardi, 1999; Kroemer, 
2000]. In addition to the release of mitochondrial factors, the dissipation of ∆ψ and PT also cause a 
loss of the biochemical homeostasis of the cell: ATP synthesis is stopped, redox molecules such as 
NADH, NADPH, and glutathione are oxidized, and reactive oxygen species (ROS) are increasingly 
generated [Kroemer, 2000; Kroemer, 1997]. Increased levels of ROS directly cause the oxidation of 
lipids, proteins, and nucleic acids, thereby enhancing the disruption of ∆ψ as part of a positive 
feedback [Marchetti, 1997]. Several possible mechanisms for PT have been proposed, but there 
appears to exist consent that a so-called permeability transition pore (PTP) is formed consisting of the 
adenin nucleotide translocator (ANT) and the voltage-dependent anion channel (VDAC) as its core 
components. ANT is the most abundant protein of the inner mitochondrial membrane and as a 
transmembrane channel is responsible for the export of ATP in exchange with ADP (antiport). 
Overexpression of ANT-1 in human cancer cell lines dominantly induces apoptosis with all its 
characteristic features whereas its closely conserved homologue ANT-2 does not, indicating a specific 
mechanistic role of ANT-1 in mitochondrial apoptosis events [Bauer, 1999]. VDAC, also called porin, 
is the most abundant protein of the outer mitochondrial membrane and forms a non-selective pore 
through the outer membrane. Indicated by direct protein-protein interactions, VDAC-ANT complexes 
presumably connect inner and outer mitochondrial membrane to so-called ‘contact sites’, 
corresponding to a close association of the two membranes and thereby possibly constituting the PT 
pore [Beutner, 1998]. Since PT, loss of ∆ψ, and release of mitochondrial proteins are of central 
importance in mediating and enhancing apoptotic pathways, those mitochondrial events must be kept 
under strict control of regulatory mechanisms which are in many ways dependent on members of the 
Bcl-2 family which will be discussed in the next paragraph.    
Introduction 
 16
1.1.5  Regulatory mechanisms in apoptosis signalling 
 
Commonly, the activation of apoptosis is regarded to occur when a cell encounters a specific death-
inducing signal such as the ligation of a death receptor by its cognate ligand or if cells are treated with 
a cytotoxic drug. This suggests that the apoptosis signalling pathways in viable cells are kept in an 
inactive state and are only turned on in response to a death stimulus. But it should be taken into 
account that the components of the apoptotic signalling network are genetically encoded and ready for 
action in most cell types. Therefore, an interesting and possibly more realistic alternative view would 
be as follows: all cells of a multicellular animal might be intrinsically programmed to self-destruct and 
indeed would die instantaneously unless cell death is continously repressed by survival signals such as 
provided by other cells of the organism, e.g. growth factors, hormones, nutrients. Those survival 
signals enhance the expression and/or activity of antiapoptotic regulatory molecules thereby keeping 
in check the activation of proapoptotic factors [Ameisen, 2002; Raff, 1993]. Indeed, a set of various 
antiapoptotic molecules and mechanisms has been identified, as well as proapoptotic factors that 
counteract those inhibitory molecules when apoptotic demise of a cell is timely and imperative.  
 
1.1.5.1  The Bcl-2 family  
 
Bcl-2, an oncogene which in follicular lymphoma is frequently linked to an immunoglobulin locus by 
the chromosome translocation t(14:18), was the first example of an oncogene that inhibits cell death 
rather than promoting proliferation. B cells transfected with Bcl-2 were shown to be rendered resistant 
towards apoptosis induced by IL-3 withdrawal: for the first time it was shown that the pathway toward 
tumorigenesis depends not only on the ability to escape growth control but also depends on the ability 
to prevent apoptosis [Vaux, 1988].  
When homologues of Bcl-2 had been identified, it became apparent that a Bcl-2 family of proteins can 
be defined by the presence of conserved sequence motifs known as Bcl-2 homology domains (BH1 to 
BH4). In mammals, up to 30 relatives have been decribed of which some belong to a group of pro-
survival members and others to a group of proapoptotic members [Borner, 2003]. In addition to Bcl-2 
itself, there are a number of other prosurvival proteins, e.g. Bcl-XL, Bcl-w, A1, and Mcl-1, which all 
possess the domains BH1, BH2, BH3, and BH4. The proapoptotic group of Bcl-2 members can be 
devided into two subgroups: the Bax-subfamily consists of Bax, Bak, and Bok that all possess the 
domains BH1, BH2, and BH3, whereas the BH3-only proteins (Bid, Bim, Bik, Bad, Bmf, Hrk, Noxa, 
Puma, Blk, BNIP3, and Spike) have only the short BH3 motif, an interaction domain that is both 
necessary and sufficient for their killing action [Cory, 2002; Mund, 2003]. 
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There has been quite some debate about how the Bcl-2 family controls apoptosis: one model proposes 
that Bcl-2 members might directly control caspase activation [Strasser, 2000], whereas another model 
claims that they mainly act by guarding mitochondrial integrity [Wang, 2001]. In support of the first 
model, the worm Bcl-2 orthologue ced-9 binds to the Apaf-1-like adaptor protein ced-4 and prevents it 
from activating the caspase ced-3 unless the BH3-only protein Egl-1 displaces ced-4 as shown in    
Fig. 1.2 [Conradt, 1998]. In contrast, the mammalian ced-4 homologue Apaf-1 obviously does not 
interact with Bcl-2-like proteins [Moriishi, 1999] but is activated by cytosolic cytochrome c (see     
Fig. 1.4), and it is the release of cytochrome c from the mitochondria that can be controlled by Bcl-2 
[Kluck, 1997; Yang, 1997]. Therefore it appears likely, that the central function of mammalian Bcl-2 
family members is to guard mitochondrial integrity and to control the release of mitochondrial proteins 
into the cytoplasm [Cory, 2002].  
How then is mitochondrial integrity affected by proapoptotic Bcl-2 family members? Central to this 
question are Bax and Bak, even though inactivation of the Bax gene alone affected apoptosis only 
slightly and disruption of Bak alone did not show any effect. However, the double knockout of Bax 
and Bak resulted in dramatic impairment of apoptosis during development in many tissues with 
superfluous cells accumulating in the hematopoietic system and in the brain. Additionally, cells 
derived from those Bax -/- Bak -/- mice are insensitive to treatment with e.g. etoposide or irradiation 
[Lindsten, 2000; Wei, 2001]. Bax is a cytosolic monomer in viable cells but during apoptosis changes 
its conformation, integrates into the outer mitochondrial membrane and oligomerizes [Nechushtan, 
2001]. Although the mechanism is controversial, Bax and Bak oligomers are believed to provoke or 
contribute to the permeabilization of the outer mitochondrial membrane (PT), either by forming 
channels by themselves [Antonsson, 2000] or by interacting with components of the PT pore such as 
VDAC [Tsujimoto, 2000].  
In contrast, antiapoptotic Bcl-2 members sequester proapoptotic Bcl-2 members by bindig to their 
BH3 domains and thereby ultimately prevent Bax or Bak activation/ oligomerization and consequently 
inhibit mitochondrial proapoptotic events: overexpression of Bcl-2 or Bcl-XL potently inhibits 
apoptosis in response to many cytotoxic insults, among others by suppressing the generation of ROS, 
stabilizing ∆ψ, preventing PT and consequently blocking the release of e.g. cytochrome c [Reed, 
1998]. Besides eliciting its antiapoptotic effects on the mitochondrial level by indirectly controlling 
the activation of the apoptosome, Bcl-2 also appears to inhibit apoptotic pathways that are independent 
of Apaf-1/caspase-9 and which might depend on caspase-7 as a central effector [Marsden, 2002]. In 
this context one might even expect the existence of another but up to now unidentified Apaf-1 
homologue that can be directly controlled by Bcl-2/Bcl-XL [Puthalakath, 2002].  
Introduction 
 18
Whereas Bax and Bak represent the central core of a proapoptotic Bcl-2 death machinery that is held 
in check by the pro-survival members Bcl-2 and Bcl-XL, members of the BH3-only subfamily are 
required for the activation of proapoptotic Bax/Bak function [Bouillet, 2002]. On the other hand, the 
killing effect of BH3-only members depends on Bax/Bak, since cells double-deficient for Bax and 
Bak do not die upon overexpression of BH3-only proteins as it would be the case in wildtype cells, 
indicating that BH3-only members function upstream of Bax and Bak [Lindsten, 2000; Wei, 2001]. 
Importantly, just as the proapoptotic activity of multidomain proteins Bax and Bak is controlled by 
their interaction with the antiapoptotic guardians Bcl-2/Bcl-XL, also most BH3-only members 
display a strong binding preference to antiapoptotic Bcl-2/Bcl-XL and in this way are kept under 
control [Scorrano, 2003].  
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Fig. 1.6  
Regulation of apoptosis by the Bcl-2 family. In a viable cell, the proapoptotic Bcl-2 family
members Bax, Bak, and BH3-only proteins are antagonized by antiapoptotic members such as
Bcl-2. In response to an apoptotic stimulus, BH3-only members are activated by transcriptional
upregulation (Bax, Noxa, Puma), subcellular relocalization (Bim, Bmf), dephosphorylation (Bad),
or proteolysis (Bid). Activated BH3-only proteins prevent antiapoptotic Bcl-2 members from
inhibiting proapoptotic members. In addition, they might directly induce a conformational change of
Bax and Bak which subsequently oligomerize and insert into the mitochondrial membrane where
they form pores either by themselves or by associating with the permeability transition pore
complex. In consequence, proapoptotic factors are released from the inner mitochondrial
membrane into the cytosol, such as cytochrome c which contributes to the formation of the
apoptosome and the subsequent activation of the caspase cascade.   
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Individual BH3-only proteins are believed to transduce specific death signals since they can be 
activated for apoptosis signalling by sensing cell stress, such as DNA damage (Noxa and Puma are 
p53-inducible genes), growth factor deprivation (Hrk and Bim mRNA expression is increased), or 
anoikis (Bmf is activated by subcellular relocalization) [Borner, 2003]. As another example, 
cytoplasmic Bid is processed by caspase-8 to its truncated form tBid, which after myristoylation 
translocates to the mitochondria where it triggers cytochrome c release by affecting Bax/Bak 
oligomerization and/or by mobilizing cytochrome c stores in cristae [Cory, 2002; Scorrano, 2002].  
In general, BH3-only proteins are thought to interfere with the fine-tuned balance of homo- or 
heterooligomerization between proapoptotic multidomain members Bax/Bak and antiapoptotic 
members Bcl-2/Bcl-XL (Fig. 1.6). It has been proposed that Bid and Bim possess BH3 domains (Bid-
like BH3 domain) which can directly mediate Bax/Bak oligomerization, whereas Bad and Bik possess 
Bad-like BH3 domains which do not directly act on Bax/Bak but preferentially interact with 
antiapoptotic Bcl-2/Bcl-XL. As a consequence, activated Bad/Bik might be able to displace Bid/Bim 
from the binding pocket of antiapoptotic Bcl-2/Bcl-XL, and - in this way released - Bid/Bim might 
provoke Bax/Bak oligomerization and cytochrome c release even at subliminal levels [Letai, 2002]. 
  
In summary, a current model of how Bcl-2 family members regulate apoptosis can be descibed as 
follows (Fig. 1.6): specific apoptotic stress signals trigger the activation of particular BH3-only 
proteins which then interact with antiapoptotic members on the outer mitochondrial (but also 
nuclear/ER) membrane, resulting in the release of Bax-like proapoptotic factors. Bax-like factors 
undergo a conformational change (possibly assisted by some BH3-only proteins), insert into the outer 
mitochondrial membrane where they provoke PT and the release of apoptogenic factors [Borner, 
2003] 
 
 
1.1.5.2  Regulation of apoptosis by IAPs 
 
Expression levels of antiapoptotic proteins such as Bcl-2, Bcl-XL, and A1 were reported to be 
upregulated by the transcription factor NF-κB which besides being a central regulator of the innate and 
adaptive immune response is commonly described as an antiapoptotic transcription factor [Heckman, 
2002; Karin, 2002], although under certain circumstances NF-κB also might positively contribute to 
apoptosis induction [Grimm, 1996b]. Besides inducing the expression of pro-survival Bcl-2 members, 
NF-κB additionally transactivates a number of other antiapoptotic genes, such as the IAPs  (inhibitors 
of apoptosis proteins).  
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IAPs are a family of antiapoptotic proteins whose prototype originally was described in baculovirus 
with many homologues found to be conserved across several species. So far, eight human IAP 
homologues have been identified, among others NAIP, c-IAP1, c-IAP2, XIAP and survivin. All IAPs 
contain baculovirus IAP repeat (BIR) domains, 70 amino acid motifs, which are essential for the 
antiapoptotic properties of IAPs [Takahashi, 1998] because it is the interaction between the BIR 
domains and caspases that is believed to confer most of the antiapoptotic activity of IAPs. Indeed, 
XIAP, c-IAP1 and c-IAP2 are thought to directly inhibit caspases-3, -7, and –9 [Salvesen, 2002a]. In 
case of XIAP, it is  the BIR3 domain that directly binds to the small subunit of caspase-9, whereas it is 
the BIR2 domain that interacts with the active-site substrate binding pocket of caspases-3 and –7 
[Huang, 2001; Srinivasula, 2001].  
In addition to the BIR domains, c-IAP1, c-IAP2, and XIAP contain a highly conserved RING domain 
at their C-terminal end which possesses E3 ubiquitin ligase activity (see paragraph 1.2.1). Via this 
RING domain, IAPs are able to catalyze their own ubiquitination, thereby targeting themselves for 
degradation by the proteasome [Yang, 2000], but they also might target other proteins such as caspase-
3 and –7 for ubiquitination and degradation [Huang, 2000; Suzuki, 2001]. Direct inhibition of caspase 
activity by c-IAPs is certainly a very important means of regulation when considered that signalling 
cascades mediated by proteolytic enzymes such as caspases is irreversible once activated and therefore 
must be precisely regulated in order to prevent locally and temporally inappropriate demise of cells. 
Importantly, Smac/Diablo, when released from the mitochondrial intermembrane space during 
mitochondrial apoptotic events, is able to counteract the inhibitory effect of IAPs on caspases since 
Smac/Diablo can bind to e.g. XIAP in a manner that displaces caspases from XIAP and enables their 
activation. Thus, Smac/Diablo is a negative regulator of IAPs and in this way unfolds its apoptosis-
enhancing property [Du, 2000]. Essential for the ability of Smac/Diablo to bind to XIAP and to release 
caspases is a conserved tetrapeptide motif which is also present in HtrA2/Omi, another mitochondrial 
proapoptotic factor [van Loo, 2002], as well as in the Drosophila proapoptotic proteins Reaper, Hid, 
Grim, and Sickle which can bind to DIAP1, a Drosophila IAP and thereby support activation of the fly 
caspase Dronc [Hawkins, 2000]. 
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1.1.6  Disease as a consequence of dysregulated apoptosis 
 
In the adult human body several hundred thousand cells are produced every second by mitosis, and a 
similar number die by apoptosis for the maintenance of homeostasis and for specific tasks such as the 
regulation of immune cell selection and activity [Fadeel, 1999b]. Dysregulation of apoptotic signalling 
can play a primary or secondary role in various diseases with insufficient apoptosis leading to e.g. 
cancer (cell acumulation, resistance to therapy, defective tumor surveillance by the immune system), 
autoimmunity (failure to eliminate autoreactive lymphocytes), persistent infections (failure to 
eradicate infected cells), whereas excessive apoptosis contributes to e.g. neurodegeneration 
(Alzheimers’ disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis), 
autoimmunity (uncontrolled apoptosis induction in specific organs), AIDS (depletion of T 
lymphocytes), and ischaemia (stroke, myocardial infarction) [Reed, 2002]. Malfunction of the death 
machinery results from the mutation of genes that code for factors directly or indirectly involved in the 
initiation, mediation, or execution of apoptosis, and several mutations in apoptosis genes have been 
identified as a causing or contributing factor in human diseases [Mullauer, 2001].  
Of special interest is the involvement of defective apoptosis pathways in tumor formation, 
progression, and metastasis as well as the occurrence of multidrug resistance during cancer therapy 
[Johnstone, 2002]. During the last years it became more and more evident that tumorigenesis is not 
merely the result of excessive proliferation due to the activation of oncogenes but to the same extent 
depends on the – frequently concurrent - impairment of apoptosis checkpoints [Hanahan, 2000; Wang, 
1999]. Intriguingly, many of the alterations that induce malignant transformation, such as oncogene-
driven deregulated proliferation and invasion, actually sensitize a cell to apoptosis, and therefore only 
those oncogenic transformed cells will survive and become malignant which additionally acquire 
defects in apoptosis pathways and therefore are protected against cell death induction [Vousden, 
2002]. A transformed cell can achieve protection against apoptosis by inappropriate activation or 
expression of antiapoptotic proteins (which usually act as oncogenes), or by the inactivation of 
proapoptotic factors (which usually are tumor-suppressors). 
 
As an example and as already mentioned (paragraph 1.1.5.1, page 13), Bcl-2 was the first apoptosis-
related gene that was recognized to play a role in tumorigenesis, and indeed, Bcl-2 is overexpressed in 
a variety of cancers, contributing to cancer cell survival through direct inhibition of apoptosis 
[Hockenbery, 1990; Reed, 1999]. Conversely, mutated or downregulated Bax and Bak are observed in 
certain cancers [Kondo, 2000; Rampino, 1997] and disruption of those genes promotes tumorigenesis 
in mice [Yin, 1997]. Further, proapoptotic Bad and procaspase-9 are negatively regulated by the 
oncogenic Akt/PKB kinase, which on the other hand is frequently constitutively active or amplified in 
many types of human cancer [Nicholson, 2002], and its antagonist, the phosphatase PTEN, is one of 
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the most commonly mutated tumor-suppressors [Yamada, 2001]. Even more underlining its potential 
as an oncogene, Akt/PKB is also stimulating the NF-κB survival pathway by phosphorylation of  IκB 
kinase α (IKK α) and it is suppressing p53 proapoptotic signalling by phosphorylation of the 
oncogene Mdm2 which thereby is activated for inhibition of p53 [Mayo, 2002]. Both, NF-κB and 
Mdm2, are themselves inappropriately activated or overexpressed in the process of transformation 
[Chene, 2003; Orlowski, 2002]. 
 
A paradigm for the central importance of apoptosis checkpoints in the defense against malignant 
transformation presents the tumor suppressor p53, which is presumably the most intensely studied 
apoptosis factor contributing to cancer because it is inactivated in presumably more than 50% of all 
human cancers [Hainaut, 2000]. p53 is a tumor suppressor protein which is activated as a transcription 
factor in response to e.g. oncogene activation, hypoxia and especially DNA damage, resulting in 
growth arrest and/or apoptosis  by stimulating the expression of various p53 target genes such as p21, 
Bax, Puma, Noxa, Apaf-1, Fas, and DR5 [Vousden, 2002] or by repressing the expression of 
antiapoptotic proteins, e.g. Bcl-2, Bcl-XL or survivin [Hoffman, 2002; Wu, 2001]. Recent evidence 
suggests transcription-independent p53 apoptosis pathways in which p53 translocates to the 
mitochondria, interacts with Bcl-XL, induces PT and the release of cytochrome c [Mihara, 2003]. 
In non-stressed, undamaged cells p53 therefore must be kept under stringent control: it is present only 
at low cellular concentrations, it is retained in the cytosol and prevented to enter the nucleus, and its 
transactivation domain is inactivated [Chene, 2003]. Central to p53 regulation is the oncogene Mdm2 
which binds to and thereby inhibits p53 (see Fig. 1.7). Mdm2 is a ubiquitin-ligase which mediates 
ubiquitination of p53, thereby targeting it for degradation by the proteasome. In this way, p53 levels 
are kept low in normal cells [Kubbutat, 1997]. The importance of Mdm2 in the control of p53 is 
demonstrated by mdm2 gene knockout mice which die early during development but are rescued from 
death by additional deletion of the p53 gene [Montes de Oca Luna, 1995].  
In response to cellular stress (such as DNA damage), p53 is phosphorylated at specific 
serine/threonine residues which prevents the Mdm2-p53 interaction, and thus p53 is stabilized and 
activated [Schon, 2002]. Moreover, p53 is central to oncogene-induced cell death because it is induced 
by oncogenes such as c-myc, adenovirus E1A, and ras as well as by loss of the retinoblastoma tumor 
suppressor pRb [Henriksson, 2001]. All those oncogenes activate the transcription factor E2F-1 which 
not only can promote cell cycle progression and proliferation but at the same time directly triggers 
expression of the tumor suppressor ARF which leads to stabilization and activation of p53 [Ginsberg, 
2002]. This explains in part why oncogene activation not always leads to uncontrolled cell 
proliferation but under certain circumstances to the stabilization of p53 and activation of cell death, 
provided that p53 signalling pathways are intact [Eischen, 1999].   
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Fig. 1.7  
The p53 network – survival and cell death regulation. In a normal growing viable cell, the p53
protein is in a metastable state, i.e. p53 is susceptible to targeted ubiquitination and subsequent
proteasomal degradation. Mdm2 directly interacts with p53 and thereby catalyzes ubiquitination of
p53. Ubiquitination of p53 can be reversed by the action of the deubiquitinating enzyme HAUSP
which thereby can rescue p53 from degradation (see also paragraph 1.2.3.2). p53 is stabilized in
response to genotoxic stress such as DNA damage which leads to the phosphorylation of p53 at
several specific serine and threonine residues. Stabilized and activated p53 can translocate into
the nucleus where it activates the transcription of proapoptotic genes and suppresses the
transcription of antiapoptotic genes what under certain conditions can result in the induction of
apoptosis. p53-mediated apoptosis signalling is dependent on the interplay of many regulatory
factors, including protooncogenes as well as tumor-suppressors. Mdm2 activity is positively
regulated by the action of the Akt kinase: when Mdm2 is phophorylated by Akt, Mdm2 is able to
translocate from the cytosol to the nucleus where it unfolds its inhibitory effect on p53. Akt kinase,
on the other hand, is activated in response to survival signals coming from growth factor
receptors. This is therefore an instructive example for the negative regulation of proapoptotic, p53-
mediated signals by survival signalling. Whereas Akt kinase positively regulates Mdm2 activity,
Mdm2-mediated suppression of p53 is blocked by the action of the ARF tumor suppressor. By
binding to Mdm2, ARF prevents the interaction between Mdm2 and p53 and therefore stabilizes
and activates p53. ARF expression is dependent on the transcription factor E2F-1 which is
regulated by the retinoblastoma (Rb) tumor-suppressor and by the action of oncogenes. As an
example, mitogenic signals lead to the activation of oncogenes such as c-myc and ras which
among others activate E2F-1, resulting in increased ARF activity, stabilization of p53 and induction
of apoptosis. Therefore, increased mitogenic signalling or inappropriate oncogenic activity not
necessarily causes excessive proliferation but in cells with intact p53 signalling pathways can act
as apoptosis inducers.   
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Therefore in many instances, an oncogenic insult only results in increased proliferation and eventually 
malignant transformation if activators of p53 (such as ARF, Chk2, or ATM), p53 itself (e.g. by Mdm2, 
the adenovirus E1B, papillomavirus E6, or SV40 large T antigen), or p53 downstream signalling 
components (p53 target genes) are inactivated (Fig. 1.7). 
On the other hand, p53-mediated apoptosis pathways can be suppressed by survival signals, such as 
growth factors binding to their cognate growth factor receptors what eventually results in activation of 
the Akt kinase [Datta, 1999]. Akt kinase is known to mediate a number of antiapoptotic mechanisms, 
such as the direct phosphorylation and inactivation of Bad and caspase-9, the activation of NF-κB 
antiapoptotic signalling via phosphorylation of IκB, but also phoshorylation and activation of Mdm2 
as an inhibitor of p53 [Mayo, 2002]. Besides phosphorylation, ubiquitination and protein-protein 
interactions, p53 is also regulated by acetylation what affects its transcriptional activity, as well as by 
sumoylation [Melchior, 2003; Appella, 2001]. 
Gaining insight into the mechanisms and alterations by which components of the apoptotic machinery 
contribute to pathogenic processes, should allow the development of more effective, higher specific 
and therefore better-tolerable therapeutic approaches. Those may include the targeted activation of 
proapoptotic tumor suppressors or alternatively the blockade of antiapoptotic oncogenes in the case of 
cancer, whereas for the treatment of premature cell death during e.g. neurodegeneration the inhibition 
of proapoptotic key components such as the caspases might be promising [Reed, 2002]. 
 
1.1.7  Non-caspase proteases also play a role in cell death processes 
 
Contrary to earlier expectations, the inhibition of caspases does not always prevent cell death, and 
some researchers even claim that e.g. the pan-caspase inhibitor zVAD-fmk never can completely save 
cells from dying, whatever death stimulus is used [Borner, 2003; Leist, 2001a]. Usually, the activation 
of caspases and the consequent cleavage of their specific substrates is responsible for many of the 
typical morphological and molecular features of apoptosis. Examples are the cleavage of genomic 
DNA into oligonucleosomal fragments by the CAD/ICAD system [Nagata, 2000], chromatin 
condensation mediated by activation of acinus [Sahara, 1999], nuclear disassembly by cleavage of 
lamins [Lazebnik, 1995], cytoplasmic morphological changes by cleavage of actin, alpha-fodrin and 
gelsolin [Earnshaw, 1999], and plasma membrane blebbing by the activation of ROCK kinases 
[Sebbagh, 2001]. Cell death occurring in the absence of caspase activity, for example in presence of 
zVAD-fmk or in cells deficient for caspase-3 such as Mcf-7, still displays incomplete chromatin 
condensation and a varying degree of apoptosis-like morphological features or results in a necrosis-
like form of programmed cell death, i.e. in the absence of chromatin condensation but still in a not 
totally uncontrolled process [Leist, 2001a]. Thus, it must be assumed that besides caspases also other 
proteases might play a role in apoptosis-like cell death processes. Indeed, many non-caspase proteases, 
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e.g. calpains, can cleave at least some of the classical caspase substrates, indicating that they might 
mimic or substitute for some of the cellular effects of caspases [Orrenius, 2003; Johnson, 2000; Leist, 
2001b; Wang, 2000].  
During recent years, the cathepsins, lysosomal cysteine proteases, were reported to possibly contribute 
to the apoptotic proteolytic network, and also the ubiquitin/proteasome system has been implicated in 
the mediation and regulation of apoptosis pathways. The next two chapters will provide an insight into 
what is known about the involvement of the ubiquitin/proteasome system in the control of apoptosis 
and about the role of cathepsins in caspase-independent cell death pathways.  
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1.2  Apoptosis and the ubiquitin/proteasome system 
 
Apoptosis signalling pathways are tightly controlled by diverse regulatory mechanisms, including 
protein-protein interactions, transcriptional regulation, phosphorylation, but also ubiquitination and 
degradation of apoptotic signalling factors by the proteasome. Indeed, accumulating evidence supports 
the importance of the ubiquitin/proteasome system as a regulator of cell proliferation and apoptosis, 
influencing the delicate balance between a cell’s life and death depending on the cellular and 
environmental context [Jesenberger, 2002; Naujokat, 2002; Yang, 2003]. Besides regulating apoptosis, 
ubiquitin-dependent pathways also have been shown to play major roles in a number of other 
biological processes, including cell cycle regulation, transcription, DNA repair, protein trafficking, 
endocytosis, and regulated intramembrane proteolysis [Hicke, 2001; Muratani, 2003; Varshavsky, 
2000]. Regulation of cellular processes involves the accurate modulation of steady state levels of key 
regulatory proteins, which can be achieved at the level of protein biosynthesis but also at the level of 
protein degradation. 
 
1.2.1  The ubiquitin/proteasome system 
 
The ubiquitin/proteasome system is the major pathway of selective protein degradation in eukaryotic 
cells. In order to target a protein for degradation, it is covalently attached to several units of the 76 
amino acid protein ubiquitin, resulting in a polyubiquitin chain tag that labels the protein to be 
recognized and eventually degraded by the 26S proteasome [Kornitzer, 2000]. 26S proteasomes are 
large multisubunit proteolytic complexes consisting of a central catalytic machine, the 20S 
proteasome, and two regulatory 19S subcomplexes [Baumeister, 1998]. Proteasomes are localized to 
the cytoplasm and to the nuclei [Wojcik, 2003]. The 20S proteasome exhibits several proteolytic 
activities, including chymotrypsine-like and trypsine-like activities, the active sites of which are 
burried in the interior of the barrel-like structure and thus are shielded from the cytoplasm and 
therefore are prevented from uncontrolled protein degradation. The 19S subcomplexes consist of 
several proteins, some of which possess ATPase-activity and are involved in the ATP-dependent steps 
of proteasomal protein degradation. The 19S complex presumably functions to recognize ubiquitylated 
proteins, unfold them, and allow them to enter the proteolytic interior chamber of the 20S particle by 
possibly changing their conformation [Kornitzer, 2000].  
Covalent conjugation of ubiquitin to a target protein is achieved by the sequential action of an 
elaborate enzymatic machinery (Fig. 1.8). Initially, ubiquitin is activated by E1 (ubiquitin-activating 
enzyme) which in a ATP-dependent reaction forms a thioester bond between a cysteine residue of its 
active site and the carboxyl group of ubiquitin’s C-terminal glycine residue. In a trans-esterification 
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reaction, the activated ubiquitin is then transferred to a cysteine of a E2 enzyme (ubiquitin-conjugating 
enzyme). E3 proteins (ubiquitin-protein ligase) are required for specific substrate recognition and for 
mediating the transfer of ubiquitin from E2 to the ε-amino group of an internal lysine residue of the 
corresponding target protein. After covalent attachment of one ubiquitin moiety to a substrate protein, 
in most cases a polyubiquitin chain is generated by the conjugation of additional ubiquitin molecules 
to the ε-amino group of the internal Lys48 of a previously added ubiquitin moiety [Ciechanover, 2000; 
Kornitzer, 2000]. Polyubiquitylated proteins are recognized by the proteasome and are degraded. In 
case that a protein is modified by a single ubiquitin (mono-ubiquitination), this modification does not 
result in its degradation but is essential for a regulatory function of the protein in various cellular 
processes such as endocytosis or histone regulation [Hicke, 2001].  
 
Protein substrate
E3
Ubiquitin conjugating enzyme
E2
E2
S
Ub
Ubiquitin protein ligase
E3
Protein
substrate
Protein
substrate
Protein substrate
Ub
Ub
Ub
Ub
n
Ub
Ub
Proteasomal
Degradation Protein remnant
Ubiquitin activating enzyme
E1
E1
Ub
S
Ub
ATP
Ub Ub Ub Ub
nDUBs
DUBs
Ub
Ub
DUBs
aided by  DUBs
Fig. 1.8 
The ubiquitin/proteasome system. The ubiquitin/proteasome system is the major molecular
machinery for the controlled degradation of specific protein substrates within the cell. A protein
substrate destined for degradation by the proteasome must be labelled by the covalent attachment
of usually several ubiquitin molecules which form a polyubiquitin chain. Ubiquitination of a protein
substrate involves the coordinated action of the ubiquitin-activating enzyme (E1), several ubiquitin-
conjugating enzymes (E2), and numerous  ubiquitin ligases (E3) in an ATP consuming process.
Multiubiquitylated proteins are generated through the sequential addition of further ubiquitin
molecules to an already ubiquitylated protein substrate, a process that is catalysed by the same
E1, E2, and E3 enzymatic complex, although sometimes requiring an additional E4 enzyme (not
shown here). The attachment of one or more ubiquitin moieties to the substrate can be reversed
by the action of deubiquitinating enzymes (DUBs) which in addition also serve other functions
within the ubiquitin/proteasome system such as the generation of monoubiquitin from polyubiquitin
precursors or from still ubiquitylated protein remnants which originate from proteasomal
degradation. 
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Interestingly, whereas there is only one single known E1 enzyme, several E2 enzymes (>25) and even 
more E3 enzymes have been identified in mammals [Pickart, 2001], also arguing that it is the 
combined action of E2/E3 complexes which confers substrate specificity. Up to now, two main types 
of E3 ubiquitin ligases have been identified, one class containing the HECT domain, the other 
containing RING finger domains [Yang, 2003]. The prototype for a HECT (homologous to E6-AP 
carboxyl terminus) domain E3 enzyme is E6-AP (E6-associated protein) which in concert with the 
human papillomavirus (HPV) protein E6 functions to catalyze the ubiquitination and degradation of 
p53 [Scheffner, 1993]. More than 30 different mammalian HECT domain E3s are expected to exist 
which are believed to bind, on one hand, to their specific substrate proteins by protein-protein 
interaction motifs such as WW domains and, on the other hand, to their cognate E2 enzyme, 
eventually transfering ubiquitin to the substrate via an active site cysteine of the E3 [Jackson, 2000]. 
Interestingly, inactivation of E6-AP leads to the neurological disease Angelman syndrome [Kishino, 
1997], whereas mutation of Nedd4, another HECT domain E3, is causative for Liddle’s syndrome 
[Abriel, 1999]. 
Recently, it has been recognized that all other E3 proteins (non-HECT domain E3s) share a distinct 
structural element, the RING finger domain [Lorick, 1999; Pickart, 2001] which consists of eight 
conserved cysteine or histidine residues, forming a cross-brace structure to chelate two zinc ions 
[Jackson, 2000]. Several E3 proteins have been identified (including Mdm2 and IAPs) which contain 
RING finger domains that proved to be essential for autoubiquitination and the ubiquitination of 
substrates [Fang, 2000; Joazeiro, 2000; Yang, 2000]. Little is known about the catalytic mechanisms 
by which RING fingers catalyze ubiquitination, they apparently do not directly participate in the 
transfer of ubiquitin from E2 to the substrate but presumably are responsible for bringing E2 and 
substrate together. Besides functioning as single polypeptide E3s, such as Mdm2 or IAPs, small RING 
finger proteins are essential components of the multi-subunit E3 complexes SCF (Skp1/Cullin/F-Box 
protein), APC (anaphase-promoting complex), and VHL-CBC (von Hippel-Lindau/Cul2/elongin 
B/elongin C). In the case of yeast SCF, the cullin protein cdc53 forms a scaffold that associates with 
the Ring finger protein Rbx1, which further recruits and activates the E2 protein Cdc34p. Skp1 binds 
to this cdc53/Rbx1/Cdc34p complex and mediates recruitment of various F-box proteins which confer 
substrate specificity to this type of E3s [Jackson, 2002; Joazeiro, 2000]. Interestingly, Rbx1 is also 
part of the VHL-CBC complex, consisting of the VHL protein (pVHL), elongin B, elongin C, and 
Cul2. In analogy to SCF, Cul2 corresponds to the cullin scaffold, elongin C to Skp1, and the pVHL 
may serve the function of a F-box protein. Indeed, VHL-CBC exhibits ubiquitin ligase activity, 
targeting the Hypoxia Inducible Factor-α (HIF-α) subunit (a transcription factor subunit) for 
polyubiquitination and subsequent degradation. pVHL-defective cells are unable to degrade HIF-α, 
resulting in the overproduction of HIF-α target genes such as VEGF and EPO, which indeed are 
frequently increased in hemangioblastomas and renal cell carcinomas, malignancies frequently 
associated with the von Hippel-Lindau hereditary tumor syndrome [Kaelin, 2002; Kondo, 2001]. 
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Unexpectedly, at the same time, the tumor-suppressor pVHL appears to protect renal carcinoma cells 
from apoptosis induced by various stimuli possibly by upregulating Bcl-2 levels [Devarajan, 2001]. 
 
 
1.2.2  Regulation of the ubiquitin/proteasome system 
 
The ubiquitin/proteasome pathway is required for a multitude of cellular functions, and therefore it is 
not surprising that its general components – the proteasome and the ubiquitin-activating enzymes – are 
constitutively active. Regulation of the proteasomal degradation of specific substrates is mainly 
achieved at the level of ubiquitination, in many instances involving the post-translational modification 
of potential substrates or by the dependence on interactions with accessory proteins [Kornitzer, 2000]. 
Short-lived proteins usually carry a degradation signal, the so called N-degron, consisting of a 
destabilizing N-terminal amino acid residue and a specific internal Lys residue, the site for the 
attachment of a polyubiquitin chain [Varshavsky, 1992]. Proteins with destabilizing residues 
(especially basic and hydrophobic amino acids) at their N-terminus are preferentially recognized by 
certain E2/E3 complexes such as Ubc2p/Ubr1p and consequently are ubiquitylated and degraded 
[Varshavsky, 2000]. 
An increasing number of proteins is known to require phosphorylation prior to their ubiquitination, 
including the mammalian G1 cyclins D and E, the cyclin-dependent kinase (CDK) inhibitors           
p21Waf1,Cip1, p27Kip1, and the inhibitor of NF-κB, IκB-α [Bornstein, 2003; Ganoth, 2001; Tanaka, 
2001]. In all those cases, phosphorylation stimulates ubiquitination by E3 ubiquitin ligases of the SCF 
type. Phosphorylation can also inhibit ubiquitination as has been described for e.g. Bcl-2: 
dephosphorylation of Bcl-2 following apoptotic stimuli renders it susceptible to degradation by the 
ubiquitin/proteasome pathway [Dimmeler, 1999]. Another important expample is the regulation of p53 
stability by targeted phosphorylation at specific serine/threonine residues. Besides phosphorylation, 
the modification of proteins by SUMO (small ubiquitin-like modifier) might interfere with 
ubiquitination as has been reported for Mdm2 and IκB-α [Muller, 2001]. 
 
1.2.3  Deubiquitinating enzymes (DUBs) 
 
Deubiquitinating enzymes (DUBs) are cysteine proteases that specifically cleave ubiquitin conjugates 
at the ubiquitin carboxy terminus. There are two major families of DUBs, the UCH (ubiquitin carboxy 
terminal hydrolase) family and the USP (ubiquitin-specific protease) family. The UCHs are small 
enzymes most probably involved in co-translational processing of polyubiquitin chains or in the 
release of ubiquitin from adducts with small peptides or amino acids. In contrast, USPs are usually
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much larger proteins which besides the core catalytic domain (consisting of a cysteine domain, an 
aspartate domain, a histidine domain, and three additional homology domains) possess N- or C-
terminal extensions which might allow the selective or even specific interaction with distinct substrate 
proteins or determines cellular localization [D'Andrea, 1998]. DUBs (especially USPs) are able to 
cleave off intact ubiquitin molecules conjugated to other proteins, potentially providing reversibility to 
the ubiquitination system. Therefore one might expect a major impact of DUBs on the regulation of 
signalling pathways that are modulated by the ubiquitin/proteasome system, especially when regarded 
in analogy to protein kinase/phosphatase signalling systems. On the other hand, DUBs act at multiple 
levels in the ubiquitin pathway, particularly also serving some quite basic functions (Fig. 1.9). 
 
 
1.2.3.1  General functions of DUBs 
 
Ubiquitin is encoded by a multigene family of which many ubiquitin genes express multimeric head-
to-tail ubiquitin repeat proteins (polyubiquitins) or ubiquitin fused to ribosomal proteins L40 and S27a 
[Archibald, 2003].  
Since only monomeric ubiquitin can be used by the ubiquitin/proteasome system, the linear 
polyubiquitins and the ubiquitin fusion proteins are assumed to be processed into monomeric ubiquitin 
units by deubiquitinating enzymes, although the responsible enzyme(s) have not been identified thus 
far [Wilkinson, 1997]. Moreover, proteasomal degradation often produces a protein remnant that is 
still attached to its branched chain polyubiquitin tag, and DUBs such as the yeast Doa4 are able to 
remove the remnant  from the polyubiquitin chain which subsequently is disassembled to 
monoubiquitin molecules by the action of isopeptidase T /USP5 [Papa, 1993; Wilkinson, 1995]. 
Therefore, certain DUBs serve general housekeeping functions by maintaining a sufficient pool of free 
monomeric ubiquitin and/or by preventing the accumulation of polyubiquitin chains, which might 
interfere with proteasomal degradation [Wilkinson, 1997]. Also a more general role might play the 
PA700 isopeptidase which is associated with the 19S proteasomal subcomplex, potentially inhibiting 
ubiquitin-mediated proteolysis by releasing ubiquitin chains from substrates before they reach the 
proteasome. PA700 thus provides a correction or proofreading function by preventing degradation of 
mistakenly ubiquitylated proteins [Kornitzer, 2000; Lam, 1997]. 
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1.2.3.2  Specific regulatory functions of DUBs 
 
Whereas only a few different mammalian UCH enzymes are known, an increasing number (> 30) of 
mammalian USP family members has been identified, further supporting the assumption that USPs 
should play a role in specific biological processes by regulating the ubiquitination status and 
consequently the stability of discrete substrate proteins (also see Box 4.1). 
An interesting example for the implication of USPs as regulatory enzymes in the response to growth 
factor signalling are DUB-1 and DUB-2. After addition of IL-3 to G1 arrested hematopoietic cells, 
DUB-1 mRNA levels were reported to be rapidly induced, but to decline again before completion of 
G1. Artificially prolonged expression of DUB-1 resulted in G1 arrest, suggesting that DUB-1 
expression must be tightly regulated and that DUB-1 may play an important role in cytokine-induced 
cell proliferation [Zhu, 1996]. Similar results were reported for the homologous DUB-2, which is 
induced by IL-2 in T lymphocytes, but no specific substrates of DUB-1 or DUB-2 have been identified 
so far [Zhu, 1997].  
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Fig. 1.9   
The various functions of deubiquitinating enzymes as part of the ubiquitin/proteasome system.
DUBs are responsible for providing monoubiquitin units to the ubiquitination system by processing
linear and branched chain polyubiquitin precursors (a) or by removing ubiquitin moieties still attached
to protein remnants that result from the degradation of a protein at the proteasome (b). In addition,
DUBs might be part of the proteasome multienzyme complex and thereby promote degradation of
proteins  by removing ubiquitin chains that otherwise would interfere with proteasome activity (c).
Finally, DUBs supposedly possess specific regulatory functions by their ability to deubiquitinate distinct
target proteins which thereby are rescued  from degradation by the proteasome (d).      
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Several DUBs seem to have important roles in development, such as the product of the fat facets gene 
(faf) in Drosophila, which is required in the pathway of eye facets development [Huang, 1995]. In flies 
with defective faf, a signal that directs the death of certain cells in the facets precluster is not generated 
and the fly eyes consequently develop with additional photoreceptor cells. The faf ─ phenotype could 
be suppressed by proteasome mutants, suggesting that one function of faf is the deubiquitination of (a) 
short-lived regulatory molecule(s) which is essential for eye patterning [Wilkinson, 1997]. A recent 
report identified the liquid facets gene (lqf) as a specific substrate for faf-mediated deubiquitination. 
Lqf regulates endocytosis and such might be involved in the control of cell-cell comunication [Chen, 
2002]. Interestingly, a faf homologue has been identified in mouse (Fam) that is expressed in rapidly 
dividing cells, among others in the apoptotic region between the digits [Wood, 1997]. Experiments 
indicated that Fam interacts with and might stabilize β-catenin by deubiquitination [Taya, 1999].  
Suggesting a role of DUBs in oncogenesis, the ubiquitin-specific protease Unp has been discussed to 
act as a pre-oncogene when overexpressed and to be elevated in lung cancers [Gupta, 1994], although 
subsequent characterization of Unp could not confirm those initial results [Frederick, 1998]. In the 
meantime, Unp has been reported to physically interact with the retinoblastoma protein (RB) further 
suggesting a possible role for this isopeptidase in cancer [DeSalle, 2001].  
Of major interest is the ubiquitin-specific protease HAUSP (herpes virus associated USP), which 
initially was described to be essential for Herpes virus infections [Everett, 1997], but recently was 
identified to specifically bind, deubiquitinate and stabilize p53 (Fig. 4.1.1). In overexpression 
experiments, HAUSP stabilized p53, enhanced p53-mediated cell death, and even rescued p53 from 
Mdm2-mediated inactivation. Moreover, prolonged overexpression of HAUSP in p53 positive but not 
p53 deficient carcinoma cell lines resulted in growth inhibition, suggesting that HAUSP might 
function as a tumor suppressor through the stabilization of p53 [Li, 2002]. Interestingly, HAUSP also 
appears to be processed in a caspase-3-dependent manner during thymocyte apoptosis, with the 
cleavage product still possessing enzymatic activity. This observation might be a possible link 
between the caspase and ubiquitin/proteasome proteolytic death pathways [Vugmeyster, 2002].  
Another example for the implication of deubiquitinating enzymes in pathways that determine cell 
survival and cell death has been described recently. CYLD is a tumor-suppressor frequently mutated 
in cases of familial cylindromatosis, an autosomal dominant predisposition to tumors of skin 
appendages. CYLD was shown to interact with IKK-γ (NEMO) of the IKK complex and to possess 
deubiquitylating enzymatic activity towards the TNF receptor associated factor 2 (TRAF2). TRAF2 in 
its ubiquitylated status positively stimulates the phosphorylation of IκB which thereupon is 
ubiquitylated and degraded, allowing the activation of NF-κB survival signalling. CYLD removes 
ubiquitin from TRAF2 and therefore interferes with NF-κB activation. Interestingly, downregulation 
of the CYLD mRNA message results in enhanced activation of NF-κB and in a reduction of cell death 
induced by TNF-α [see Fig. 4.1.2 and Brummelkamp, 2003; Kovalenko, 2003; Trompouki, 2003].    
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1.2.4  Involvement of the ubiquitin/proteasome system in apoptosis 
 
1.2.4.1  The proteasome and its impact on survival and cell death 
 
The ubiquitin/proteasome system appears to be required for both, survival and cell death processes, 
presumably depending on the cellular and physiological context. First indications for an apoptosis 
promoting function of the ubiquitin/proteasome system came from studies focusing on developmental 
cell death occuring in abdominal intersegmental muscles of the tobacco hawkmoth, Manduca Sexta. 
This apoptotic muscle regression is accompanied by a dramatic increase in ubiquitin expression and 
proteasomal proteolytic activity, as well as a change in proteasome subunit composition [Naujokat, 
2002]. Proteasomal activity also might be required for the progression of apoptosis in non-
proliferating, differentiated cells, since apoptotic cell death of resting thymocytes and differentiated 
neuronal cells was inhibited in the presence of proteasome inhibitors [Grimm, 1996a]. 
In contrast, rapidly proliferating cells, including most cancer cell lines in culture, appear to display 
abnormally high proteasomal expression and activity, suggesting that the 26S proteasome plays a 
pivotal role in maintaining survival and proliferation of abnormally growing cells [Ichihara, 1995; 
Ichihara, 1993]. Supporting this “survival hypothesis”, proteasome inhibitors have been reported to 
induce apoptosis in neoplastic and rapidly growing mammalian cells of hematopoietic, neuronal, 
mesenchymal, and epithelial origin [Naujokat, 2002].  
Underlying those observations, the proteasome was discovered as a target for cancer therapy, and 
selective proteasome inhibitors, such as PS-341, are currently evaluated as novel chemotherapeutic 
agents in cancer patients with advanced disease [Adams, 2000]. The role of proteasome inhibition in 
cancer therapy may ultimately lie in its ability to overcome chemoresistance, and indeed, proteasome 
inhibitors were shown to sensitize cancer cells to conventional cytotoxic drugs [Shah, 2001]. The 
molecular mechanisms responsible for the impact of proteasome inhibitors on apoptotic pathways are 
not fully understood but they certainly eventually lead to an interference with the delicate balance of 
apoptotic and survival signals which are under the control of the ubiquitin/proteasome system. A 
recent example is the observation that the proteasome inhibitor PS-341 sensitizes various cancer cells 
to TRAIL-induced apoptosis. This effect is likely due to the enhanced expression of the TRAIL 
receptors DR4 and DR5 [Johnson, 2003]. 
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1.2.4.2  Apoptosis pathways regulated by ubiquitin/proteasome-dependent 
proteolysis 
 
A manifold of apoptotic signalling factors are direct targets for ubiquitination with consequent 
degradation by the proteasome (Fig. 1.10), and several survival and death signalling pathways are 
regulated at multiple points by the ubiquitin/proteasome system (Fig. 1.11). One of the most 
prominent examples is the regulation of the p53 signalling network which involves oncogene-
regulated (e.g. Mdm2, E6) ubiquitination of p53 that is dependent on the p53 phosphorylation status 
and the interplay of p53 with regulatory factors such as ARF and the ubiquitin-specific protease 
HAUSP (Fig. 1.7 and Fig. 4.1.1).  
 
Another example is NF-κB signalling which usually is regarded as a survival pathway that can 
suppress apoptosis by promoting the expression of antiapoptotic molecules such as Bcl-2, c-FLIP and 
IAPs. NF-κB is kept inactive when sequestered in the cytoplasm by its inhibitor IκB. In response to 
survival signals (e.g. activation of Akt kinase or TNF-α survival pathways), IκB is phosphorylated, 
ubiquitylated and degraded by the proteasome, resulting in the translocation of NF-κB into the nucleus 
where it is active as a transcription factor. Dysregulated proteasomal degradation of IκB can result in 
abnormal high levels of NF-κB activity in neoplastic cells [Guzman, 2001; Izban, 2001], and it is the 
stabilization of IκB and the consequent blockade of NF-κB signalling that might be one major mode 
of action of proteasome inhibitors in the sensitization of tumor cells to cell death induction [Adams, 
2000]. Target genes of NF-κB such as IAPs and Bcl-2 are themselves targets for ubiquitination and 
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Fig. 1.10       
Apoptosis factors as targets of ubiquitination and degradation by the proteasome. Selected
proteins which have been described to be ubiquitylated and degraded by the ubiquitin/
proteasome system [Yang, 2003; Naujokat, 2002; Jesenberger, 2002]. 
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proteasomal degradation in response to apoptosis induction [Naujokat, 2002], with IAPs possessing 
RING-mediated ubiquitin ligase activity, resulting in their auto-ubiquitination as well as ubiquitination 
of caspases.  
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Apoptosis and survival pathways are regulated at multiple points by the ubiquitination/
proteasome system. Several factors of the p53 signalling network are targets for ubiquitination,
i.e. p53 itself but also its central regulator Mdm2 which is a E3 ubiquitin ligase. Auto-ubiquitination
of Mdm-2 can be influenced by modification with the ubiquitin-like protein SUMO. Also the stability
of the central apoptosis-inducers Bax and of caspases-3 and -7 is dependent on the
ubiquitin/proteasome system. Moreover, the activation and mediation of survival signalling
pathways is affected by ubiquitination at several points, particularly on the level of NF-κB
activation. The inhibitors of apoptosis (IAPs) possess E3 ubiquitin ligase activity and mediate auto-
ubiquitination as well as ubiquitination of caspases [Jesenberger, 2002; Yang, 2003]. 
Introduction 
 36
1.3  Lysosomes and their possible involvement in apoptosis 
 
1.3.1  Lysosomes are ‘suicide bags’  
 
Lysosomes are the major compartment for cellular catabolism and contain about 40 types of hydrolytic 
enzymes mostly active at acidic pH, e.g. proteases, nucleases, lipases, and glycosidases [deDuve, 
1966]. Christian de Duve, soon after his discovery of these organelles, nicknamed them ‘suicide bags’ 
and suggested that an uncontrolled leakage of their enzymes to the cytoplasm might be lethal for cells 
[deDuve, 1969]. For many years, only non-selective degradation of long-lived intracellular and 
extracellular proteins was attributed to lysosomal proteases, but accumulating evidence suggests an 
implication of lysosomes in more selective types of protein degradation contributing to various 
biological processes [Turk, 2000]. The largest group of lysosomal proteases are the papain-like 
cysteine proteases, the cathepsins, which besides being part of the general proteolytic machinery 
inside the lysosome, are also involved in more specific processes such as the maturation of MHC class 
II molecules (cathepsins L, S, and V), bone remodeling (cathepsin K), or specifically processing 
protein substrates [Reinheckel, 2001; Turk, 2000].  
 
1.3.2  Evidence for a role of lysosomes and cathepsins in cell death 
 
Numerous observations suggest that cathepsins may also act as mediators of programmed cell death, 
since in response to various apoptotic stimuli, cathepsins appear to translocate from the lysosomes to 
the cytosol [Antunes, 2001; Brunk, 2001; Kessel, 2000; Neuzil, 2002]. This translocation is believed 
to be the result of a more or less severe damage to the lysosomal membrane, and it is not likely that 
distinct enzymes (such as cathepsins), are selectively released from the damaged lysosomes but that 
most lysosomal hydrolytic enzymes should be able to diffuse into the cytosol [Brunk, 2001; Turk, 
2002]. It has been proposed that there might be a quantitative relationship between the extent of 
lysosomal rupture and the resulting mode of cell death. According to this model, a partial rupture of 
the lysosomal membrane would cause a limited release of lysosomal content resulting in apoptosis, 
whereas a complete rupture would lead to necrosis [Leist, 2001b]. Although cathepsins are actually 
expected to be largely inactive at neutral cytoplasmic pH, cathepsins (as reported for cathepsin B) 
might still display endopeptidase activity under cytosolic conditions [Leist, 2001b]. Another obstacle 
for cathepsins being proteolytically active in the cytoplasm would be the presence of intracellular 
protease inhibitors, the stefins. Interestingly, stefin B knockout resulted in substantial cerebellar 
apoptosis, further supporting a possible involvement of cathepsins in neuronal cell death. Also in  
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agreement with an active role of cathepsins in apoptosis, inhibition of cathepsin activity by e.g. 
overexpression of stefin A or by synthetic cathepsin inhibitors, was reported to block cell death 
induced by a variety of stimuli [Guicciardi, 2001; Hishita, 2001; Kagedal, 2001b; Kiso, 2001; 
Mathiasen, 2001; Turk, 2002].  
 
 
1.3.3  Cathepsins - proteases with proapoptotic activity 
 
The mechanisms by which cathepsins, once released to the cytoplasm, might contribute to apoptosis 
pathways are still not completely understood, but might include the cleavage and activation of Bid and 
the consequent release of cytochrome c from mitochondria to the cytosol, whereas the direct activation 
of caspases by cathepsins remains questionable [Fig. 1.12 and Guicciardi, 2000; Stoka, 2001]. 
Overexpression as well as microinjection of the aspartic lysosomal protease cathepsin D (cath-D) were 
reported to result in apoptosis induction [Deiss, 1996; Roberg, 2002], and ceramide, which possibly 
acts as an apoptosis-inducing second messenger, was reported to trigger the autocatalytic proteolysis 
and activation of cath-D [Gewies, 2000a; Heinrich, 1999]. Moreover, there are reports that suggest a 
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Fig. 1.12 
Cathepsins as putative mediators of cell death signals. Lysosomes have been proposed to be
an integral part of certain apoptosis pathways. Apoptosis-inducing signals such as TNF-α or
oxidative stress were reported to result in a (partial) rupture of the lysosomes and in the release of
their hydrolytic content into the cytosol. Therefore, lysosomal cysteine proteases, the cathepsins,
might mediate proteolysis-dependent activation of cytosolic processes, such as the processing of
the Bcl-2 member Bid with subsequent cytochrome c release from the mitochondria, or even direct
activation of the caspase cascade. Thus far, the mechanisms by which cathepsins might act in
apoptosis signalling have not been elucidated in detail.  
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role for cath-D in the mediation of extrinsic and intrinsic apoptosis pathways, for example by initiating 
mitochondrial apoptotic events such as activation of Bax [Bidere, 2003; Demoz, 2002; Kagedal, 
2001a; Roberg, 2001]. 
Accumulating evidence appears to implicate cathepsin B (Cath-B) in the mediation of proapoptotic 
signalling what might prove to be important in terms of a possible connection between tumorigenesis, 
apoptosis, and its exploitation for novel therapeutic approaches. Cath-B expression levels, but also 
those of Cath-L, are frequently strongly elevated in tumors of diverse origin and in their secreted form 
are thought to contribute to cancer progression and metastasis either by directly degrading the 
extracellular matrix or by proteolytically activating other extracellular proteases [Turk, 2000; 
Chauhan, 1991; Duffy, 1996; Konduri, 2001; Kos, 1998; Sloane, 1990; Yan, 1998]. Therefore, Cath-B 
and Cath-L are usually regarded as tumor markers correlated with bad prognosis. On the other hand, in 
recent years there has been increasing evidence that particularly Cath-B might be involved in the 
mediation of apoptotic cell death triggered by various stimuli. Most importantly, cells deficient or 
downregulated in Cath-B appear to be more resistant to TNF-α-mediated apoptosis [Guicciardi, 
2000;Foghsgaard, 2001]. Inhibitor experiments further supported the view that CathB might act as a 
dominant executioner protease in TNF-α-induced apoptosis pathways [Foghsgaard, 2001]. Caspase-8, 
which is the immediate initiator caspase in the TNF-alpha death pathway, might be able to trigger 
lysosomal release of CathB, and it has been shown in vitro that Cath-B triggers cytochrome c release 
from the mitochondria into the cytosol [Guicciardi, 2000], although the latter observation seems to be 
somewhat controversial [Stoka, 2001]. In conflict with a direct proapoptotic activity of Cath-B is a 
recent report according to which the microinjection of Cath-D but not of Cath-B does trigger apoptosis 
[Roberg, 2002]. Considering the possible proapoptotic activity of cathepsins, it has been even 
hypothesized that e.g. Cath-B-like proteases, despite their implication as bad prognosis factors in the 
promotion of metastasis and tumor invasion, may prove useful in selectively targeting tumor cells for 
apoptosis-induction, exploiting the fact that tumors frequently express high levels of cathepsins 
[Foghsgaard, 2001]. Nevertheless, it should be kept in mind that the mechanisms by which cathepsins 
possibly contribute to apoptosis and the significance of cathepsin-mediated cell death under certain 
physiological or pathological conditions remain somewhat elusive and require further investigation. 
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1.4  Specific Aims of this Thesis 
 
Even though the previous chapters primarily were intended to give an insight into some of the basic 
concepts of what is currently known about apoptosis, this introduction also should have raised 
awareness about the multitude and complexity of signalling pathways and factors involved in the 
induction, mediation, and execution of programmed cell death as illustrated in Fig. 1.5. Currently, 
about 10.000 scientific reports are published in the field of apoptosis research every year, and 
presumably several hundreds of factors have already been recognized to contribute to mechanisms that 
control apoptosis [Melino, 2001]. Nevertheless, our understanding of the network of interactions 
between the various factors that determine whether a cell is committed to survive or to die, remains 
limited. It also must be assumed that there are still proteins which, up to now, have not been 
recognized to play a role in the induction or regulation of the apoptotic machinery, and which 
eventually might prove to be missing links in the effort to find a complete description of the pathways 
involved. In this context, the main goal of this doctoral thesis was the isolation, identification, and 
characterization of genes which induce apoptosis upon overexpression by the application of a genetic 
expression screening procedure as described by Grimm and Leder [Grimm, 1997]. Several well-
described apoptosis factors, e.g. p53, FADD, Bax, and caspases, are known to possess dominant 
apoptosis-inducing activity when overexpressed [Chinnaiyan, 1995; Fernandes-Alnemri, 1994; Li, 
2002; Li, 2001b; Pastorino, 1998], and therefore it is justified to assume that application of the genetic 
expression screen is an appropriate approach for the identification of further proteins with 
proapoptotic activity. 
 
This thesis describes the characterization of two cDNAs which during the screening procedure were 
identified to induce apoptosis-like morphological changes when overexpressed in 293T human kidney 
cells. One cDNA was determined to code for the ubiquitin-specific protease UBP41, the other for the 
lysosomal cysteine protease cathepsin-L, i.e. both cDNAs encode enzymes that are part of the cellular 
apparatus for the proteolytic destruction of proteins. Importantly, UBP41 and cathepsin-L are non-
caspase cysteine proteases, and recently the importance of alternative proteolytic pathways in the 
mediation of caspase-independent apoptosis signalling has been discussed intensely [Jaattela, 2003]. 
During the last few years there has been accumulating evidence that both, the ubiquitin/proteasome 
system, to which UBP41 belongs, as well as the lysosomes, to which cathepsin-L localizes, might 
have significant impact on the mediation and regulation of programmed cell death (see chapters 1.2 
and 1.3, respectively). The two projects described here contribute to the expanding knowledge about 
the possible connections that exist between protein degradation and apoptosis. 
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2  Materials and Methods 
 
2.1  Materials 
 
2.1.1  Fine Chemicals and Biochemicals 
 
If not indicated different in following listing, all fine chemicals were from Sigma (Taufkirchen). 
Restriction enzymes were from MBI Fermentas (St.Leon-Rot), and further chemicals and enzymes 
used but not listed here are indicated in the text. 
 
Acetic acid (Merck, Darmstadt); Aceton (Merck, Darmstadt); Acrylamide – 30 % Acrylamide, 0,8 % 
Bisacrylamide, 37.5:1 (Roth, Karlsruhe); Agarose (Biomol, Hamburg); Bacto Agar (Difco, Detroit, 
USA); Boric acid (Merck, Darmstadt); Bromphenol blue (Merck, Darmstadt); Calcium chloride 
(Merck, Darmstadt); Chloroform (Merck, Darmstadt); Chloroform/Isoamylalkohol - 24:1 (Roth, 
Karlsruhe); DTT - Dithiothreitol (BioTech, St. Leon-Rot); Dry Milk Powder (Milupa, Friedrichsdorf); 
EGTA - Ethylene glycol-bis-(2-aminoethyl)-N,N,N', N'-tetraacetic acid (Biomol, Hamburg); Ethanol  
(Riedel-de Haen, Seelze); Formaldehyde (Merck, Darmstadt); D(+)-Glucose (Merck, Darmstadt); L-
Glutamine (Gibco BRL, Eggenstein); Glycerin (Merck, Darmstadt); Glycine (Merck, Darmstadt); 
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Biomol, Hamburg); Isopropanol 
(Merck, Darmstadt); Magnesium chloride (Merck, Darmstadt); Magnesium sulfate (Merck, 
Darmstadt); Mercaptoethanol (Merck, Darmstadt); Methanol (Merck, Darmstadt); Phenol/ 
Chloroform/Isoamylalkohol - 25:24:1, pH 8 (Roth, Karlsruhe); Potassium acetate (Riedel-de Haen, 
Seelze); Potassium chloride (Merck, Darmstadt); 2-Propanol (Merck, Darmstadt); Sodium acetate 
(Merck, Darmstadt); Sodium chloride (Merck, Darmstadt); Sodium dihydrogenphosphate (Merck, 
Darmstadt); Sodium dodecylsulfate – SDS (Roth, Karlsruhe); Sodium hydrogenphosphate (Merck, 
Darmstadt); di-Sodium hydrogenphosphat (Merck, Darmstadt); Sodium hydroxid (Merck, Darmstadt); 
Sodium pyruvate (Gibco BRL, Eggenstein); Saccharose = Sucrose (Merck, Darmstadt); TNF-α, 
human, recombinant (Biomol, Hamburg or Bachem, Weil am Rhein); Triton X-100 (Roth, Karlsruhe); 
Urea (Merck, Darmstadt); Yeast extract (Difco, Detroit, USA); zVAD-FMK (Enzyme Systems, 
Livermore, USA) 
 
2.1.2  Reagents for Cell Culture 
 
Dulbecco modified Eagle-Medium - DMEM (Sigma, Taufkirchen); FBS - Fetal Bovine Serum 
(Sigma, München); L-Glutamine - 100 x (LifeTechnologies, Karlsruhe); Penicillin/Streptomycin - 100 
x (Life Technologies, Karlsruhe); RPMI-1640 medium (Sigma, Taufkirchen); Sodium pyruvate - 100 
x (Life Technologies, Karlsruhe); Trypsine/EDTA - 10 x (Life Technologies, Karlsruhe). 
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2.1.3  Laboratory Equipment 
 
Centrifuges 5417R, 4K15, and RC 5B Plus (Eppendorf, Sigma, Sorvall); Electrophoresis chambers 
(own construction by MPI workshop); Flow Cytometer FACS-Calibur (Becton Dickinson, 
Heidelberg); Fluorescence Plate Reader (Fluoroskan Ascent FL Labsystems); Incubators (Heraeus, 
Hanau); Power-Supplies EPS 600 (Pharmacia Biotech); Microscope Axiovert 25 (Zeiss, Oberkochen); 
Microscope Axiophot IM-35 (Zeiss, Oberkochen); Microscope Axioscop 2 (Zeiss, Oberkochen); 
Micropipets (Gilson, Middleton, USA); PCR MasterCycler Personal / Gradient (Eppendorf, 
Hamburg); Shaking Incubator (own construction by MPI workshop); SpeedVac Concentrator 5301 
(Eppendorf, Hamburg); Spectrophotometer DU 530 (Beckman, Fullerton, USA); Sonicator Cell 
Disruptor B15 (Branson); Table top Centrifuges (Eppendorf, Hamburg); UV Illuminator UVT-14L - 
Eagle Eye II Herolab (Stratagene, La Jolla, USA) 
 
  
2.1.4  Kits and Ready-to-Use Reagents 
 
Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Weiterstadt); BioRad 
Protein Microassay (BioRad, München); Caspase-3 Activity Assay (Roche, Mannheim); Expand Long 
Template PCR Kit (Roche, Mannheim); Protease-Inhibitor-Complete Cocktail (Roche, Mannheim); 
QIAquick Gel Extraction Kit (QIAGEN, Hilden); Effectene Transfection reagent (QIAGEN, Hilden); 
QIAGEN Plasmid Kit - Mini, Midi, Maxi (QIAGEN, Hilden); QIAquick Spin Gel Extraction Kit 
(QIAGEN, Hilden); RNeasy Mini Kit - RNA-Isolation (QIAGEN, Hilden); Super Signal West Femto 
Maximum Sensitivity Substrate (Pierce, Rockford, USA) 
 
 
2.1.5  Standard Buffers and Stock Solutions 
 
Coomassie-staining solution: 50% (v/v) Methanol, 10% Acetic acid, 0.1% (w/v) SERVA Blue R 
Denhardt’s Reagent:   50x1% Ficoll 400, 1% polyvinolpyrrolidon, 1% BSA fraction V in H2O 
DNA sample buffer, 6 x:  0.25% bromophenol blue, 15% Ficoll 
Hypotonic Lysis Buffer - 20 µg/ml Propidium iodide, 0.1% (w/v) Na3Citrate, 0.1% Triton X-100 
PI FACS buffer:  in PBS 
PBS:    140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 
7,4  
Ponceau staining solution: 0,1% Ponceau S, 5% (v/v) Acetic Acid 
SDS-Gel Running buffer: 25 mM Tris, 192 mM Glycine, 0,1% (w/v) SDS 
SDS Sample buffer, 2x:  100 mM Tris-HCl pH 6.8, 4% SDS, 10% mercaptoethanol,  
20% glycerol, 0.05% bromophenol blue 
SDS stacking gel buffer: 1.5 M Tris/HCl, pH 6,8 
SDS separation gel buffer: 1,0 M Tris/HCl, pH 8,8 
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SSC, 20 x:   0,3 M Trinatriumcitrate, 3 M NaCl, pH 7,0 adjusted with HCl 
TAE  buffer:    40 mM Tris acetate, 2 mM EDTA pH 8.0 
TBS-Tween buffer:  150 mM NaCl, 10 mM Tris/HCl, pH 8,0,  0,05% Tween 20 
TE Buffer:   10 mM Tris/HCl, 1 mM EDTA, pH 8,0 
Transfer Buffer:   47,9 mM Tris, 38,6 mM Glycin, 0,04% (w/v) SDS, 20% (v/v) Methanol 
Triton-X lysis buffer:  50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% TritonX-100 
 
2.1.6  Antibodies 
 
Anti-ß-Actin, mouse (Sigma); Anti-Caspase-3 (CPP32), mouse (Pharmingen - Transduction Labor-
atories); Anti-Cathepsin B, mouse (Oncogene, Ab-2); Anti-Cathepsin D, mouse (Oncogene, Ab-1); 
Anti-Cathepsin-L, mouse (Pharmingen - Transduction Laboratories); Anti-Cyclin-B1, mouse 
(Promega); Anti-HA High affinity, rat (Roche, Basel); Anti-Mouse IgG, HRP-gekoppelt, goat 
(Amersham-Pharmacia); Anti-p21, mouse (Promega); Anti-p27, mouse (Promega); Anti-Rabbit IgG, 
HRP-gekoppelt, goat (Amersham-Pharmacia); Anti-Rat IgG, HRP-gekoppelt, goat (Amersham-
Pharmacia); Anti-Tim-23, mouse (Pharmingen - Transduction Laboratories); Anti-Ubiquitin, rabbit 
(Sigma);  
 
2.1.7  Oligonucleotides 
 
For RT PCR cloning of human ubiquitin-specific proteases (USPs): 
 
 
Outer primers (for first round of “nested PCR”): 
 
hUBP41 Fwd outer:    ATgCTCAACAAAgCCAAgAATT 
hUBP41 Rev outer:   gAAAggAAAAAAgggACgTg 
  
hUSP18 Fwd outer:   CTgggggTTTTggAgTgATC 
hUSP18 Rev outer:   CCAggAACggAAATggAAAA 
 
hUSP21 Fwd outer:   CCCTgTTCAgCATACggACA 
hUSP21 Rev outer:   TAAAgggCTTCACAggTgCC 
 
 
Inner primers (containing restriction site linkers and Kozak sequence for cloning into pHA vector) : 
 
hUBP41-HA Fwd:    ATAT AAgCTT CCACC ATgCTCAACAAAgCCAAgAATT 
hUBP41-HA Rev:   ATTT gcggccgc A CATTCgggAgggCgggC 
 
hUSP18-HA Fwd:   ATAT ggTACC CCACC ATGAGCAAGGCGTTTGGGC 
hUSP18-HA Rev:   ATTT gcggccgc A GCACTCCATCTTCATGTAA 
 
hUSP21-HA Fwd:   ATAT ggTACC CCACC ATGATATCCGCCCGGTCCTC 
hUSP21-HA Rev:   ATTT gcggccgc A CAGGCACCGgggTggcT 
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For site-directed mutagenesis of the active site of the USPs: 
 
hUBP41 C24A Fwd:  gggAACACggCCTTCATgAACT 
hUBP41 C24A Rev:  AgTTCATgAAggCCgTgTTCCC 
 
hUSP18 C64A Fwd:  ggACAgACCgCCTgCCTTAAC 
hUSP18 C64A Rev:  gTTAAggCAggCggTCTgTCC 
 
hUSP21 C37A Fwd:  gAAACACggCCTTCCTgAATg 
hUSP21 C37A Rev:  CATTCAggAAggCCgTgTTTC 
 
 
 
For the ImmunoPeptide (IP-B) fragment for insertion into pGex-4T-1: 
 
IP-B Fwd:   ATATggATCCAACgAggTgAACCgAgTg 
IP-B Rev:   ATTTgCggCCgCTTTTCTCCACATCTgTCg 
 
 
 
 
For RT PCR cloning of human ubiquitin from human poly-ubiquitin gene cDNA: 
 
hUbiquitin Fwd:  ATAT ggTACC T CCACC ATgCAgATCTTCgTgAAgAC 
hUbiquitin Rev:  ATTT gCggCCgC CTACCCACCTCTgAgACggAgT 
 
 
 
For site-directed mutagenesis of human ubiquitin: 
 
hUbiquitin K48R Fwd:  CTTTgCCggAAgACAgCTgg 
hUbiquitin K48R Rev:  CCAgCTgTCTTCCggCAAAg 
 
hUbiquitin G76A Rev:  ATTT gCggCCgC CTACgCACCTCTgAgACggAgT 
 
 
 
 
For RT PCR cloning of human cathepsins: 
 
 
hCath-L Fwd:   ATAT ggATCC AgATATgAATCCTACACTCATC 
hCath-L Rev:   ATTT CTCgAg gTCAAgTCCTTCCTCATCAC 
 
hCath-B Fwd:   ATAT ggATCC CCAACATgTggCAgCTCTgg 
hCath-B Rev:   ATTT CTCgAg ACAggCCCACggCAgATTAg 
 
hCath-D Fwd:   ATAT AAgCTT CgCCATgCAgCCCTCCAgC 
hCath-D Rev:   ATTT CTCgAg gCCTTgggAACTAgAggCgg 
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For RNAi experiments using the pSUPER vector: 
 
 
pSuper-hUBP41-#1 sense: gATCTCCCACTCgggAgTTgAgAgATTTCAAgA… 
                            …gAATCTCTCAACTCCCgAgTgTTTTTggAAA 
 
pSuper-hUBP41-#1 antisense: AgCTTTTCCAAAAACACTCgggAgTTgAgAgATT… 
   …CTCTTgAAATCTCTCAACTCCCgAgTgggA 
 
pSuper-hUBP41-#2 sense: gATCTCCCCTCgATCATCTTCCTgATTTCAAgAgAA… 
    …TCAggAAgATgATCgAggTTTTTggAAA 
 
pSuper-hUBP41-#2 antisense: AgCTTTTCCAAAAACCTCgATCATCTTCCTgATTCTCTT… 
    … gAAATCAggAAgATgATCgAggggA 
 
pSuper-hCath-L sense:  gATCTCCgAATTgCCTCAgCTACTCTTTCAAgAgAA… 
    … gAgTAgCTgAggCAATTCTTTTTggAAA 
 
pSuper-hCath-L antisense: AgCTTTTCCAAAAAgAATTgCCTCAgCTACTCTTCTC… 
    … TTgAAAgAgTAgCTgAggCAATTCggA 
 
pSuper-hCath-B sense:  gATCTCCCgTgTCggATgAgCTggTCTTCAAgAgAgA… 
    …CCAgCTCATCCgACACgTTTTTggAAA 
 
pSuper-hCath-B antisense: AgCTTTTCCAAAAACgTgTCggATgAgCTggTCTCTC… 
    …TTgAAgACCAgCTCATCCgACACgggA 
 
  
 
2.1.8  Plasmid Clones 
 
For cloning, following standard plasmids were used: 
pcDNA3 (Invitrogen, eukaryotic expression vector with CMV promoter), pcDNA3∆ (pcDNA3 with 
neomycin resistance gene deleted), pHA(3’) (based on pcDNA3∆ for C-terminal HA-tagging), 
pEYFP(3’) (based on pcDNA3∆ with C-terminal EYFP-tag inserted between the XhoI, XbaI 
restriction sites with reading frame being compatible to that of the pHA(3’) vector when using the 
NotI site for cloning), and pGex-4T-1 (Amersham, for N-terminal GST-tagging). For RNAi 
experiments, annealed oligonucleotides for the target sequence were ligated into the pSuper vector 
(Oligoengine). 
 
Clone in vector 5’ cloning site 3’ cloning site
  
hUBP41-HA pHA(3’) Hind III Not I
hUBP41-C24A-HA pHA(3’) Hind III Not I
hUSP18-HA pHA(3’) Kpn I Not I
hUSP18-C64A-HA pHA(3’) Kpn I Not I
hUSP21-HA pHA(3’) Kpn I Not I
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hUSP21-C37A-HA pHA(3’) Kpn I Not I
  
hUBP41-EYFP pEYFP(3’) Hind III Not I
hUBP41-C24A-EYFP pEYFP(3’) Hind III Not I
hUSP18-EYFP pEYFP(3’) Kpn I Not I
hUSP18-C64A-EYFP pEYFP(3’) Kpn I Not I
hUSP21-EYFP pEYFP(3’) Kpn I Not I
hUSP21-C37A-EYFP pEYFP(3’) Kpn I Not I
  
GST-IP-B pGex-4T-1 BamH I Not I
  
hUbiquitin-HA pHA(3’) Kpn I Not I
hUbiquitin-K48R,G76A-HA pHA(3’) Kpn I Not I
  
hCathepsin-L pcDNA3∆ BamH I Xho I
hCathepsin-B pcDNA3∆ BamH I Xho I
hCathepsin-D pcDNA3∆ Hindd III Xho I
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2.2  Methods 
 
2.2.1  Prokaryotic Cell Culture 
 
E.coli DH5α [Hanahan, 1983] and E.coli Sure cells (Stratagene, La Jolla, USA) were used for 
transformation and extraction of plasmid DNA, whereas protease deficient E.coli BL21 cells were 
used for recombinant protein expression. All E.coli straines were grown in liquid LB medium (LB 
Broth, Sigma) in a shaking incubator at 37°C or on LB-Agar (Sigma) at 37°C. 
 
2.2.2  Transformation of E.coli 
 
Chemo-competent E.coli cells were used for transformation. For generation of chemo-competent cells, 
a pre-culture of E.coli was grown in 100 ml LB medium containing 50 µg/ml tetracyclin up to an OD 
(600 nm) of 1. Cells were then cooled down on ice, spun down (10 min, 4000 rpm, 4°C) and 
resuspended in 20 ml of icecold 0.1 M CaCl2. After centrifugation the pellet was resuspended in 4 ml 
of 0.1 M CaCl2, then 830 µl of glycerol (87%) were added and aliquots were frozen at -80°C. For 
transformation, aliquots of chemo-competent E.coli were thawn on ice, the corresponding plasmid 
DNA was added to the cells. After 15 min of incubation on ice, the cells were treated by heat shock 
(45 s at 42°C) with subsequent quick chill on ice (1 min). Then 1 ml of SOC medium (2% tryptone, 
0.5% yeast extract, 10 mM NaCl, 10 mM MgCl2, 10 mM MgSO4, 2.5 mM KCl, 20 mM glucose) was 
added to the transformed cells for incubation at 37°C for 30 min in order to give the cells time for 
resistance gene expression. Afterwards, transformed E.coli were either given into LB medium 
containing the appropriate antibiotic (usually 100 µg/ml ampicillin) or were plated onto LB agar 
containing the appropriate antibiotic (usually 100 µg/ml ampicillin) and cultured over night. 
 
2.2.3  Extraction of plasmid DNA from E.coli 
 
For extraction of plasmid DNA from transformed E.coli, the transformed bacteria were grown in a 
shaking incubator at 37°C over night in a volume of 3 ml LB (miniprep) or 100 ml LB (maxiprep). 
The plasmid DNA was extracted from the cells using the QIAprep Spin Miniprep (Qiagen) or the 
QIAGEN Plasmid Maxi Prep (Qiagen) according to the manufacturers instructions.  
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2.2.4  Eukaryotic cell culture 
 
Eukaryotic cell culture was performed under a laminar flow hood (Heraeus, Hanau) using sterile glass 
pipets and disposable plastic cell culture dishes (Greiner, Solingen, Nunc, Wiesbaden). Cells were 
maintained in DMEM (HeLa, 293T, McA RH 7777 cells) or RPMI (PC3 cells) supplemented with 
10% fetal bovine serum (FBS), 2 mM glutamine, 1 mM Na-pyruvate, 100 U/ml penicillin and 0.1 
mg/ml streptomycin. Cells were kept at 5% CO2 and 37°C in an incubator (Heraeus, Hanau). Cells 
were harvested by washing the cells once with PBS and subsequent incubation with 0,25% trypsine 
solution for approximately 5 min at 37°C. The detached cells were transferred into a sterile tube 
containing 5 ml of complete medium (for inactivation of trypsine). After centrifugation for 2 min at 
250g the supernatant was removed by aspiration and the cell pellet was resuspended in fresh medium 
and distributed to culture dishes of the desired format. Cells were splitted and reseeded every 2-3 days. 
For long-term storage, eukaryotic cells were harvested as described and resuspended at a concentration 
of about 107 cells per ml medium. Then an equal volume of 2x Freezing Medium (appropriate culture 
medium containing 20% FCS and 20% DMSO) was added and aliquots of 1.8 ml were immediately 
transferred into cryo-vials and cooled down to –80°C. Subsequently cells were transferred into liquid 
nitrogen. For bringing frozen cells back to culture, cells were rapidly thawn, washed in culture 
medium and seeded in 10 cm culture dishes. 
 
2.2.5  Transfection of eukaryotic cells 
 
2.2.5.1 Transfection of 293T cells 
 
293T cells were transfected by the calcium phosphate transfection method. The cells were seeded one 
day prior to transfection so that on the day of transfection the cell density was about 70%. About 30 
min prior to transfection, chloroquine was added to the cells at a final concentration of 40 µM. For the 
6 well format, 2 µg plasmid DNA (plus 0.2 µg of pEGFP vector as transfection control) was diluted to 
90 µl final volume in water. 10 µl CaCl2 (2.5 M) were added to the DNA and subsequently 100 µl of 
2xHBS buffer (280mM NaCl,1.5mM Na2HPO4, 50mM Hepes) at a pH between 6.9 and 7.1 
(empirically to be determined). After 10-15 min of incubation at RT the DNA precipitate was added to 
the cells and incubated for 6 h under culture conditions whereafter medium was changed. Transfection 
efficiencies as determined by the percentage of EGFP-positive cells (FACS analysis) were usually 
approximately 50 to 60 percent. Up- and downscaling of the protocol was possible taking into account 
the size of the well or culture dish used. 
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2.2.5.2 Transfection of HeLa cells 
 
HeLa cells were transfected using the Effectene transfection reagent (Qiagen). The cells were seeded 
one day prior to transfection so that on the day of transfection the cell density was about 70%. For the 
10 cm culture dish format, 0.8 µg plasmid DNA was diluted in 400 µl of EC-Buffer together with 0.2 
µg pEGFP vector (Clontech). 6.4 µl Enhancer was added, thoroughly mixed, incubated for 5 min, and 
then 8.0 µl Effectene were added with subsequent incubation of 15 min at RT. During incubation 
times, the cells were prepared for transfection by washing with PBS and addition of 10 ml fresh RPMI 
(10% FCS) medium. The DNA-Effectene complex was added to the prepared cells and was kept in the 
medium for 6 to 10 hours. Then the cells were washed once with PBS and supplied with fresh 
medium. Transfection efficiencies as determined by the percentage of EGFP-positive cells (FACS 
analysis) were approximately 70 to 80 percent. If even higher eficiencies or stronger expression was 
required, the described transfection protocol was changed by using double the amounts of DNA, 
Enhancer and Effectene in the same volume of EC-Buffer (400 µl). Up- and downscaling of the 
protocol was possible taking into account the size of the well or culture dish used.   
 
2.2.5.3  Transfection of PC3 and McA RH 7777 cells 
 
PC3 and McA RH 7777 cells were transfected using the Effectene transfection reagent (Qiagen) 
according to the protocol described for HeLa cell transfection using 1.6 µg DNA, 12.8 µl Enhancer 
and 16 µl Effectene in 400 µl EC-Buffer for the 10 cm culture dish format. Transfection efficiencies as 
determined by the percentage of EGFP-positive cells (FACS analysis) were approximately 40 to 50 
percent. Up- and downscaling of the protocol was possible taking into account the size of the well or 
culture dish used. 
 
2.2.5.4  Transfection for generation of stable pool clones 
 
Cells were transfected with the pcDNA3 vector containing either the coding sequence of cathepsin-L 
or cathepsin-B. Since the pcDNA3 vector carries a neomycin resistance gene which codes for an 
aminoglycoside-phosphotransferase, transfected cells could be selected by treatment with the 
antibiotic geneticin (G418) at a concentration of 400 µM. Surviving cells were continously kept in 
presence of G418 and checked for stable integration of the expression plasmid by immunoblot and 
cathepsin enzymatic assay. 
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Fig. 3.1 
The screening procedure for 
dominant apoptosis-
inducing genes. For details 
see the text in paragraph 2.2.6 
and paragraph 3.1.1. 
2.2.6  The Screen for dominant apoptosis-inducing genes 
 
The screen was performed as described by Grimm and Leder [Grimm, 1997]. For the generation of a 
normalized cDNA library , mRNA was extracted from kidneys of 4-6 week-old FVB mice. 
Normalization  of this mRNA was achieved by its hybridization with first strand cDNA during which 
highly abundant mRNA species associate much more rapidly than rare mRNA species. After two 
rounds of hybridization, the non-associated, normalized mRNA was used as template for cDNA 
synthesis using a cDNA synthesis kit (Gibco BRL) and the obtained cDNA was ligated into the 
pcDNA3.1 vector lacking the neomycin resistance cassette, designated pcDNA3d, via a BstXI adaptor 
and NotI digest. The plasmids were then transformed into E.coli SURE cells  thus delivering the 
desired cDNA library. Transformed bacteria were diluted and subsequently seeded into 96 deep-well 
plates in a way that on the average a pool of only a few different E.coli clones (corresponding to about 
5 different cDNAs per pool) were raised within each single well. Plasmid DNA was prepared from the 
96-well bacteria cultures and transfected into 293T human kidney cells using the calcium phosphate 
method in a 24 well format. The bacteria pool whose plasmid DNA caused morphological signs of 
apoptosis in the transfected 293T cells was identified and spread on plates. Plasmid DNAs from 
individual bacteria colonies were again transfected into 293T cells to isolate the active clone. 
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2.2.7  Apoptosis and Cell Death Assays 
 
2.2.7.1 DNA ladder 
 
Floating cells and adherent cells were combined by harvesting with a cell scraper. After centrifugation 
at 800g for 2 min, the cells were taken up in 1 ml PBS and transfered into a microfuge tube and spun 
down at 800g for 2 min. The pellet was resuspended in Hypotonic Lysis Buffer B (10 mM Tris-HCl, 
10 mM EDTA, 0.2% Triton X-100, pH 7.2) and incubated on ice for 10 min. After centrifugation for 
10 min at 14000 rpm at 4 degrees celsius in a microfuge, the supernatant was transfered into a new 
microfuge tube, and 1 volume equilibrated phenol solution (Roth) was added and mixed by vortexing. 
Then the samples were spun for 10 min at 14000 rpm at RT: the liquid upper phase was transfered into 
a new microfuge tube and mixed with 1 volume of phenol/chloroform (1:1) solution (Roth).  After 
centrifugation for 10 min at 14000 rpm at RT the liquid upper phase was transfered into a new tube 
and first 45 µl of 5 M NaCl and then 1.5 ml icecold ethanol were added following incubation for at 
least 2h at -20 degrees celsius. The sample was spun at maximum speed in a microfuge at 4 degrees 
celsius and the DNA pellet was air dried. The pellet was redissolved in 15 µl TE buffer by incubation 
at 50 degrees celsius for at least 1 h. Then 3 µl of RNase A (10 mg/ml, Qiagen) were added and 
incubation at 37 degrees celsius for 90 min followed. The sample was mixed with loading buffer (15% 
Ficoll type 400, 0.05 % bromphenolblue) and loaded onto a 2% agarose gel (Biomol) containing  0.5 
µg/ml ethidiumbromide. The gel was run at 60 V for about 2.5 h, and the gel monitored with the Eagle 
Eye II system (Stratagen). 
 
 
2.2.7.2 PI FACS analysis of HeLa cells and McA RH 7777 cells 
 
Cells were harvested by trypsination, resuspended in PBS and taken up in 3 volumes of hypotonic PI-
buffer (20 µg/ml propidium iodide, 0.1% w/v Na-citrate, 0.1% Triton X-100 in PBS). The resulting 
cell nuclei were analysed by flow cytometry for sub-G1 DNA content using the FACScalibur (BD) 
machine in FL-2 and subsequent evaluation using the CellQuest Software allowing to calculate the 
percentage of cells containing fragmented DNA. If not indicated different, the apoptotic cell 
population was calculated by taking into account the percentage of transfected, i.e. GFP-positive cells 
which was determined in parallel by FACS analysis in FL-1 using an aliquot of the corresponding cell 
sample. Each datapoint was usually represented by triplicates and the result was confirmed in several 
independent experiments. 
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2.2.7.3 PI FACS analysis of 293T cells 
 
DNA fragmentation in 293T cells by PI FACS analysis was determined applying a more sensitive 
protocol including a citrate-phosphate buffer extraction step essentially as described by Gong et al 
[Gong, 1994]. In brief, the cells were harvested by trypsination, resuspended in Hanks buffered saline 
and fixed by addition of 10 volumes of 70% ethanol and subsequent storage for several hours at -20 
degrees celsius. The cells were spun down at 800g for 5 min and the ethanol thoroughly removed. 
Then the cells were resuspended in 500 µl of phosphate-citrate buffer consisting of 192 parts of 0.2 M 
Na2HPO4 and 8 parts of 0.1 M citric acid (pH 7.8), and incubated at RT for at least 30 min. After 
centrifugation at 1000g for 5 min, the supernatant was removed, and the pellet resuspended in PBS 
containing 20 µg/ml propidium-iodide. The cells were then analysed by FACS as described above for 
PI FACS analysis of HeLa cells. 
 
2.2.7.4 Caspase-3 Activity Assay 
 
The caspase-3 activity assay was purchased from Roche and was used as recommended. Each 
datapoint was measured at least in triplicates and was confirmed by several independent experiments. 
Alternatively to the expensive Roche Caspase-3 Activity Assay kit, a procedure was developed that is 
similar to the Roche Kit protocol but uses own reagent components. The cells were harvested, washed 
twice with PBS, and then lysed 5 min on ice in Caspase-3 Activity Buffer (CAB: 10 mM HEPES pH 
7.2, 50 mM KCl, 2 mM MgCl2, 5 mM EGTA, 0.5% Igepal) containing freshly added aprotinin, 
leupeptin, pepstatin at a final concentration of each 2 µg/ml as well as 1mM PMSF and 10 mM DTT. 
After centrifugation (10,000 rpm, 8 min, 4°C) the supernatants were transferred into a new microtube 
and the protein concentration was measured using the Bradford assay. The extracts were preferentially 
directly used for the subsequent caspase assay (without being frozen), and thus samples were kept on 
ice until used. For the caspase-3 activity assay, a 96 well fluorescence microtiter plate (FluoroNUNC 
C96 white MaxiSorp, NUNC) was coated with 2.5 µg/ml of the anti-CPP32 monoclonal antibody 
(Transduction Laboratories, clone 19) in 100 µl of Antibody Coating Buffer (50 mM Na2CO3, pH 
9.6) for 1 hour at 37°C. Then the plate was blocked with 3 mg/ml BSA in PBS for 30 min at RT. After 
washing the wells of the plate 3 times with CAB buffer, 100 µg/well protein extract in a total volume 
of 100 µl (adjusted with CAB buffer) were incubated for 1 hour at 37°C. Then the wells were washed 
3 times with CAB buffer, and finally 50 µM zDEVD-AMC caspase-3 substrate in 100 µl CAB buffer 
(freshly supplemented with 10 mM DTT) were added to the wells. After incubation in the dark for 2 
hours at 37°C, AMC fluorescence was measured with a Fluoroskan Ascent FL fluorecence plate 
reader (Labsystems) at a wavelength of 380 nm for excitation and 450 nm for emission. 
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2.2.7.5 MTT proliferation / viability assay 
 
Cells were transfected in 10 cm petri dishes as described, 24h later cells were harvested and reseeded 
in equal numbers (approximately 7500  cells/well) in the wells of 96 well plates. 24h after reseeding, 
cells were treated as indicated in a total volume of 100 µl DME-Medium. At time of analysis, 10 µl of 
a MTT stock solution (5 mg/ml in PBS) was added per well and cells were incubated for 4h at 37°C 
and 5% CO2. Then 100 µl of 0.04 N HCl in 2-propanol was added to the wells and mixed vigorously 
with a multichannel pipet. Within an hour, formazan absorbance was measured on an ELISA plate 
reader (Dynatech MR7000) at 590 nm and a reference wavelength of  750 nm. The blank value (MTT 
in absence of cells) was substracted from all sample values and results were calculated in terms of 
“loss of viability, %” according to following equation: (U – S) / U * 100, where U = absorption value 
of untreated control, S = absorption value of sample.  
 
2.2.8  Protein- and Immunochemical Methods 
 
2.2.8.1  Immuno Blotting (Western Blotting) 
 
For detecting protein expression, cells were harvested by trypsinization, washed with PBS, and lysed 
in TritonX buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% TritonX-100) 10 min on ice. After 
centrifugation at 14,000xg in a microfuge, supernatants were obtained as cytoplasmic extracts which 
were quantified for protein content using the Bradford reagent (BioRad). Equal amounts of protein 
were loaded after boiling with 1 volume of 2x sample buffer (100 mM Tris-HCl pH 6.8, 4% SDS, 
10% mercaptoethanol, 20% glycerol, 0.05% bromophenolblue) on a 12% SDS-polyacrylamide gel 
(stacking gel: 4.8% PA, 125 mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% APS, 0,1% TEMED;   separating 
gel 10-15% PA, 375 mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS, 0,05% TEMED), separated in an 
electric field of approximately 20 V/cm in Running Buffer (25 mM Tris, 192 mM Glycin, 0,1% (w/v) 
SDS), and transferred to a PVDF membrane in a semidry blotting device using Transfer Buffer (47,9 
mM Tris, 38,6 mM Glycin, 0,037% (w/v) SDS, 20% (v/v) Methanol) and an electric field 
corresponding to about 4 mA/cm2 of PVDF membrane with a blotting time of 1 h. The membrane was 
blocked for 1h with 5% drymilk powder in TBS-Tween (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 
0.05% Tween) and probed overnight at 4 degrees celsius with primary antibodies at appropriate 
dilution (usually about 1 µg/ml). Membranes were washed three times with milk, and then were 
probed for 1h at RT with secondary HRP-conjugated antibodies (usually at 1:5000 dilution, Roche). 
After washing four times with TBS-tween, the blot was developed using Super Signal enhanced 
chemiluminescence reagents (Pierce) and by exposition to BioMax MR films (Kodak). 
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2.2.8.2  Coomassie and Ponceau staining 
 
Proteins in polyacrylamid gels were stained using Coomassie Brilliant Blue staining solution 
(Coomassie Blue R250 in 10% acetic acid, 50% methanol, and 40% H2O), and destained with 10% 
acetic acid, 50% methanol, and 40% H2O. Proteins on PVDF blotting membranes were visualized 
using reversible Ponceau staining (0.1% Ponceau S in 5% acetic acid). 
 
 
2.2.8.3 Immunofluorescence 
 
Cells were seeded on cover glasses and 24h later were incubated for 16h in absence or presence of 
NDI-HCl, CHX, or TNF-α/CHX. Cells were then fixed with methanol for 5 min at RT. Then cells 
were incubated for at least 30 min in blocking buffer (PBS supplemented with 10% FCS and 0.1% 
Triton-X). Then cells were incubated with anti-Cath-L mAb (1:100, Transduction Laboratories, cat 
#78820) in blocking buffer for 45 min. After 3 times washing with blocking buffer, cells were 
incubated with a FITC-conjugated polyclonal Ab (1:500, Pharmingen, cat #12064D) for 45 min. Cells 
were then washed again several times in blocking buffer and finally placed on object slides in 
embedding buffer (0.5 M Tris-HCl pH 8.2, 0.02 g/ml DTT, 0.04 g/ml polyvinyl alcohol, 40% 
glycerol). Fluorescence was observed under a fluorescence microscope (Axioscop 2, Zeiss, Jena, 
Germany) and pictures taken with a digital camera (Visitron Systems, Puchheim, Germany) using the 
IPLab imaging software (Spectra Services, NY, USA). 
 
 
2.2.8.4 Generation of polyclonal antibodies 
 
2.2.8.4.1 Expression of GST-fusion proteins  
 
The antigenic UBP41 peptide for the immunization of a rabbit was expressed as a GST-fusion protein. 
The DNA fragment encoding the amino acids residues 119-150 of hUBP41 was generated by PCR and 
was cloned in frame with GST into the pGEX.4T1 (?) expression vector. The resulting GST-IP-B (IP-
B stands for Immuno Peptide B) construct was transformed into E.coli BL21 cells which were seeded 
for an overnight preculture in 50 ml LB medium containing 100 µg/ml ampicillin. 4 ml of the 
preculture were then transferred into 500 ml LB medium containing 100 µg/ml ampicillin and were 
further incubated. When the cell density reached an OD (600 nm) of 0.5, IPTG was added to a final 
concentration of 1 mM (1:1000 of a 1M IPTG stock solution) and the bacteria were incubated for 
another 3 hours. The bacteria were harvested by centrifugation and the pellet could be stored at –80°C 
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or it was immediately resuspended thoroughly in PBS whereafter lysozyme was added to a 
concentration of 1 mg/ml with subsequent incubation on ice for 30 min. The bacteria were then lysed 
by sonification for 10 min in a pulse modus (sonificator) and the cell extract was obtained after 
centrifugation (20,000g,  4°C, 10 min) as the supernatant. Since the extracts were frequently still 
cloudy, they were usually cleared by ultracentrifugation (100,000g for 30 min at 4°C) using 
ultracentrifuge model.   
 
2.2.8.4.2 Purification of GST-fusion proteins 
 
Glutathione Sepharose beads suspension (Amersham) were washed 3 times in an equal volume of PBS 
supplemented with 500 mM NaCl and 1 mM EDTA. Beads were intermediately kept on a rotating 
wheel and were pelleted at 500g. Washed beads were incubated with GST-fusion protein (e.g. GST-
IP-B) for 1 hour on the rotating wheel at 4°C (50 ml extract + approximately 1.5 ml bead bed volume). 
The beads were then given onto a disposable plastic column (BioRad) and washed with 100 x bed 
volumes PBS supplemented with 500 mM NaCl + 1 mM EDTA + 1 mM DTT (icecold). After 
washing, the GST-fusion protein was eluted in two 5 ml fractions of PBS containing 50 mM 
glutathione. Successful expression and purification of the GST-peptides was checked by SDS PAGE 
and subsequent Coomassie staining of the gel. Following purification on the GSH-sepharose affinity 
column, the obtained eluate was further purified on a small Sephadex G200 gel filtration column 
(Pharmacia). 0.5 ml fractions were collected and the fractions containing the desired protein were 
identified by SDS PAGE / coomassie staining. 
 
2.2.8.4.3 Immunization of rabbit against hUBP41 
 
Rabbits were immunized using an antigenic peptide consisting of amino acids 119-150 of hUBP41 as 
a fusion protein with GST (GST-IP-B) for appropriate expression and purification as described above. 
For initiation of the immunization, 100 µg of GST-IP-B in a volume of 500 µl PBS were emulsified 
with 500 µl Titer Max Gold adjuvant (Sigma) using two syringes and a double hub emulsifier needle 
system. The emulsion was then injected intramuscularly using a 18 gauge needle. On day 30, the 
animal was boosted with another 100 µg of antigen (500 µl) which this time was emulsified in an 
equal volume of Freund Adjuvant (Sigma). On day 43, a small blood sample (3 ml) was drawn from 
the animal and serum prepared as follows: blood was stirred for 1 min with a glass pasteur pipet, then 
the blood was kept at 4°C over night, after repeated stirring with a pasteur pipet the blood was 
centrifuged at 5000g for 30 min and the supernatant taken as serum. The titer of the serum was tested 
by immunoblot analysis using the serum at a dilution of 1:5000. The serum was able to recognize 
overexpressed hUBP41-HA in HeLa extracts as well as 50 ng of the GST-IP-B antigen itself. The 
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animal was boosted one more time using 200 µg of GST-IP-B in Freund Adjuvant on day 44 and was 
killed by bleeding on day 70 giving approximately 100 ml blood. Serum was prepared on the larger 
scale as descibed above. 
 
2.2.8.4.4 Affinity purification of the polyclonal anti-hUBP41 antibodies 
 
For affinity purification, GST as well as the GST-linked hUBP41 immunopeptide GST-IP-B were 
expressed and purified over a GSH column from 2 l cultures of BL21 E.coli. Yield was 30 µg protein 
in 10 ml PBS containing 10 mM glutathione and protein inhibitor cocktail (Roche). 3 ml of the GSH-
purified protein eluate were dialysed against 5 l of Dialysis Buffer (200 mM NaCl + 0.1 M NaHCO3, 
pH8.3) over night at 4°C using a 6-8 kDa membrane to remove GSH and protein inhibitors. Dialysis 
buffer was exchanged the next morning and dialysis continued for another 3 h. After dialysis the 
protein concentration was still 3 µg/ml as measured by Bradford assay with a total volume of about 3 
ml. 1.5 g of freeze-dried CNBr-activated sepharose 4B (Amersham) was prepared by swelling in 50 
ml of 1 mM HCl and subsequent washing twice in 50 ml 1 mM HCl and once in 50 ml Coupling 
Buffer (0.1M NaHCO3 + 500 mM NaCl, pH 8.3). For coupling, 3 ml of  dialysed GST (approximately 
10 mg) and 1 ml of dialysed GST-IP-B (about 3 mg) were added to approximately 3 ml swollen beads 
of the prepared CNBr-activated sepharose 4B in a total volume of 13 ml adjusted with Coupling 
Buffer and kept on a rotator at 4°C over night. Then the beads were spun down at 1500xg for 2 min 
and in the supernatants no protein could be detected anymore. For blocking of remaining CNBr active 
sites, beads were incubated for 2 h at 4°C with 25 ml of 0.1 M Tris-HCl, pH 8.0. Then beads were 
washed in three cycles of first 5 volumes of Acetate Buffer (0.1 M acetate, pH 4.0), then 5 volumes of 
0.1 M Tris-HCl, pH 8.0 + 500 mM NaCl. For immunodepleting anti-GST antibodies from the GST-IP-
B-immunized rabbit antiserum, 20 ml of the serum were incubated on a rotating wheel overnight at 
4°C with the GST-coupled beads in a final volume of about 50 ml by filling up with PBS. Beads were 
spun down (from which anti-GST antibodies could be eluted as described below for anti-hUBP41 
antibodies), and the supernatant was transferred to the GST-IP-B-coupled sepharose beads with 
subsequent incubation over night at 4°C on a rotating wheel. The beads were then washed several 
times with Washing Buffer (PBS + 500 mM NaCl) until no protein was detectable in the Washing 
Buffer as determined by Ponceau staining of samples spotted on nitrocellulose membranes. The beads 
were then loaded into a glass wool plugged pasteur pipet and washed again with 10 ml of Washing 
Buffer. Bound antibodies were eluted with Elution Buffer (0.2 M acetic acid, pH 2.7 +  500 mM NaCl) 
in about 400 µl fractions which were immediately neutralized by prelaid 100 µl of 1 M Tris base. 
Fractions were tested by spotting of 2 µl onto nitrocellulose and Ponceau staining. Protein was present 
in fractions 4 to 8 which were combined, aliquoted and frozen at –80°C. 1:5000 dilutions of the eluate 
were able to detect 50 ng of purified GST-IP-B as well as hUBP41-HA overexpressed in 293T cells. 
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2.2.9  DNA and RNA techniques 
 
2.2.9.1 Polymerase Chain Reaction (PCR) 
 
For the amplification of specific DNA fragments, the PCR technology was used which originally was 
developed by Kary B. Mullis in 1987 [Mullis, 1987]. Reactions were usually performed in a total 
volume of 50 µl containing 1 µl of DNA template (cDNA or plasmid DNA), 1 µl of 10 mM forward 
and reverse oliginucleotide primers (final concentration 200 nM of each primer), 1 µl of 10 mM dNTP 
mix (final concentration 200 µM of each nucleotide), 5 µl of 10x Reaction Buffer, and 1 µl 
polymerase. In most cases the Expand Long Template PCR System (Roche) was used. The reaction 
cycle profile was usually as follows: 30 s at 95°C for denaturation, 40 s at the appropriate annealing 
temperature, 90 s at 68°C for elongation, 28 cycles.  
 
2.2.9.2 Agarose gel electrophoresis of DNA 
 
Agarose gels were prepared at concentrations of 0.8% up to 1.5 % by boiling of the agarose in TAE 
Buffer. The dissolved agarose was poured into the electrophoresis chamber with a slot comb inserted 
into the forming gel which after solidification was covered with TAE Buffer. Up to  500 ng of a DNA 
sample was mixed with 1/5 volume of 6x Sample Buffer (0.25% Bromophenol blue + 15% Ficoll) and 
loaded into the gel slots together with size markers as a reference (Eurogentec). The gel was run at 
about 100 V and the separated DNA bands were visualized by staining of the gel in ethidium bromide 
solution (10 µg/ml in TAE Buffer), subsequent destaining in TAE Buffer and eventual illumination 
with UV light on a transilluminator with the Eagle-Eye II imaging system (Stratagene). 
 
2.2.9.3 Isolation of DNA from agarose gels 
 
For the isolation of DNA from agarose gels the Qui Quick Spin System (Qiagen) was used. 
 
2.2.9.4 Restriction reactions 
 
For specific cleavage of DNA fragments from plasmid vectors or generation of restiction sites from 
linker sequences, about 1 µg DNA was incubated for at least 2 h in presence of each 10 U of the 
respective restriction enzymes (usually in double digests) under the appropriate buffer conditions in 
usually 50 µl total volume. 
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2.2.9.5 Ligation reactions 
 
For ligation of a DNA fragment into a linearized vector, the appropriately restricted DNA fragments 
(about 50 ng of vector DNA and a 5-fold molar excess of insert fragment) were incubated over night at 
4°C with 10 U of T4 DNA ligase (New England Biolabs) in presence of Ligation Buffer in a total 
volume of 20 µl. 5 µl of the ligation reaction were usually taken for transformation of chemo-
competent E.coli.   
 
2.2.9.6 Dephosphorylation of vector DNA 
 
In order to prevent religation of incompletely cut vector DNA, the digested vector DNA was 
occasionally (when necessary) dephosphorylated by incubating 1 µg cut plasmid with 1 U of calf-
intestine alkaline phosphatase (CIAP) in presence of the appropriate buffer in a total volume of 20 µl. 
After 30 min incubation at 37°C, CIAP was inactivated by adding an equal volume of equilibrated 
phenol (Roth). After mixing for 5 min, phases were separated by centrifugation at 5000 rpm in a 
microcentrifuge for 5 min. The upper aqueous phase was transferred into a new microvial and 
incubated with an equal volume of a 1:1 mixture of equilibrated phenol/chloroform (Roth) as 
described for the phenol step. Finally, the aqueous phase was equilibrated with choroform as well. 
Then the aqueous phase was transferred into a new vial and precipitated by adding 1:10 volumes of 7 
M ammonium acetate and then 2 volumes of ice-cold ethanol for at least 30 min at –20°C. Afterwards, 
precipitated DNA was spun down at maximum speed in a microcentrifuge at 4°C and washed once 
with ice-cold 70% ethanol. After centrifugation, the (invisible) pellet was air-dried and dissolved in 
usually 20 µl sterile water. 
 
2.2.9.7 DNA Sequencing 
 
For DNA sequencing the Big Dye Terminator Cycle Sequencing RR-Mix (Applied Biosystems) was 
used based on the chain termination dideoxynucleotide method by Sanger [Sanger, 1977]. 0.5 µg 
template DNA were mixed with 0.8 pmol of a sequencing primer (usually T7 or BGH primer) and 4 µl 
of Big Dye Mix in a total volume of 20 µl. After 2 min of denaturation at 96°C, following 40 cycle 
profile was run: 10 s at 96°C for denaturation, 5 s at 50°C for annealing, 4 min at 60°C for elongation. 
The analysis by sequence gel electrophoresis was done by a commercial provider (SeqLab, 
Göttingen). 
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2.2.9.8 RNA isolation and generation of cDNA by RT PCR 
 
For isolation of total RNA from cultured cell lines, the RNeasy Kit (Qiagen) was used. For synthesis 
of cDNA from extracted total RNA, the Superscript II system (Gibco BRL) was applied according to 
the manufactorer’s recommendations. 
 
2.2.9.9  Northern Hybridization 
 
For the Multiple Tissue Northern (MTN) blot and the Matched Tumor/Normal Expression Array (both 
from Clontech), the coding sequence of hUBP41 was excised from the expression plasmid and 
approximately 25 ng were labelled with 5’-[α32P]-dCTP (3000 Ci/mmol, Amersham) using the 
RediPrime random prime labelling kit (Amersham). Excessive radioactive dCTP and random prime 
oligonucleotides were removed using the Nucleotide Removal Kit (Qiagen). Labelled probes were 
eluted in 200 µl TE and 2 µl of this eluate were tested for sufficient incorporation by measuring 
Cherenkov-radiation in a scintillation counter.  
The blots were prehybridized for 3h at 65 degrees celsius in 40 ml of Hybridization buffer (6x SSC, 5x 
Denhardt’s reagent, 0.5% SDS, sheared and freshly denatured 0.1 mg/ml salmon sperm DNA), then 10 
ml of a 50% dextrane sulfate solution was added, and finally the denatured, labbelled DNA probe 
(approximately 5x107 cpm) was added to the Hybridization solution and incubated at 62 degrees 
celsius for 16h. The blot was washed with Wash buffer 1 (4x SSC, 0.5% SDS) for 1h at 62 degrees 
celsius and then for 5 min with Wash buffer 2 (2x SSC, 0.5% SDS). The blot was exposed to a Fuji 
BAS 2500 phosphoimager screen and the signals analyzed and quantified using the Image Gauge 
V3.01 software. 
 
2.2.9.10 RNAi 
 
For targeted downregulation of gene expression, the RNAi technology was applied by using the pSuper 
vector system (Oligoengine) which is a mammalian expression vector that directs intracellular 
synthesis of siRNA-like transcripts. The vector uses the polymerase-III H1-RNA gene promoter, as it 
produces a small RNA transcript lacking a polyadenosine tail and has a well-defined start of 
transcription and a termination signal consisting of five thymidines in a row. Most important, the 
cleavage of the transcript at the termination site is after the second uridine, yielding a transcript 
resembling the ends of synthetic siRNAs, which also contain two 3’ overhanging T or U nucleotides. 
The pSuper knockdown constructs were obtained by inserting 64-mer synthetic DNA 
oligonucleotides, of which complementary sequences were annealed in a way that overhanging 
restriction sites were generated, into the Hind III / Bgl II restriction sites of pSuper.  
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The 64-nt oligonucleotides contained a 19-nt sequence which by databank analysis was determined to 
be unique for a portion of the target gene. Within the 64-nt oligos, the 19-nt target appears in both 
sense and antisense orientation, separated by a 9-nt spacer sequence. The resulting transcript is 
predicted to fold back on itself to form a 19–base pair stem-loop structure. Within the cell, the stem-
loop precursor transcript is quickly cleaved to produce a functional siRNA because the hairpin had 
been designed to be an optimal substrate for the enzyme Dicer, which cleaves the hairpins to generate 
the short dsRNA, both strands having the two-uridine 3’ overhang. This processed construct is an 
efficient effector of RNAi and complies with the design principles established for synthetic short 
interfering RNAs by the work of Tuschl and colleagues [Elbashir, 2001].  
 
pSuper cloning procedure: 
For annealing, each 1 µl of the sense and antisense oligonucleotide (3 µg/µl) were incubated in 48 µl 
of Annealing Buffer (100 mM KOAc + 30 mM HEPES-KOH pH 7.4 + 2 mM MgOAc) for 4 min at 
95°C, then for 10 min at 70°C with subsequent slow cool down to 4°C. The annealed oligos were 
phosphorylated by mixing 2 µl of the annealing reaction, 1 µl T4 PNK buffer, 1 µl ATP (10 mM), 1 µl 
T4 PNK, and 5 µl H2O. Following to incubation at 37°C for 30 min, the T4 PNK was inactivated by 
incubation at 70°C for 10 min. 2 µl of the phosphorylation reaction were ligated into the pSuper vector 
(which prior to its use in ligation was treated with calf intestine alkaline phosphatase (CIAP), 
subsequently purified with phenol/chloroform and precipitated with ethanol). 
 
2.2.10 Cathepsin zFR-AMC Enzymatic Assay 
 
Cells were left untreated or were transfected with pcDNA3d expression vector containing the ORFs of 
cathL, or cathB. The cells were harvested by trypsination, spun down at 400xg at 4°C for 3 min, 
washed 2x PBS, and the were lysed for 5 min on ice in SDS buffer A (50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 0.5 % NP-40, 0.05% SDS) in absence of proteinase inhibitors. Lysates were spun at 
maximum speed in a microfuge (14.000 rpm) at 4°C for 5 min and the supernatant was transferred into 
a new microtube. Extracts were preferentially immediately used for the enzymatic assay since freezing 
at   -80°C appears to result in a partial loss of enzymatic activity. Protein concentration of the samples 
were determined by the Bradford assay (BioRad), and 100 µg total protein (in a maximum of 50 µl 
lysate) were pipetted into 200 µl of Urea Buffer (20 mM NaOAc pH 5.0, 4 mM EDTA, 0.4 M urea), 
freshly substituted with 10 mM DTT and 400 µM zFR-AMC (i.e. 4 µl of a 20 mM stock solution of 
zFR-AMC in DMSO into 200 µl Urea Buffer, Enzyme Systems Products). Samples were incubated 
approximately for 1h at 37°C, and AMC fluorescence was measured with a Fluoroskan Ascent FL 
fluorescence plate reader (Labsystems) at a wavelength of 380 nm for excitation and 450 nm for 
emission.  
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2.2.11  Cell-free activation of caspases for inhibitor experiments with 
E64d 
 
Cytoplasmic extracts were prepared and activated by addition of cytochrome c and dATP in the 
absence or presence of various concentrations of E64d and were analysed by a caspase enzymatic 
assay essentially as described [Gewies, 2000b].  
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3 Results 
 
3.1  Identification and characterization of UBP41 as a 
dominant apoptosis-inducing factor 
3.1.1 Isolation of ubp41 in the genetic screening procedure for 
apoptosis-inducing genes 
 
For the identification of dominant apoptosis-inducing factors, the direct functional genetic screening 
procedure was applied as described by Grimm and Leder [Grimm, 1997]. In this screen, a normalized 
cDNA library was prepared from murine kidney tissue and was transformed into E.coli cells. The 
transformed E.coli cells were diluted and distributed into 96 well plates, in a way that per well only 
about 1 to 5 different cDNA clones were amplified. Plasmid DNA was prepared from those small 
bacteria pool clones and was transfected into human embryonic kidney 293T cells which subsequently 
were inspected microscopically for an  apoptotic phenotype. The plasmid DNA pools which upon 
transfection were identified to induce signs of apoptosis in 293T cells, were retransformed into E.coli 
and plasmid DNA from single colonies was extracted in order to identify the single cDNA clone that 
was responsible for apoptosis induction (for more details see Materials and Methods 2.2.6).  
 
The large-scale application of this screen in our laboratory led to the isolation of several cDNAs which 
dominantly induce apoptosis upon transient transfection into 293T cells. Some of those cDNAs were 
identified to be genes which were already known to be involved in apoptotic pathways and have the 
capacity to dominantly induce apoptosis upon overexpression such as FADD, ANT-1, CIDE-A and -B 
or ZIP kinase and which serve as positive controls for the functionality of the screen [Bauer, 1999; 
Chinnaiyan, 1995; Inohara, 1998; Kawai, 1998]. The adenine-nucleotide translocator 1, ANT-1, serves 
as an instructive example for the specificity by which the described screening procedure allows the 
identification of distinct apoptosis-inducing factors of potential physiological relevance: whereas 
overexpression of ANT-1 results in the induction of cell death, its highly conserved homologue ANT-
2 does not induce apoptosis. This observation indicates that the observed cell death is not 
unspecifically induced by an inappropriate accumulation of ANT-1 and concurrent misfolding of the 
ANT-1 protein within the inner mitochondrial membrane, because – if this were true – the same effect 
would have to be expected in case of the almost identical ANT-2 protein. Thus, ANT-1 appears to 
specifically exert its proapoptotic activity by acting as a component of the permeability transition pore 
complex which is known to play an essential role in the mediation of apoptosis signals at the 
mitochondria [Bauer, 1999].    
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One of the cDNA clones that was selected from the genetic screen (by myself in collaboration with 
Ulla Cramer) was designated UI64, which not only induced the typical apoptotic morphological 
changes in 293T cells but also produced oligonucleosomal DNA fragmentation as a hallmark event of 
apoptosis (Fig 3.1.1).  
 
 
 
 
DNA sequencing of the UI64 cDNA clone and sequence analysis (Fig 3.1.2) using BLAST [Altschul, 
1997] identified UI64 as the mouse orthologue (gi:7949157) of the ubiquitin-specific protease UBP41 
(also denominated USP2) which recently had been isolated and characterized in chicken skeletal 
muscle [Baek, 1997]. 
 
 
 
 
Fig. 3.1.1  
The cDNA clone UI64 causes cell death when transiently transfected into 293T cells.
(A) 293T cells were transfected with a control plasmid (left)or with the conpicuous plasmid
clone UI64 from the screen for dominant apoptosis inducing genes (right). 48h post
transfection, the phenotype was observed by phase contrast microscopy. (B) 293T cells
were transfected with a control plasmid or with UI64. 48h post transfection the cells were
harvested, DNA was extracted and separated on a 2% agarose gel, stained with
ethidiumbromide and visualized on a transilluminator. 
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                       Cys-Domain                                         
 
     UI64   ---------MNSKSAQGLAGLRNLGNTCFMNSILQCLSNTRELRDYCLQR 
   mUBP41   ----MLNKAKNSKSAQGLAGLRNLGNTCFMNSILQCLSNTRELRDYCLQR 
   hUBP41   ----MLNKAKNSKSAQGLAGLRNLGNTCFMNSILQCLSNTRELRDYCLQR 
   gUBP41   MAARMAPTPRSSKVVQGLTGLRNLGNTCFMNSILQCLSNTKELRDYCLQN 
 
                                                          
     UI64   LYMRDLGHTSSAHTALMEEFAKLIQTIWTSSPNDVVSPSEFKTQIQRYAP 
   mUBP41   LYMRDLGHTSSAHTALMEEFAKLIQTIWTSSPNDVVSPSEFKTQIQRYAP 
   hUBP41   LYMRDLHHGSNAHTALVEEFAKLIQTIWTSSPNDVVSPSEFKTQIQRYAP 
   gUBP41   QYLRDLNNNSRMRTALMSEFAKLIQLLWTSSPNDSVSPSEFKTQIQRYAP 
 
                        Asp-Domain               
                                                       
     UI64   RFMGYNQQDAQEFLRFLLDGLHNEVNRVAARPKASPETLDHLPDEEKGRQ 
   mUBP41   RFMGYNQQDAQEFLRFLLDGLHNEVNRVAARPKASPETLDHLPDEEKGRQ 
   hUBP41   RFVGYNQQDAQEFLRFLLDGLHNEVNRVTLRPKSNPENLDHLPDDEKGRQ 
   gUBP41   RFVGYNQQDAQEFLRFLLDGLHGEVNRVLVRPRANADTLDHLPDDEKSRQ 
 
                     Homology-Domain I 
                                                         
     UI64   MWRKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDXSLPIAKR 
   mUBP41   MWRKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDLSLPIAKR 
   hUBP41   MWRKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDLSLPIAKR 
   gUBP41   MWRRYQEREDSRVSDLFVGQLKSSLTCSECGYCSTAFDPFWDLSLPIPKK 
 
                 Homology- 
                                                        
     UI64   GYPEVTLMDCMRLFTKXDILDGDEKPTCCRCRARKRCIKKFSVQRFPKIL 
   mUBP41   GYPEVTLMDCMRLFTKEDILDGDEKPTCCRCRARKRCIKKFSVQRFPKIL 
   hUBP41   GYPEVTLMDCMRLFTKEDVLDGDEKPTCCRCRGRKRCIKKFSIQRFPKIL 
   gUBP41   GYGEVTLMDCLRLFTKEDVLDGDEKPTCCRCKARTRCTKKFSIQKFPKIL 
 
            Domain II                                     His- 
                                                        
     UI64   VLHLKRFSESRIRTSKLXTFVNFXLRDLDLREFASENXNHAVYNLYAVSN 
   mUBP41   VLHLKRFSESRIRTSKLTTFVNFPLRDLDLREFASENTNHAVYNLYAVSN 
   hUBP41   VLHLKRFSESRIRTSKLTTFVNFPLRDLDLREFASENTNHAVYNLYAVSN 
   gUBP41   VLHLKRFSEARIRASKLTTFVNFPLKDLDLREFASQSCNHAVYNLYAVSN 
 
            Domain                         Homology-Domain III 
                                                    
     UI64   HSGTXMGGXYTAYCRSPVTGEWHTFNDSSVTPMSSSQVRTSDAYLLFYEL 
   mUBP41   HSGTTMGGHYTAYCRSPVTGEWHTFNDSSVTPMSSSQVRTSDAYLLFYEL 
   hUBP41   HSGTTMGGHYTAYCRSPGTGEWHTFNDSSVTPMSSSQVRTSDAYLLFYEL 
   gUBP41   HSGTTMGGHYTAYCKSPISSEWHSFNDSRVTPMSSSHVRSSDAYLLFYEL 
 
             
     UI64   ASPPSRM 
   mUBP41   ASPPSRM 
   hUBP41   ASPPSRM 
   gUBP41   ASPSSRM 
 
 
For the isolation of the human orthologue of UBP41, PCR primers were designed based on the 
Genbank entry for hUBP41 (gi: 4759291) with the forward primer containing the start ATG and the 
reverse primer representing a region downstream of the stop codon. The obtained PCR product 
confirmed the published sequence with the exception of a few residues at the extreme carboxy-
terminus which was determined to be identical to the mouse amino acid sequence. Therefore, the PCR 
product was regarded to represent human UBP41, subsequently designated hUBP41. A carboxy-
terminal HA-tag sequence was added to  hUBP41, resulting in the HA-fusion protein hUBP41-HA for 
convenient detection in immunoblot analysis using anti-HA antibodies. Interestingly, the alignment of 
its human, murine, and chicken amino acid sequences (Fig. 3.1.2) indicates that UBP41 is highly 
conserved not only within the catalytic or homology domains but also in the regions in between those 
domains.  
Fig. 3.1.2  
The cDNA clone UI64 is
identified as the mouse
orthologue of UBP41.
BLAST sequence analysis
revealed that the isolated
apoptosis-inducing clone
UI64 encodes the mouse
orthologue of the ubiquitin-
specific protease UBP41.
The UBP41 protein
sequence is highly
conserved between homo
sapiens (hUBP41), mus
musculus (mUBP41), and
gallus gallus (gUBP41).
Identical residues are
marked by blocks. Homology
domains characteristic for
ubiquitin-specific proteases
are indicated, such as the
cysteine, aspartate and
histidine domain, as well as
three additional homology
domains. The catalytic
cysteine is marked by an
asteriks. 
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3.1.2 Characterization of hUBP41-induced apoptosis 
 
For being able to address the question whether the enzymatic activity of hUBP41 is essential for its 
proapoptotic activity, site-directed mutagenesis was performed to generate the enzymatically inactive 
hUBP41-C24A-HA variant by replacing the active site cysteine with alanine [Baek, 1997]. 
Transfection of 293T cells with hUBP41-HA resulted in apoptosis induction as judged by the 
apoptotic phenotype when observed under the microscope as well as by oligonucleosomal DNA 
fragmentation (Fig. 3.1.3 A,B). In contrast, control transfected 293T cells or cells expressing the 
inactive site mutant hUBP41-C24A-HA did not show significant signs of apoptosis, although 
hUBP41-C24A-HA expression was comparable to that of hUBP41-HA (Fig. 3.1.3 A). 
 
 
 
 
 
 
 
 
 
Fig. 3.1.3 
Characterization of cell death induced by human UBP41 (hUBP41). (A) Human UBP41 induces
cell death that is dependent on the integrity of the catalytic center of the protease. 293T cells were
transfected with a control vector, with wild type hUBP41-HA, or with the active-site mutant hUBP41-
C24A-HA in which the catalytic cysteine had been replaced by an alanine residue. Degradation of
cellular DNA was analysed 48h post transfection (upper panel). Equal expression of hUBP41-HA
and hUBP41-C24A-HA was confirmed by an anti-HA immunoblot yielding bands of the expected
size (lower panel). (B) Only the wild type UBP41 construct induces the characteristic phenotype of
apoptosis in 293T cells. 293T cells were transfected with hUBP41-HA or hUBP41-C24A-HA together
with an expression vector forEGFP. The upper panel shows phase contrast pictures 48h post
transfection, whereas the lower panel presents EGFP fluorescence microscopical images by which
apoptosis frequently can be easier observed. 
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UBP41 belongs to the large family of ubiquitin-specific proteases (USPs). Therefore it was of interest 
whether also other USPs would be able to induce apoptosis upon overexpression. To this end, we 
isolated the two most homologous human family members of hUBP41, i.e. hUSP18 (gi:32313609; 
[Schwer, 2000]), and hUSP21 (gi: 6693823; [Gong, 2000]) with 25% or 45% identity to hUBP41, 
respectively (Fig. 3.1.4).  
 
 
   hUSP18   ------------------------MSKAFGLLRQICQSILAESSQSPADL 
   hUBP41   MLNKAKNSK---S-----------AQGLAGLRNLGNTCFMNSILQCLSNT 
   hUSP21   -MISARSSEPFYSDDKMAHHTLLLGSGHVGLRNLGNTCFLNAVLQCLSST 
 
               
   hUSP18   EEKKEEDSNMKREQPRERPRAWDYP-HGLVGLHNIGQTCCLNSLIQVFVM 
   hUBP41   RELR--DYCLQRLYMRDLHHGSNAHTALVEEFAKLIQTIWTSSPNDVVSP 
   hUSP21   RPLR--DFCLRRDFRQEVPGGGRAQ-ELTEAFADVIGALWHLDSCEAVNP 
 
                  
   hUSP18   NVDFTRILKRITVPRGADEQRRSVPFQMLLLLEKMQDSRQKAVR------ 
   hUBP41   -SEFKTQIQRYAPRFVGYNQQDAQEFLRFLLDGLHNEVNRVTLR------ 
   hUSP21   -TRFRAVFQKYVPSFSGYSQQDAQEFLKLLMERLHLEINRRGRRAPPILA 
 
                  
   hUSP18   --PLELAYCLQKCNVPLFVQHDAAQLYLKLWNLIKDQITDVHLVERLQAL 
   hUBP41   --PKSNPEN----LDHLP---DDEKGRQ-MWRKYLERE-DS----RIGDL 
   hUSP21   NGPVPSPPRRGGALLEEPELSDDDRANL-MWKRYLERE-DS----KIVDL 
 
                  
   hUSP18   YTIRVKDSLICVDCAMESSRNSSMLTLPLSLFDVDSKP-LKTLEDALHCF 
   hUBP41   FVGQLKSSLTCTDCGYCSTVFDPFWDLSLPIAKRGYP--EVTLMDCMRLF 
   hUSP21   FVGQLKSCLKCQACGYRSTTFEVFCDLSLPIPKKGFAGGKVFLRDCFNLF 
 
                  
   hUSP18   FQPRELSSKSKCFCENCGKKTRGKQVLKLTHLPQTLTIHLMRFSIRNSQT 
   hUBP41   TKEDVLDGDEKPTCCRCRGRKRCIKKFSIQRFPKILVLHLKRFSESRIRT 
   hUSP21   TKEEELESENAPVCDRCRQKTRSTKKLTVQRFPRILVLHLNRFSASRGSI 
 
                  
   hUSP18   RKICHSLYFPQSLDFSQILPMKRESCDAEEQSGGQYELFAVIAHVGMADS 
   hUBP41   SKLTTFVNFP-----LRDLDLR--EFASENTNHAVYNLYAVSNHSGTTMG 
   hUSP21   KKSSVGVDFP-----LQRLSLG--DFASDKAGSPVYQLYALCNHSGSVHY 
 
                  
   hUSP18   GHYCVYIRNAVDGKWSCFNDSNICLVSWEDIQCTYGNPNYHWQETAYLLV 
   hUBP41   GHYTAYCRSPGTGEWHTFNDSSVTPMSSSQVRTSDA------YLLFYELA 
   hUSP21   GHYTALCRCQTG--WHVYNDSRVSPVSENQVASSEG------YVLFYQLM 
 
                  
   hUSP18   YMKMEC- 
   hUBP41   SPPSRM- 
   hUSP21   QEPPRCL 
 
 
Fig. 3.1.4 
Sequence alignment of human USP members most homologous to hUBP41. hUSP21
(Genbank Accession AF134213; gi: 6693823) shares 45% sequence identity with hUBP41,
whereas hUSP18 (Genbank Accession NM_017414; gi:32313609) is to about 25% identical to
hUBP41. hUSP18 and hUSP21 additionally were the only USP members found that were of
comparable size as hUBP41. The catalytic-site cysteine residues are C24, C37, and C64 for
hUBP41, hUSP21, and hUSP18, respectively. 
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Fig. 3.1.5 
hUBP41 but not hUSP18 or hUSP21 induce apoptosis in 293T cells. (A) 293T cells were 
transfected with expression constructs for hUBP41, hUSP18, and hUSP21, as well as with the
corresponding active-site mutants. The cells were harvested and stained with propidium iodide (PI) in 
Hypotonic Lysis Buffer. Cells with with sub-G1 DNA content were detected by FACS analysis. Shown 
are the means and the standard deviations of three values measured in parallel. (B) 293T cells were
transfected as given in (A), harvested, washed with PBS, and lysed for detection of caspase-3 
activity. Each data point was accessed at least in triplicate. (C) Expression of the HA-constructs was 
confirmed by anti-HA immunoblot analysis. 
 
hUSP18 and hUSP21 were generated as the carboxy-terminally HA-tagged proteins hUSP18-HA and 
hUSP21-HA, as well as their corresponding active site mutants hUSP18-C64A-HA and hUSP21-
C37A-HA. Whereas overexpression of hUBP41-HA in 293T cells resulted in apoptotic DNA 
fragmentation as measured by propidium iodide FACS analysis and in the induction of caspase-3 
enzymatic activity, hUSP18-HA and hUSP21-HA did not show any significant signs of apoptosis in 
293T cells  (Fig. 3.1.5 A,B).  
In those experiments, expression levels of hUSP18-HA and hUSP21-HA were usually clearly lower 
than those of hUBP41-HA and could not reproducibly be adjusted to the same level (Fig. 3.1.5 C). 
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Fig. 3.1.6 
hUBP41 also induces apoptosis when transfected into PC3 cells. Transfection of hUBP41-
HA into the prostatic carcinoma cell line PC3 cells resulted in cell death as observed by its
phenotype. Here the fluorescence microscopic pictures are shown after cotransfection with
hUBP41 and pEGFP for better detection sensitivity. Transfection of the enzymatic inactive form
hUBP41-C24A-HA or hUSP18-HA and hUSP21-HA did not show clear signs of cell death.
Pictures were taken at 200-fold magnification. 
 
To test whether hUBP41 overexpression also induces cell death in other cell systems, the prostatic 
carcinoma cell line PC3 was transfected. As shown in Fig. 3.1.6, only hUBP41-HA triggered clear 
signs of cell death in the transfected cells.  
 
 
 
The most reproducible and the highest transfection efficiencies could be obtained in HeLa cells using 
the Effectene transfection reagent (Qiagen). Therefore, the HeLa cell system was used to further 
investigate the UBP41-mediated apoptosis induction. Overexpression of hUBP41-HA in HeLa cells 
resulted in strong cell death induction displaying typical membrane blebbing already 24 to 30 hours 
post transfection (Fig. 3.1.7 D), whereas in 293T cells clear signs of apoptosis were usually observed 
earliest about 40 hours post transfection. In contrast to the response in 293T cells, in HeLa cells also 
overexpression of the active site mutant hUBP41-C24A-HA (Fig. 3.1.7 C) and hUSP21-HA (Fig. 
3.1.7 H) resulted in significant signs of apoptosis. This observation also could be confirmed by 
measuring DNA fragmentation by FACS analysis (Fig. 3.1.8). 
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Fig. 3.1.8 
Apoptosis induction by USP overexpression in HeLa cells as measured by PI FACS analysis.
USP expression plasmids were cotransfected with pEGFP. In case of hUBP41 different amounts of
plasmid DNA were transfected. Approximately 36 h post transfection cells were analysed in PI FACS
analysis for DNA content. The percentage of cells with hypoploid DNA content (“sub-G1 population”)
was considered to be a measure for the percentage of apoptotic cells. Values given were calculated by
taking into acount the transfection efficiency as measure by EGFP-positive cells. Each data point was
measured in triplicate. 
 
Fig. 3.1.7 
Overexpression of various USPs in HeLa cells. HeLa cells were transfected with expression vectors
for (A) Luciferase as a negative control, (B) the hUBP41 sequence with its start ATG deleted, (C) the
active-site mutant hUBP41-C24A-HA, (D) wildtype hUBP41-HA, (E) the active-site mutant hUSP18-
C64A-HA, (F) wildtype hUSP18-HA, (G) the active-site-mutant hUSP21-C37A-HA, and (H) wildtype
hUSP21-HA. All constructs were cotransfected with pEGFP for better visualization of transfected cells.
The pictures were taken about 30 h post transfection. Cells are shown at 200-fold magnification. 
 
Results 
 69
 
Since HeLa cells spread tightly on the surface of cell culture dishes or on glass cover slips, they could 
be used for studying the intracellular localization of the various USPs by fluorescence microscopy. 
Determination of the intracellular distribution of hUBP41 was of interest because it might have 
allowed to gain some information about the subcellular location at which hUBP41 overexpression 
unfolds its proapoptotic action. hUBP41, hUBP41-C24A, hUSP18, and hUSP21 were subcloned into a 
vector with a carboxy-terminal EYFP tag, the resulting EYFP fusion proteins were expressed in HeLa 
cells, and the intracellular distribution of the proteins was observed under the fluorescence microscope 
(Fig. 3.1.9). hUBP41-EYFP usually displayed a uniform distribution within the whole cell, whereas 
the hUBP41-C24A-EYFP fusion protein in addition displayed larger spots of higher fluorescence 
intensity, possibly representing protein aggregates. hUSP21-EYFP was evenly distributed in the cells, 
albeit occasionally displaying spots of higher fluorescence intensity, whereas hUSP18-EYFP was 
excluded from the nucleus (Fig. 3.1.9).  
In order to further characterize the mode of cell death induced by overexpression of hUBP41, HeLa 
cells, transfected with hUBP41-HA, were cultivated in absence or presence of the pan-caspase 
inhibitor zVAD-fmk. Propidium iodide FACS analysis and visual inspection of the cells indicated a 
suppression of cell death in the presence of zVAD-fmk, suggesting a caspase-dependent, i.e. apoptotic 
mode of cell death (Fig. 3.1.10 A,B).  
Also the co-transfection of hUBP41-HA with the antiapoptotic Bcl-2 family member Bcl-XL resulted  
Fig. 3.1.9 
Cellular localization of overexpressed USP proteins tagged with EGFP. HeLa cells adherent
to a cover glass were transfected with EYFP fusion constructs of hUBP41, hUBP41-C24A,
hUSP18, and hUSP21. About 24 h post transfection, cells were stained with DAPI and observed
by fluorescence microscopy displaying EYFP fluorescence (upper panels) and DAPI fluorescence
(lower panels). Magnification is 600-fold. 
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in the inhibition of hUBP41-induced cell death, further indicating that major apoptotic signalling 
events such as those regulated by the Bcl-2 family are involved in hUBP41-induced cell death (Fig. 
3.1.10 C,D). It might be worth noting that while zVAD-fmk and Bcl-XL were able to inhibit typical 
features of apoptosis, i.e. the typical morphological changes as well as DNA fragmentation, some of 
the cells nevertheless displayed an unusual phenotype by forming long, extended shapes or by 
containing large open, vacuole-like structures (Fig. 3.1.10 B,D).  
 
 
Fig. 3.1.10 
Apoptosis induced by overexpression of UBP41 in HeLa cells can be suppressed by the pan-
caspase inhibitor zVAD-fmk and by coexpression of the antiapoptotic Bcl-2 member Bcl-XL.
(A,B) HeLa cells were transfected with the hUBP41-HA expression vector in the absence or
presence of the pan-caspase inhibitor zVAD-fmk (50 µM) which was added to the cells at the time
point of media change during the transfection procedure. About 30 h post transfection the
percentage of apoptotic cells was measured in terms of DNA fragmentation by PI FACS analysis (A)
or cells were investigated by fluorescence microscopy at 200-fold magnification (B). (C,D) HeLa
cells were transfected with the hUBP41-HA expression vector in absence or presence of additional
Bcl-XL co-expression, and the cells were analysed as indicated under (A,B). 
Results 
 71
 
Surprisingly, in contrast to the situation in HeLa cells, hUBP41-induced apoptosis in 293T cells could 
not be suppressed but was enhanced by co-transfection of Bcl-XL. As expected, Bcl-XL could almost 
completely block Bax-induced apoptosis under the same experimental settings. This effect could be 
observed reproducibly by microscopical inspection (not shown) as well as by caspase-3 enzymatic 
activity assay which for the 293T cell system proved to be more sensitive than PI FACS analysis in 
case of hUBP41-mediated cell death (Fig. 3.1.11). 
 
3.1.3 Evaluation of possible modes of action for the UBP41-mediated 
proapoptotic effect 
 
In the attempt to find possible explanations for the observed proapoptotic effect of UBP41 
overexpression, various scenarios were taken into consideration and subsequently were tested 
experimentally for their potential significance. The most obvious issue was to test the impact of  
Fig. 3.1.11 
In 293T cells, Bcl-XL unexpectedly does not inhibit UBP41-induced apoptosis but even
enhances the killing effect of UBP41 overexpression. (A) 293T cells were co-transfected
with the hUBP41 expression vector and a luciferase expression vector (pLuc) or  with a Bcl-XL
expression vector using equal DNA amounts for transfection. As a control, the same was done
with the active-site-mutant hUBP41-C24A-HA. Moreover, Bcl-XL was transfected on its own or
co-transfected with the pLuc vector. Cells were harvested for a caspase-3 activity assay about
40 h post transfection. (B) 293T cells were co-transfected with an expression vector for Bax
together with pLuc or Bcl-XL using a DNA ratio of 1:3. Cells were harvested for the caspase-3
activity assay about 24 h post transfection. (C) The same experiment described under (A) was
performed in HeLa cells. 
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UBP41 overexpression on the ubiquitination status of proteins. As a protein with deubiquitylating 
activity, UBP41 was expected to be able to remove ubiquitin from multi-ubiquitylated protein 
substrates but it remained to be determined whether UBP41 acts on a selected set of proteins or on a 
broad range of proteins. Another question was whether it is the deubiquitination of proteins or rather 
the possibly concomitant accumulation of the mono-ubiquitin pool that triggers the induction of 
apoptosis. 
 
To first answer the question whether overexpression of UBP41 has an impact on the total 
ubiquitination status of endogenous proteins,  293T cells were transfected with pLuc as a control, 
hUBP41-HA, its enzymatically inactive mutant hUBP41-C24A-HA, or its homologues hUSP18-HA 
and hUSP21-HA. About 42h post transfection, total protein extracts were prepared from the 
transfected cells, equal amounts of protein were separated in SDS gel electrophoresis, and the 
subsequent immunoblot was probed with anti-ubiquitin antibodies. As can be seen in Fig. 3.1.12, 
overexpression of hUBP41-HA resulted in a dramatic deubiquitination of a wide range of substrates, 
whereas all other transfected constructs did not show any significant effect, although in some 
experiments the ubiquitin-signal in hUSP21-HA transfected 293T also appeared to be slightly 
diminished. The same results were obtained in transfection experiments using HeLa cells (data not 
shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
As a consequence of the dramatic deubiquitylating activity mediated by hUBP41-HA overexpression 
(Fig. 3.1.12), free monomeric ubiquitin could be expected to accumulate within the cell. An 
inappropriately increased ubiquitin pool then might interfere with cellular processes, e.g. by its 
putative chaotropic action towards other proteins as described by Wenzel and Baumeister  
Fig. 3.1.12 
UBP41 overexpression results in the
deubiquitination of a broad range of
proteins. 293T cells were transfected with a
negative control vector,  the various USP gene
constructs, as well as with a vector encoding
the HA-tagged ubiquitin double mutant Ub
K48R, G76A. 42 hours post transfection cells
were harvested and lysed. 100 µg of total
protein were loaded in each lane of a 15% SDS
PAGE gel for immunoblot analysis using  anti-
ubiquitin polyclonal antibodies. Equal loading
was confirmed by an anti-ß-actin control blot. 
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Fig. 3.1.13 
Overexpression of the  ubiquitin
double mutant      Ub K48R,
G76A does not result in
apoptosis induction. An
expression vector for hUBP41-HA
or for the aminoterminally HA-
tagged ubiquitin double mutant
HA-Ub K48R, G76A was
transfected into HeLa cells
(pEGFP was co-transfected). (A)
The percentage of cells with
fragmented DNA was analysed by
PI FACS analysis about 35 h post
transfection. (B) The same cells
that were analysed in (A) are
shown here under the fluorescence
microscope showing the
transfected, i.e. EGFP-positive
cells. (C) Expression of the
ubiquitin double mutant HA-Ub
K48R, G76A was confirmed by
anti-HA immunoblot analysis. 
 
[Wenzel, 1993]. To test this hypothesis, wildtype ubiquitin was overexpressed in HeLa cells and 293T 
cells, but no effect concerning cell death induction could be observed (data not shown). In this context 
it also should be noted that in anti-ubiquitin immunoblots very high basal levels of monoubiquitin 
were observed in control transfected 293T as well as in HeLa cells which did not recognizably change 
upon hUBP41-HA overexpression (see the intense band at < 10 kDa in Fig. 3.1.12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the attempt to interfere with the ubiquitination system in an alternative and potentially similar way 
as does the overexpression of hUBP41, a HA-tagged double mutant of ubiquitin, HA-Ub K48R,G76A, 
was generated and overexpressed in HeLa cells. Overexpression of HA-Ub K48R,G76A is expected to 
result in, on the average, shorter ubiquitin chain lengths of ubiquitin-modified proteins, since the 
K48R mutation lacks the common lysine residue for chain elongation, whereas the G76A mutation 
still allows conjugation to a growing ubiquitin chain but is more resistant to deubiquitination [Finley, 
1994]. As depicted in Fig. 3.1.13, overexpression of HA-Ub K48R,G76A was confirmed by anti-HA 
immunoblot analysis, but in contrast to hUBP41 overexpression did not result in any signs of 
apoptosis.  
 
The next experiments focused on the question whether the observed deubiquitylating activity of 
UBP41 affects the stability of proteins that normally are polyubiquitylated and degraded by the 
proteasome. In presence of elevated hUBP41 levels those proteins should be expected to be  
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deubiquitylated and thus saved from degradation. To test this hypothesis, the destabilized ubiquitin-
GFP fusion protein Ub-G76V-GFP was employed as an artificial test substrate [Dantuma, 2000]. 
When Ub-G76V-GFP was co-expressed with an arbitrary HA-tagged protein as a control, only a small 
fraction of transfected cells displayed GFP fluorescence, likely due to immediate degradation of the 
ubiquitin-labelled GFP. In contrast, co-expression of hUBP41-HA strongly increased the number of 
GFP-positive cells, indicating a stabilizing effect of hUBP41-HA on the test substrate (Fig. 3.1.14 A) 
Fig. 3.1.14 
The artificial test substrate Ub-G76V-GFP is stabilized by UBP41 overexpression but the tested 
endogenous candidate substrates are not. (A) 10 ng of an expression vector encoding the test
substrate Ub-G76V-GFP were co-transfected with the various USP expression constructs either in 293T
cells (upper graph) or in HeLa cells (lower graph). As a control, Ub-G76V-GFP was expressed together 
with an arbitrary HA-tagged protein. The percentage of GFP-positive cells was determined by FACS 
analysis about 24 h post transfection. (B) UBP41 does not stabilize various known endogenous 
substrates of the proteasome. HeLa cells were transfected with a control vector, with hUBP41-HA or its 
active-site mutant hUBP41-C24A-HA. Alternatively, the cells were treated with 1 µM of the proteasome
inhibitor MG312. Extracts were prepared 25 hours after transfection or start of treatment. Equal amounts 
of extracts were used for immunoblot analysis, probing with antibodies to the indicated proteins. 
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in both, HeLa and 293T cells. Unexpectedly, also co-expression of the active site mutant hUBP41-
C24A-HA resulted in stabilization of the GFP test substrate, almost as efficient as hUBP41-HA itself, 
and co-expression of hUSP18-HA, hUSP21-HA and their corresponding active-site mutants also led to  
a significant extent of stabilization. Irrespective of those unexpected observations, the stabilizing 
effect of hUBP41 on the artificial substrate Ub-G76V-GFP still allowed to assume that ubiquitylated 
proteins might be stabilized by the deubiquitinating property of hUBP41.  
 
Therefore, the influence of hUBP41-HA on the stability of endogenous target proteins was examined. 
Potential candidate target proteins were the cell cycle proteins p21Cip1/Waf1, p27Kip1, cyclin B1, and p53, 
which are known to be regulated by ubiquitination and proteasomal degradation [Elledge, 1998; 
Zhang, 1998]. As a positive control, HeLa cells were treated with the peptide aldehyde proteasome 
inhibitor MG132 which has been described to potently block the degradation of p21Cip1/Waf1, p27Kip1, 
and cyclin B1 [Chang, 1998; Fan, 2001; Maki, 1996; Nahreini, 2001; Naujokat, 2000]. In the HeLa 
cell system investigated in this study, the protein levels of p21Cip1/Waf1, p27Kip1 and cyclin B1 increased 
markedly in presence of MG132 (Fig. 3.1.14 B). In contrast to treatment with MG132, overexpression 
of hUBP41-HA obviously did not cause any detectable stabilization of p21Cip1/Waf1, p27Kip1 or cyclin 
B1. Therefore, even though a broad range of proteins is deubiquitylated upon hUBP41 overexpression 
(Fig. 3.1.12), apparently not all those proteins can be expected to be stabilized as a consequence of 
deubiquitination (Fig.4.1.14 B).  
 
Consistent with its stabilizing effect on cell cycle inhibitors such as p21Cip1/Waf1 and p27Kip1, the 
proteasome inhibitor MG132 is known to induce cell cycle arrest, eventually leading to the activation 
of apoptosis pathways [Emanuele, 2002; Lee, 1998]. In order to compare the drug MG132 with 
hUBP41 overexpression regarding their respective impact on the cell cycle and concurrent apoptosis 
induction, HeLa cells were either treated with MG132 or transfected with hUBP41-HA. At various 
times, cellular DNA content was evaluated by propidium iodide FACS analysis, allowing the 
quantification of hypoploid apoptotic cells as well as the assessment of the cell cycle distribution of 
the non-apoptotic cell population.  
 
As shown in Fig. 3.1.15, MG132 primarily induced cell cycle arrest in G2/M and only moderately 
triggered apoptosis induction, possibly as a consequence of the cell cycle arrest. In contrast, hUBP41-
HA did not arrest the cells in G2/M but obviously was driving cells directly into apoptosis. These data 
indictate that hUBP41-mediated cellular changes are different from those caused by a general block of 
proteasomal activity as caused by the proteasome inhibitor MG132. 
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Fig. 3.1.15 
Comparison of the effects induced by
hUBP41 overexpression and
treatment with the proteasome
inhibitor MG-132. The proteasome
inhibitor MG132 primarily results in a
G2/M arrest and only moderately induces
apoptosis, whereas overexpression of
hUBP41 triggers apoptosis without prior
G2/M arrest. HeLa cells were transfected
with hUbp41-HA or treated with the
proteasome inhibitor drug MG-132 (1
µM) for the indicated times. Apoptosis
(upper panel) and cell cycle arrest (lower
panel) was quantified by PI staining and
FACS analysis. Each data point was
measured in triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.4 Generation and characterization of a polyclonal anti-hUBP41 
antibody 
 
The data presented thus far resulted from experiments that were based on the overexpression of 
hUBP41 in various cell lines. In order to gain more insight into the biochemical properties of hUBP41 
and its physiological roles in cell biology as well as its possible involvement in pathological 
conditions such as cancer, we decided to investigate expression of endogenous hUBP41. To this end, a 
specific polyclonal anti-hUBP41 antibody was raised in rabbit: a peptide (GST-IP-B) comprising the 
amino acids 119-150 of hUBP41 as the antigenic determinant was expressed as a GST-fusion protein 
using the pGEX vector system in the E.coli strain BL21, purified on a GSH-sepharose column and 
subsequently on a sephadex 200 column, and eventually was used for immunization.  
The crude serum obtained after final bleeding indeed recognized the immunogenic peptide as well as 
overexpressed hUBP41 but certainly also contained anti-GST antibodies (Fig. 3.1.16 A). For this 
reason and to eliminate as many cross reactivity as possible, the crude serum was affinity purified in a 
two-step protocol first depleting anti-GST antibodies by incubation with GST-linked cyanogen 
bromide sepharose and in the second step by binding to and eventually eluting from GST-IP-B-
coupled cyanogen bromide sepharose. The affinity purified eluate indeed still recognized the 
immunopeptide GST-IP-B as well as overexpressed hUBP41 but did not crossreact with GST (Fig. 
3.1.16 B). 
Results 
 77
Fig. 3.1.17 
Immunoblot analysis of cell extracts
using the anti-UBP41 polyclonal
antibodies. Cell extracts (100 µg protein)
from untreated 293T, HeLa, and PC3 cells
were analysed by western blot, probing the
membrane with affinity purified anti-UBP41
polyclonal antibodies (1:1000). Extracts from
hUBP41-transfected cells were loaded as a
positive control (last lane). Several bands
were detected in the extracts from untreated
cells which might represent isoforms of the
USP2 protein family. No band of the size
expected for hUBP41 was observed. 
 
The affinity purified anti-hUBP41 antibodies were then applied to determine the endogenous 
expression status of hUBP41. In extracts from HeLa, PC3, 293T and PC3 cells a pattern of up to five 
protein bands was detected of which no band did correspond to the expected size of overexpressed 
hUBP41, indicating that hUBP41 might be expressed as several alternative isoforms with the 41 kDa 
form not being detectable in the cell lines investigated (Fig. 3.1.17). Indeed, UBP41 is known to be a 
member of the USP2 family of isoforms, and in chicken, for example, four isoforms have been 
described [Baek, 1998]. 
 
 
 
Fig. 3.1.16 
Evaluation and affinity purification of the polyclonal anti-hUBP41 antibodies.  
(A) The crude serum of the immunized rabbit recognized the immunopeptide (GST-IP-B) against it
was raised. It also recognized hUBP41 in extracts of hUBP41-transfected cells. Since the
immunopeptide was a GST fusion peptide, the crude serum also crossreacted with GST. (B) After
affinity purification, the obtained antibody eluate still recognized GST-IP-B and overexpressed
hUBP41 but did not significantly crossreact with GST. 
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In the attempt to confirm the identity of some of the endogenous bands shown in Fig. 3.1.17 as a 
member of the USP2 isoform family, an approach using the RNAi technology was chosen [Elbashir, 
2001]. Two target sequences unique to the human USP2 sequence were selected and were inserted into 
the pSuper vector system. To test the capability of those RNAi target sequences in suppressing the 
expression of the hUBP41 message, the hUBP41 expression plasmid was co-expressed with either the 
pSuper-hUBP41 #1 or pSuper-hUBP41 #2 RNAi construct, respectively. Only the pSuper-hUBP41 #1 
construct could reproducibly diminish hUBP41 expression, whereas the pSuper-hUBP41 #2 construct 
as well as another unrelated RNAi construct did not alter hUBP41 expression (Fig. 3.1.18). Expression 
of the SAIP-HA protein - whose expression vector was additionally co-transfected as an internal 
control - was not affected by the pSuper-hUBP41 #1 RNAi construct suggesting its specific activity 
towards the hUBP41 message.  
 
Even though the RNAi construct pSuper-hUBP41 #1 could successfully suppress hUBP41-HA 
expression in a co-transfection experiment (Fig. 3.1.18), transfection of pSuper-hUBP41 #1 into HeLa 
cells did not alter the signal intensities of any of the putative endogenous USP2 bands that are detected 
by the anti-hUBP41 polyclonal antiserum (not shown).  
Fig. 3.1.18 
Evaluation of candidate RNAi constructs for the downregulation of hUBP41 in a co-
transfection experiment. In the HeLa cell system, the hUBP41-HA expression plasmid was co-
transfected with both, an expression plasmid for the SAIP-HA protein, as well as with one of the
RNAi constructs pSuper-hUBP41 #1, pSuper-hUBP41 #2, or the unrelated pSuper-N57 construct.
20 hours post transfection, the cells were harvested, lysed and and equal amounts of the extracts
were loaded on a SDS-PAGE gel for immunoblot analysis using an anti-HA antibody. hUBP41
expression was clearly decreased in the presence of the pSuper-hUBP41 #1 RNAi construct but not
in presence of pSuper-hUBP41 #2 or pSuper-N57. Expression of SAIP-HA was not affected by
pSuper-hUBP41 #1.  
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In conclusion, the generated polyclonal anti-hUBP41 antibody does recognize the overexpressed 
hUBP41 protein (Fig. 3.1.16) but in extracts of untreated cells a corresponding endogenous hUBP41 
protein of the expected molecular size could not be detected when using this antibody in immunoblot 
analyses, possibly because hUBP41 is not strongly expressed enough in the cell lines investigated. 
Instead, the antibody recognized a number of endogenous proteins of different size (Fig. 3.1.17) which 
might correspond to the hUSP2 isoforms of the hUBP41 protein. The attempt to clearly identify those 
proteins bands as isoforms of hUBP41 by using RNAi technology was not successful. Therefore, the 
polyclonal anti-hUBP41 antibody could not be further used for expression analysis of endogenous 
hUBP41 or its hUSP2 isoforms, respectively. Instead, northern hybridization experiments were 
performed to study hUBP41/hUSP2 expression.  
 
3.1.5 Analysis of hUBP41 / hUSP2 expression by northern hybridization 
 
For northern hybridization, the radioactively labelled hUBP41 cDNA was used as a probe. This probe 
was expected to recognize the human UBP41 transcript but also its described longer USP2 isoforms. 
The design of a sequence-specific hybridization probe for discriminating between hUBP41 and its 
isoforms was not possible because the hUBP41 cDNA sequence is virtually identical to the entire 3’ 
terminal end of its two isoforms. Therefore, the subsequently shown hybridization experiments 
represent the expression profile of the hUSP2 isoform family rather than that of hUBP41 alone.  
 
First of all, the tissue distribution of hUBP41 expression was examined by hybridization of a multiple 
tissue northern blot (Clontech) using the radioactive hUBP41 cDNA probe. As shown in Fig. 3.1.19, 
the hUBP41 cDNA probe hybridized with two bands of approximately 3.5 and 4.0 kb, respectively, 
suggesting the presence of two alternative transcripts, which could be detected most strongly in 
skeletal muscle and kidney, but also in brain, heart and liver.  
 
Subsequently, the same hUBP41 cDNA probe was used to hybridize a Cancer Profiling Array blot 
provided by Clontech which allowed the comparison of expression levels in normal tissue and tumor 
tissue from the same patient (Fig. 3.1.20). Analysis of the signal intensities as measured by a 
phosphoimager revealed a decrease of the hUBP41 hybridization signal in tumor specimen of the 
kidney when compared to normal kidney tissue whereas between samples of other organ origin no 
significant differences could be detected (Fig. 3.1.21). This would suggest a possible correlation 
between tumorigenesis of the kidney and a decrease of hUSP2 transcript expression.  
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Fig. 3.1.19 
Tissue expression pattern of human
USP2 isoforms. A multiple tissue
northern blot (Clontech) was hybridized
with the human UBP41 cDNA probe
which can hybridize to transcripts of the
USP2 isoform family (upper panel). The
same blot was probed with β-actin probe
as a loading control (lower panel). The
hUBP41 cDNA probe recognizes two
main transcripts which are most strongly
expressed in kidney, skeletal muscle,
heart and brain. 
 
 
 
 
Fig. 3.1.20 
Hybridization of a hUBP41 cDNA probe with the Cancer Profiling Array (Clontech).
Hybridization of a radioactive hUBP41 cDNA probe with the Cancer Profiling Array blot from
Clontech. The Cancer Profiling Array contains pairs of cDNA which were generated from tumor and
corresponding normal tissue samples from individual patients,  spotted side by side on a nylon
membrane (Normal at the left/ tumor at the right). This blot revealed equal expression of the
hUBP41 mRNA message in all normal/tumor tissues except in tumors of the kidney which in many
cases apparently display a decrease of the hUBP41 signal in tumor samples when compared to that
in normal tissue. 
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Fig. 3.1.21 
Evaluation of the Cancer Profiling Array hybridized with the hUBP41 cDNA probe. The
Cancer Profiling Array (Fig. 3.1.17) was evaluated for normal/tumor pairs of tissues for which a
sufficient number of samples (n > 14) were available. For evaluation the signal intensities were
used that were measured and processed with the Fuji BAS 2500 phosphoimager and the Image
Gauge V3.01 software. For representation of the data in this figure, the ratio of the corresponding
tumor:normal signal intensity pair was calculated and from this the percentage of deviance from
an intensity ratio of 1 (if the signals were the same for tumor and normal sample) was deduced.
The number of samples belonging to a certain range of deviance were combined to groups
representing a bar in this histogram. A negative value of deviance corresponds to a decrease of
signal intensity in tumor compared to its normal counterpart, therefore suggesting a
downregulation (down) of the hUSP2 transcript expression in tumor. A positive deviance value
describes an increase in signal intensity in tumor compared to its normal counterpart, suggesting
an upregulation (up) of the hUSP2 message in tumor. 
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Fig. 3.2.1 
293T cells transfected with a cDNA clone from
the screen encoding cathepsin-L. This is an
original photo of 293T cells transfected with a
cDNA clone that was identified by our group to
encode cathepsin-L.  
3.2  Investigation of a possible involvement of cathepsin-L 
and cathepsin-B in apoptosis induction 
 
3.2.1  A mouse cathepsin-L cDNA was identified to cause morphological 
changes in 293T cells when overexpressed 
 
The cDNA for murine cathepsin-L was identified by our group as one of the cDNA clones that 
became conspicuous during the screening procedure for apoptosis-inducing genes according to the 
method described by Grimm and Leder [Grimm, 1997]. The original photo from the screen (Fig. 
3.2.1) shows 293T cells which were transfected with the cDNA clone that was later identified to code 
for cathepsin-L: a significant number of cells display a detached, rounded and sometimes fragmented 
phenotype. 
 
 
 
 
 
 
 
 
 
 
 
3.2.2  Transient overexpression of cathepsin-D but not of cathepsin-L 
and cathepsin-B results in significant induction of apoptosis 
 
Towards a further investigation of the initial observation from the screen that suggests a possible 
apoptosis-inducing effect of cathepsin-L overexpression, the human cathepsin-L coding sequence 
(hCath-L) was isolated by RT-PCR and cloned into the pcDNA3 expression vector lacking the 
neomycin resistance cassette. For comparison, the human coding sequences of the related lysosomal 
cysteine protease cathepsin-B (hCath-B) and that of the lysosomal aspartate protease cathepsin-D 
(hCath-D) were also cloned. Successful overexpression of the cathepsins upon transient transfection 
into HeLa cells could be confirmed by western blot analysis (Fig. 3.2.2 A) as well as by the 
measurement of hCath-L and hCath-B enzymatic activity using zFR-AMC as a substrate (Fig. 3.2.2 
B).   
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Fig. 3.2.2 
Effect of high level overexpression of cathepsin-L, -B, and –D in HeLa cells.    (A) HeLa
cells were transfected with expression plasmids for human cathepsin-L (hCath-L), cathepsin-B
(hCath-B), and cathepsin-D (hCath-D). Expression was checked by western blot analysis
about 24h post transfection. (B) Overexpression and activity of hCath-L and hCath-B was
controlled by performing a cathepsin enzymatic activity assay using the zFR-AMC substrate
using extracts from transfected HeLa cells. (C) For an apoptosis assay, DNA fragmentation
(PI FACS analysis) was measured in HeLa cells transfected with the cathepsin expression
plasmids as well as with the hUBP41-HA expression plasmid as a positive control about 30h
post transfection. (D) HeLa cells were treated as described under (C) and caspase-3 activity
was measured. (E) The phenotype of HeLa cells as observed by fluorescence microscopy
when co-transfected with cathepsin espression plasmids and the pEGFP vector. 
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As expected from a previous publication [Deiss, 1996], transient overexpression of hCath-D in HeLa 
cells resulted in cell death induction as observed by DNA fragmentation, caspase-3 enzymatic activity 
and cell morphology (Figs. 3.2.2 C,D,E), and thus served as a positive control in this overexpression 
experiment. Overexpression of the ubiquitin-specific protease hUBP41-HA also triggered apoptosis 
and therefore was regarded as an additional positive control. In contrast, overexpression of hCath-L 
and hCath-B did not result in significant cell death, even though in case of hCath-L overexpression a 
slight increase in DNA fragmentation values and caspase-3 activity could occasionally be detected 
(Figs. 3.2.2 C,D), concomittant with an increased number of round and detached cells (Fig. 3.2.2 E). 
As a conclusion, the directed overexpression of the cathepsin-L coding sequence in HeLa cells (but 
also in 293T cells; data not shown) resulted in only minor detectable changes that resembled the 
phenotypical features of apoptosis. However, the effect of cathepsin-L overexpression was not strong 
enough to be unequivocally attributed to apoptosis since the available apoptosis assays were not 
sufficiently sensitive to detect and quantify the small fraction of affected cells in a reproducible and 
significant manner. The initial observation from the expression screen which suspected cathepsin-L to 
be a putative dominant apoptosis-inducing factor therefore could not be reliably confirmed. 
 
3.2.3  The cysteine protease inhibitors E64d and CA074Me suppress 
TNF-mediated apoptosis in HeLa cells 
 
Although overexpression of hCath-L and hCath-B did not by itself result in sufficient induction of 
apoptosis to be studied on its own (see paragraph 3.2.2), it nevertheless appeared worthwhile to further 
study a possible correlation between hCath-L and hCath-B expression levels and the sensitivity of 
cells to apoptosis induction. Major interest in this topic was justified in light of several studies during 
recent years which provided evidence for a potential involvement of cathepsins in the apoptotic cell 
death process. For many different cell types it was reported that apoptosis induced by various stimuli 
could be decreased in the presence of cathepsin inhibitors [Foghsgaard, 2001; Ishisaka, 1999; Kagedal, 
2001b; Katz, 2001; Kingham, 2001; Kiso, 2001; Mathiasen, 2001], and several publications focused 
on the possible contribution of Cath-B in the mediation of the TNF-α mediated cell death signal 
[Foghsgaard, 2001; Guicciardi, 2000; Guicciardi, 2001].  
In this context, it was investigated whether lysosomal cysteine proteases might be involved in 
apoptosis induced by TNF-α in the cervical carcinoma cell line HeLa which was supposed to serve as 
a model cell system. Cell death was induced by co-treatment of HeLa cells with TNF-α and 
cycloheximide (CHX) since TNF-α alone was not sufficient to induce apoptosis in this cell system. 
The pan-caspase inhibitor zVAD-fmk could completely prevent TNF-α/CHX-triggered DNA 
fragmentation indicating an apoptotic mode of cell death (Fig. 3.2.3 A). Cell death as assessed by  
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flow cytometric measurement of DNA fragmentation could also be inhibited in presence of the broad 
spectrum cysteine protease inhibitor E64d in a dose-dependent manner, albeit not as efficiently as with 
zVAD-fmk (Fig. 3.2.3 A). When CA074Me was used, a described specific Cath-B inhibitor, a 
likewise decrease of  TNF-induced DNA fragmentation could be measured (Fig. 3.2.3 B). In order to 
confirm the inhibitory effect of cathepsin-inhibitors on TNF-α-induced apoptosis in a further cell 
system, the prostatic carcinoma cell line PC3 was treated with TNF-α/CHX in absence or presence of 
E64d, CA074Me, and additionally of the cathepsin inhibitor zFA-FMK [Rasnick, 1985]. Also in PC3 
cells the inhibitors could reduce TNF-α/CHX-induced DNA fragmentation (Fig. 3.2.4). 
 
To address the question whether the observed inhibitory effect of E64d on apoptotic DNA 
fragmentation can be generally observed upon cell death induction, the impact of E64d on UV-
mediated cell death was tested in HeLa cells. As shown in Fig. 3.2.3 C,  E64d did not suppress DNA 
fragmentation induced by UV irradiation under the conditions used.  
 
 
 
Fig. 3.2.3 
Effect of cathepsin inhibitors on TNF-α or UV-induced apoptosis in HeLa cells. HeLa cells
were preincubated for 3h with the indicated amounts of E64d or CA074Me and then cotreated with
10 ng/ml TNF-α and 5 µg/ml CHX (A, B) or irradiated with 40 mJ/cm2 UV light (C). During treatment
or after irradiation, respectively, the cells were further kept in the presence of the indicated
concentrations of inhibitor and were analysed 12h (TNF-α) or 20h (UV) later by propidium iodide
FACS analysis. The values for every datapoint were acquired in triplicate and are given as the
percentage (mean +/ s.d.) of apoptotic cells with sub-G1 chromosomal DNA content. The data
shown are representative for several independent experiments. 
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3.2.4  Cathepsin-B-like cysteine proteases are responsible for mediating 
the E64d- and CA074Me-sensitive TNF signal  
 
The observation that the Cath-B inhibitor CA074Me is able to reduce TNF-induced DNA 
fragmentation in HeLa cells (Fig. 3.2.3 B) suggested an involvement of Cath-B in this cell death 
process. Consequently, the specificity of CA074Me on Cath-B activity was examined. To this end, 
hCath-B or hCath-L were transiently overexpressed in HeLa cells for subsequent inhibitor studies. 
Cathepsin activity was measured in extracts of Cath-B- or Cath-L-transfected cells which were grown 
for 3 hours in the presence or absence of 25 µM E64d or 25 µM CA074Me, respectively. 
Concentrations in the range of 25 µM had been used in recent reports [Foghsgaard, 2001; Varghese, 
2001] and in this study were necessary to elicit a clear inhibitory effect as seen in Fig. 3.2.3. 
As expected E64d could strongly inhibit both, hCath-L and hCath-B enzymatic activity (Fig. 3.2.5). 
Unexpectedly, the supposedly specific Cath-B inhibitor CA074Me not only inhibited the enzymatic 
activity of the overexpressed hCath-B but also that of the overexpressed hCath-L. However, this 
observation is in line with a recent report [Montaser, 2002] which revealed that prior to cleavage by 
cellular esterases the methyl ester CA074Me cannot be regarded as a specific Cath-B inhibitor but also 
affects other lysosomal cysteine proteases such as cathepsin-L. The methyl group of CA074Me is 
necessary for its ability to permeate the cell membrane. Additionally, the effect of of E64d on caspase 
Fig. 3.2.4 
Effect of cathepsin inhibitors on TNF-induced apoptosis in PC3 cells. PC3 cells were
preincubated for 3h with 50 µM of E64d (A), CA074Me (B) or zFA-FMK (C) and then were cotreated
with 10 ng/ml TNF and 2 µg/ml CHX. During treatment,  the cells were further kept in the presence of
inhibitor and were analysed   20 h  later by propidium iodide FACS analysis. The values for every
datapoint were acquired in triplicate and are given as the percentage (mean +/ s.d.) of apoptotic cells
with sub-G1 chromosomal DNA content. The data shown are representative for several independent
experiments. 
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enzymatic activity was tested in vitro: caspase activity induced by addition of cytochrome c and dATP 
to cell extracts in a cell-free system was not significantly reduced in presence of 50 µM E64d in the 
extract (data not shown), therefore excluding the possibility that the effect of E64d on TNF-induced 
apoptosis is due to concurrent inhibition of caspases. In conclusion, Cath-B but also related lysosomal 
cysteine proteases such as Cath-L should be responsible for mediating the E64d- and CA074Me-
sensitive TNF signal.  
 
3.2.5  Augmented Levels of hCath-L or hCath-B fail to sensitize HeLa or 
McA RH 7777 cells to TNF-induced cell death 
 
Since inhibitors of cathepsin enzymatic activity could suppress TNF-α-mediated apoptotic DNA 
fragmentation (Fig. 3.2.3 and Fig. 3.2.4), we speculated that elevated cathepsin expression levels 
might influence the sensitivity of HeLa cells to the apoptosis inducing signal triggered by TNF-α. As 
shown in Fig. 3.2.2, overexpression of hCath-B and hCath-L could be obtained by transient 
transfection of HeLa cells in terms of both, protein levels detected in immunoblots (Fig. 3.2.2 A) as 
well as cathepsin activities (Fig. 3.2.2 B). These experiments usually indicated an increase of 
cathepsin activity by at least 6- to 10-fold for hCath-L or by 10- to 20-fold for hCath-B when 
compared to endogenous cathepsin activity. This extent of increased enzymatic activity is comparable  
Fig. 3.2.5 
Test of the specificity of E64d and CA074Me as inhibitors of cathepsin-B and cathepsin-L.
Expression vectors containing the cDNAs of hCath-L  or hCath-B were transfected into HeLa cells.
24h post transfection, cells were incubated for 3 h in absence or presence of the indicated
inhibitor, harvested, washed thoroughly in PBS, lysed and the resulting extracts were assayed for
cathepsin zFR-AMC enzymatic activity by monitoring AMC fluorescence with a fluorescence plate
reader. AMC fluorescence values were used to calculate relative enzymatic activity by
normalization to values measured in extracts from non-transfected cells. Therefore, relative
activity values represent the fold activity in comparison to endogenous cathepsin enzymatic
activity levels. Each data point was measured in triplicate. 
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to the situation found in malignant human tumor cells for which elevated cathepsin-expression and -
activity levels have been described [Chauhan, 1991; Lah, 1998; Yan, 1998]. 
 
As shown in Fig. 3.2.6 A, HeLa cells transiently transfected with hCath-L or hCath-B did not show 
any increased apoptosis when compared to control transfected cells. In addition, HeLa cell pools were 
generated that stably overexpressed hCath-L and hCath-B at levels of 2-fold or 4-fold enzymatic 
activity, respectively, compared to control cells. Also those stable expression pool clones of HeLa 
cells did not exhibit an enhanced response to TNF-induced apoptosis (Fig. 3.2.6 B). Since Cath-B has 
been reported to play a major role in apoptosis of hepatocytes [Guicciardi, 2000; Guicciardi, 2001; 
Roberts, 1999], hCath-L or hCath-B were transiently overexpressed in the rat hepatoma cell line McA 
RH 7777. Treatment of these McA RH 7777 cells with TNF did not yield any significant differences 
in apoptosis levels between control- and cathepsin-transfected cells (Fig. 3.2.6 C). 
 
Fig. 3.2.6 
Sensitivity to the TNF-mediated death signal is not enhanced by overexpression of hCath-L or
hCath-B. (A) Hela cells were transfected with pLuc, hCath-L, or hCath-B expression vectors, and 36h
post transfection the cells were incubated in absence or presence of 5 µg/ml CHX alone or 10 ng/ml
TNF + 5 µg/ml CHX. After 12h of treatment, cells were harvested for propidium iodide FACS analysis.
Transfection efficiency in this experiment was 40% as determined by pEGFP cotransfection and EGFP
FACS analysis, (B) HeLa cell pools selected for stable expression of pcDNA3, hCath-L, or hCath-B
were incubated in absence or presence of 5 µg/ml CHX alone or 10 ng/ml TNF + 5 µg/ml CHX. After
12h of treatment, cells were harvested for propidium iodide FACS analysis, (C) McA RH 7777 rat
hepatoma cells were transiently transfected with pLuc, hCath-L, or hCath-B expression vectors, and
36h post transfection were incubated in absence or presence of 1 µg/ml CHX alone, 10 ng/ml TNF + 1
µg/ml CHX, or 50 ng/ml TNF + 1 µg/ml CHX. After 12h of treatment cells were harvested for propidium
iodide FACS analysis. Transfection efficiency in this experiment was 40% as determined by pEGFP
cotransfection and EGFP FACS analysis. Data points were measured in triplicate and the data shown
are representative for several independent experiments. 
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3.2.6  Treatment of HeLa cells with TNF-α/CHX apparently triggers partial 
redistribution of lysosomal content into the cytosol 
 
The mode of action of lysosomal proteases in apoptosis signalling is assumed to involve release of 
lysosomal content into the cytosol where lysosomal proteolytic activity is expected to trigger 
activation of proapoptotic factors such the Bcl-2 family member Bid with subsequent release of 
cytochrome c from the mitochondria and activation of caspases [Guicciardi, 2000; Turk, 2002]. 
Although the results presented thus far do not indicate any correlation between cathepsin expression 
levels and sensitivity of HeLa cells to TNF-α/CHX-mediated death, it was tested whether the integrity 
of lysosomes in TNF-α/CHX-treated HeLa cells is disturbed so that elevated cathepsin levels within 
the lysosomes can be expected to result in accordingly higher amounts of cathepsin in the cytosol in 
response to the TNF-α stimulus.  
 
 
As a positive control, HeLa cells were treated with the lysosomotropic detergent N-dodecyl-imidazole 
hydrochloride (NDI-HCl), which was reported to accumulate in the lysosomes and eventually to 
damage the lysosomal membrane with subsequent release of lysosomal content into the cytosol 
[Dubowchik, 1995]. Anti-Cath-L immunofluorescent staining of untreated control HeLa cells showed 
the expected spot-like lysosomal distribution pattern of endogenous Cath-L (Fig. 3.2.7 A). 
Fig. 3.2.7 
Impact of TNF-α and NDI-HCl on lysosomal integrity. HeLa cells were cultivated for 16h
untreated (A) or in presence of 100 µM NDI-HCl (B), 2 µg/ml CHX (C), or 10 ng/ml TNF + 2 µg/ml
CHX (D). Cells were then fixed and immunostained using an anti-Cath-L mAb and a secondary
FITC-labeled anti-mouse mAb. Cells were microscopically inspected by fluorescence microscopy
(upper panels) or by Differential Interference Contrast microscopy (lower panels), and images were
taken using a digital imaging system. Magnification was 400-fold. 
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Treatment of HeLa cells with NDI-HCl resulted in an uniform staining of Cath-L within still viable 
cells, indicating effective lysosomal rupture and release of its content into the cytosol (Fig. 3.2.7 B). 
Treatment of HeLa cells with TNF-α/CHX resulted in a considerable number of cells with a decrease 
in the staining intensity of discrete lysosomal spots and an apparent partial redistribution of Cath-L 
from those spot-like structures to a more evenly distributed pattern as shown in (Fig. 3.2.7 D). Upon 
treatment with CHX alone such a redistribution effect could not be seen (Fig. 3.2.7 C). 
 
3.2.7  The lysosomotropic detergent NDI-HCl does not induce enhanced 
cell death in HeLa cells overexpressing hCath-L or hCath-B  
 
As shown above, the lysosomotropic detergent NDI-HCl efficiently triggers redistribution of 
lysosomal content into the cytosol as indicated by the release of Cath-L (Fig. 3.2.7 B). It was now 
examined, whether the cell death effect induced by NDI-HCl can be enhanced by overexpression of 
hCath-L or hCath-B.  
Fig. 3.2.8 
Cell death induced by NDI-HCl is not enhanced by overexpression of hCath-L or hCath-B.
HeLa cells were transfected with pLuc, hCath-L, or hCath-B expression vectors, 24h later equal
cell numbers were reseeded in wells of a 96 well plate and again 24h later were incubated in
absence or presence of the indicated amounts of NDI-HCl in absence or presence of either 50
µM zVAD-fmk or 50 µM E64d. After 22h of treatment, cells were analysed by MTT assay as
described in Materials and Methods. Transfection efficiency was determined by pEGFP
cotransfection and was > 50%. The data shown are the means of 4 independent experiments in
which each datapoint was measured in hexaplicate. 
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As shown in Fig. 3.2.8, expression levels of hCath-L or hCath-B did not have any significant effect on 
NDI-HCL-induced cell death in HeLa cells as determined by MTT assays. Cell death could be 
partially suppressed in  presence of the pan-caspase inhibitor zVAD-fmk indicating the involvement of 
caspase-dependent mechanisms in NDI-HCL-mediated cell death. Interestingly, this type of cell death 
could not be inhibited at all in presence of the broad specificity cysteine protease inhibitor E64d (Fig. 
3.2.8). 
 
3.2.8 RNAi as an approach to specifically downregulate cathepsin 
expression 
 
As shown in paragraph 3.2.4, the commonly used cathepsin protease inhibitors cannot be regarded 
specific for a distinct type of cathepsin. CA074Me not only blocks Cath-B enzymatic activity but also 
Cath-L activity and maybe also that of other cysteine proteases. Specific downregulation of a distinct 
cathepsin acticity would be necessary in order to unambiguously identify those cathepsins or 
cathepsin-like proteases that contribute to TNF-mediated apoptosis signalling. Targeted 
downregulation of cathepsins should be possible by using the recently described RNAi  approach 
which allows the knockdown of gene expression at the level of the mRNA message [Elbashir, 2001].  
 
Fig. 3.2.9 
Downregulation of hCath-L by RNAi. A. Test of the hCath-L RNAi construct in a cotransfection
experiment: HeLa cells were left untreated or were cotransfected with the hCath-L expression
vector together with the pSuper-hCath-L RNAi construct or the pSuper-hCath-B RNAi construct
(the latter serving here as a negative control). 24h post transfection, the cells were harvested and
the extracts were tested for zFR-AMC cathepsin enzymatic activity. B. Downregulation of
endogeneous hCath-L: HeLa cells were transfected with the pSuper-hCath-L construct or as
negative controls with pSuper-hCath-B or the arbitrary pSuper-N57 construct. 48h post
transfection, endogeneous hCath-L levels were detected by anti-hCath-L immunoblot analysis
(upper panel). Equal loading was verified by anti-Tim23 immunoblot analysis.   
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RNAi  plasmid constructs against hCath-L and hCath-B were generated using the pSuper vector system 
(Oligoengine, for oligo sequences see chapter 2.1.6). In the scope of this thesis, thus far only a RNAi 
construct was identified that successfully allowed the downregulation of hCath-L. In a cotransfection 
experiment the hCath-L overexpression vector was cotransfected together with the pSuper-hCath-L 
RNAi construct. As shown in Fig. 3.2.9 A, pSuper-hCath-L  but not pSuper-hCath-B could suppress 
the overexpression of hCath-L as measured by the cathepsin zFR-AMC enzymatic assay. Transfection 
of the pSuper-hCath-L construct also could downregulate endogeneous hCath-L levels as shown in 
Fig. 3.2.9 B. In contrast, the tested pSuper-hCath-B RNAi construct for specifically downregulating 
hCath-B expression proved to be inactive in a hCath-B cotransfection experiment (data not shown). 
Therefore additional target sequences will have to be tested for successful downregulation of hCath-B. 
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4  DISCUSSION 
 
Two projects are described within the scope of this thesis. Project 1 characterizes the ubiquitin-
specific protease UBP41 as a dominant apoptosis-inducing protein whereas project 2 investigates the 
possible involvement of the cathepsins-B and –L in proapoptotic signalling. Interestingly, UBP41 and 
the cathepsins-B and –L have something in common: all of them are cysteine proteases that are 
components of one of the two major systems of protein degradation: UBP41 is a member of the large 
family of ubiquitin-specific proteases (USPs) that are an integral part of the ubiquitin/proteasome 
system whereas cathepsin-B and –L are major components of the hydrolytic content of the lysosomes. 
At the same time, the two projects discussed here represent examples for the impact of non-caspase 
cysteine proteases on apoptosis. The existence of caspase-independent mechanisms and the 
involvement of non-caspase proteases in the mediation and execution of programmed cell death has 
been discussed intensely during the last years. Initially, there was the common belief that apoptosis is 
inevitably linked to the activation of the caspases which are regarded to be the backbone of the 
apoptotic machinery (see paragraph 1.1.4.2). However, evidence accumulates that there exist caspase-
independent apoptotic death pathways and that programmed cell death can occur in the complete 
absence of caspases (see paragraph 1.1.7). The existence of alternative, caspase-independent apoptosis 
mechanisms is actually not surprising when taking into account that it would be dangerous for a 
multicellular organism to exclusively depend on the functional integrity of a single protease family for 
such an essential biological process [Jaattela, 2003]. A number of factors have been proposed to 
mediate apoptotic events independently of caspases. Among those are proteins that are released from 
the mitochondria into the cytosol, such as the apoptosis-inducing factor (AIF), endonuclease G 
(endoG) and the serine protease Omi/HtrA2. Other factors that are suspected to contribute to caspase-
independent cell death pathways are the cytosolic calpain proteases as well as the lysosomal cathepsin 
proteases. Thus, cathepsins have already been recognized previously as potential proapoptotic factors 
and, in this context, the isolation of a cathepsin-L cDNA in the genetic screen for apoptosis-inducing 
genes raised special interest and stimulated its further investigation (project 2), the results of which 
will be discussed in paragraph 4.2. In contrast, a direct link between ubiquitin-specific proteases and 
apoptosis did not exist at the time when the cDNA for UBP41 had been isolated from our screen for 
proapoptotic genes. Nevertheless, there were several reasons to believe that USPs, such as UBP41, 
might indeed play a role in the regulation of apoptosis. One reason was that a link between the 
ubiquitin/proteasome system and apoptosis had already been established because, e.g., many apoptosis 
signalling factors were known to be regulated by proteasome-mediated degradation (see paragraph 
1.2.4). Since USPs were expected to play a major role in regulating ubiquitin/proteasome-dependent 
proteolysis by possibly targeting specific proteins for deubiquitination, it could be assumed that among 
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those putative USP targets there also might be proteins that are involved in apoptosis. Therefore, I 
decided to further characterize the UBP41-mediated apoptosis effect (project 1) which will be further 
discussed in paragraph 4.1.  
 
4.1  UBP41 - a dominant apoptosis-inducing factor 
 
The mouse orthologue of the ubiquitin-specific protease UBP41 was identified in the screen for 
dominant apoptosis-inducing genes (Fig. 3.1.1). It was demonstrated that also transfection of the 
human form of UBP41 (hUBP41) induces cell death in various human cell lines. The apoptotic mode 
of cell death induced by hUBP41 overexpression is supported by the detection of oligonucleosomal 
DNA fragmentation (Fig. 3.1.3), activation of caspase-3 (Fig. 3.1.5), and by the fact that cell death can 
be inhibited by the caspase inhibitor zVAD-fmk  (Fig. 3.1.10).  
 
4.1.1  Ubiquitin-specific proteases as possible regulators of apoptotic 
processes 
 
The family of ubiquitin-specific proteases (USPs) represents an integral component of the ubiquitin-
proteasome system in participating presumably in both, house-keeping and regulatory processes (see 
paragraph 1.2.3, and Box 4.1). As part of their house-keeping functions, USPs are able to remove 
ubiquitin-moieties from ubiquitylated proteins or peptides thereby influencing the available pool of 
monoubiquitin molecules as well as influencing the efficiency by which proteins are degraded at the 
level of the proteasome. Expecting an involvement of USPs in the regulation of the 
ubiquitin/proteasome system, it has been speculated that some USPs, via their deubiquitylating 
activity, might act to rescue distinct ubiquitylated protein substrates from degradation, whereas others 
may promote the degradation of distinct substrates by removing sterically inhibitory polyubiquitin 
chains and thereby enhancing the substrate’s accessibility to the proteasome [D'Andrea, 1998].  
Therefore, USPs are expected to have highly specific roles in regulating various biochemical and 
biological processes such as development, growth, and transcription, but also apoptosis. Indeed, there 
is accumulating evidence for an involvement of the ubiquitin-proteasome system in apoptosis by 
regulating the stability and activity of several factors including the Bcl-2 family of proteins, the IAPs, 
p53, IkB, as well as IKK [Jesenberger, 2002]. However, thus far there have been only few reports 
implicating USPs in the apoptotic process. Evidence for an impact of USPs on apoptosis could only be 
assumed, such as the fat facets gene product (Faf) in Drosophila or the related Fam protein in mouse 
which both appear to be crucial in development by contributing to the regulation of cell number 
[Fischer-Vize, 1992; Wood, 1997]. Intact Faf is necessary to maintain the correct number of 8 
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BOX 4.1 Selected members of the USP family
USP2: There is a number of isoforms belonging to the USP2 family: UBP41 was identified first from chicken [Baek, 1997]. Other chicken
isoforms are UBP46, UBP52, and UBP66 [Baek, 1998]. All those gallus gallus USP2s share strong sequence similarity within the core enzymatic
region and differ by N- or C-terminal extensions. Chicken USP2s were shown to hydrolyze various ubiquitylated test substrates. DNA sequences
coding for human USP2 homologues were identified and were published in Genbank. UBP41 expression was reported to be stimulated in response
to parathyroid hormone and thus might be involved in maintaining bone homeostasis [Miles, 2002].  
 
USP4: USP4 is the synonym for Unp (ubiquitous nuclear protein) which initially was proposed to be an oncogene elevated in lung tumors [Gray,
1995]. The Unp locus is at 3p21.3 which is frequently deleted or rearranged in lung cancers. Two isoforms, UnpEL and UnpES, were identified
which both are moderately expressed in various cell lines and appear to be localized mostly cytosolic, not nuclear [Frederick, 1998]. Results of
this study contradict a role of Unp as an oncogene, rather supporting a possible function as a tumor suppressor. Interestingly, Unp contains a Rb
binding motif, LxCxE, and indeed was shown to physically interact with the Rb protein in vivo [deSalle, 2001]. 
 
USP5: USP5 corresponds to the isopeptidase T (IsoT) protein of which two isoforms exist, IsoT-S and IsoT-L. IsoT can process linear and
branched polyubiquitin chains. It has been proposed that IsoT physiologically acts at the terminal step of ubiquitin-dependent proteolysis,
disassembling the polyubiquitin chain following the action of the poteasome on the target protein, presumably targeting free polyubiquitin chains
after the chains are released from the target protein [Wilkinson, 1995]. 
 
USP6: USP6 corresponds to the Tre2 oncogene which was identified in a transfection screen as a gene able to transform mouse NIH 3T3 cells,
however, Tre2 exists exclusively in the hominoid lineage of primates and only recently evolved during evolution (about 30 million years ago)
from the chimeric fusion of two genes, USP32 and TBC1D3 [Paulding, 2003]. 
 
USP7: USP7 is the systematic name for the ubiquitin-specific protease HAUSP (herpesvirus-associated ubiquitin-specific protease) which
originally was identified to associate with the herpes simplex virus activator of gene expression protein Vmw110. HAUSP was reported to be
localized in the nucleus, in part within PML nuclear bodies [Everett, 1997]. Importantly, HAUSP was recently identified as a p53-interacting
protein, mediating deubiquitination and therefore stabilization of p53 [Li, 2002]. HAUSP could rescue p53 from Mdm2-mediated ubiquitination
and degradation and it also activated p53 for transactivation and apoptosis induction. 
 
USP8: USP8 corresponds to UBPY, which was identified as a ubiquitin-specific protease that accumulates upon growth stimulation. Moreover,
UBPY levels decreased in response to growth arrest, and downregulation of the UBPY transcript by an antisense approach caused G1 arrest.
Therefore, UBPY appears to be a growth-regulated USP which itself has important impact on proliferation. Overexpression of wildtype UBPY
resulted in an overall decrease of protein ubiquitination and in a severe inhibition of cell growth [Naviglio, 1998]. 
 
USP9: One form of USP9 is localized on the male Y chromosome and is therefore called USP9Y. USP9Y is suspected to be a male infertility
gene since it is frequently deleted in infertile male mice with defective spermatogenesis [Lee, 2003]. Another variant of USP9 can be located on
the X chromosome and is called USP9x. Interestingly, USP9y and USP9x appear to be the homologous proteins of the Drosophila fat facets (faf)
gene and the mouse Fam gene. 
 
USP16: USP16 was described as Ubp-M, being a protein which is phosphorylated during G2/M transition and is dephosphorylated during
metaphase/anaphase transition. Interestingly, Ubp-M is able to deubiquitinate histone H2A and might be involved in the regulation of mitotic
events, even though it localizes mainly to the cytoplasm. An active site mutant of Ubp-M accumulated with metaphase chromosomes and caused
cell cycle arrest with subsequent apoptosis induction, possibly by binding to the ubiquitylated portion of histone H2A and by this interfering with
normal structure and function of chromatin [Ying, 1999]. 
 
USP18: USP18 was originally identified in mice and was named UBP43 which was demonstrated to cleave ubiquitin from the test substrate Ub-
ß-galactosidase and was proposed to play a role in hematopoiesis [Liu, 1999]. Human USP18 was later identified to be an IFN-ß inducible gene in
human melanoma cells but also in various other cell lines and was proposed to contribute to growth control and differentiation [Kang, 2001].
Recently, it was reported that USP18 preferentially cleaves ISG15 conjugates rather than ubiquitin conjugates and might be regarded to be the first
ISG15-specific protease [Malakhov, 2002]. 
 
USP21: USP21 was found to be able to cleave both, ubiquitin and Nedd8 conjugates and thus is a unique UBP with dual specificity for ubiquitin
and Nedd8. Moreover, USP21 was able to deubiquitinate a broad range of ubiquitylated proteins, and overexpression of USP21 resulted in
profound inhibition of cell growth [Gong, 2000]. 
 
DUB-1 and DUB-2: DUB-1 and DUB-2 are two USPs thus far only described in mouse, and yet no name has been assigned according to the
unified USP nomenclature [Baker, 1999]. DUB-1 is an IL-3 inducible gene, whereas DUB-2 expression is induced by IL-2, and both might play
an important role in cytokine-induced cell proliferation. Indeed, prolonged expression of DUB-1 inhibited cellular proliferation with little effect on
cellular viability [Zhu, 1996]. 
 
CYLD: CYLD has been identified as a tumor-suppressor frequently mutated in cases of familial cylindromatosis. CYLD was shown to
negatively regulate the NFkB survival signalling pathway by removing ubiquitin from the TRAF2 protein. Downregulation of the CYLD mRNA
message results in enhanced activation of NFkB and in a reduction of cell death induced by TNF-α [Brummelkamp, 2003; Kovalenko, 2003;
Trompouki, 2003]. 
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photoreceptor cells per facet by specifically targeting the liquid facets protein (Lqf) for 
deubiquitination and stabilization. Lqf is involved in endocytosis and has been proposed to enable the 
communication between the photoreceptor cells and their neighbours, thereby preventing positive 
differentiation signals [Chen, 2002]. The mus musculus Fam protein is homologous to the Drosophila 
Faf protein and even can substitute for Faf function in the Drosophila eye [Chen, 2000b]. In mouse, 
Fam interacts with β-catenin and Af-6, two proteins involved in cell-cell junctions, and it is expressed 
in rapidly dividing cells, for example in the apoptotic region between the digits [Taya, 1999; Wood, 
1997].  
Of major interest are recently published data which demonstrate that the ubiquitin-specific protease 
HAUSP is able to directly deubiquitinate the tumor-suppressor protein p53 [Li, 2002]. HAUSP-
mediated deubiquitination of p53 resulted in p53 stabilization and enhanced the proapoptotic activity 
of p53 (Fig. 4.1.1). In a colony-formation assay, HAUSP caused growth inhibition in cells with intact 
p53 status but not in p53 deficient cells. HAUSP presents the first example for a direct influence of 
USP-mediated deubiquitination on the stability and activity of an apoptosis-mediating factor (see also 
paragraph 1.2.3.2). It should be mentioned that, in contrast to my results found with hUBP41, 
overexpression of HAUSP alone did not result in significant cell death [Li, 2002].  
 
Another example for the direct involvement of a deubiquitinating enzyme in the regulation of survival 
and thus cell death pathways is the recently described CYLD gene product. As already mentioned in 
paragraph 1.2.3.2, CYLD is a tumor-suppressor which is frequently mutated in cases of familial 
cylindromatosis, an autosomal dominant predisposition to tumors of skin appendages. CYLD is a 
negative regulator of the pro-survival NF-κB signalling pathway by deubiquitylating the TNF receptor 
associated factor 2 (TRAF2) and thereby preventing the phosphorylation and activation of the IKK 
p53 p53
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HAUSP
ARF
Apoptosis,
Cell Cycle Arrest
Fig. 4.1.1 
p53 is a specific target for the deubiquitinating enzyme HAUSP.  Stability of p53 is
regulated by Mdm2-mediated ubiquitination and subsequent degradation by the proteasome.
HAUSP can deubiquitylate p53 and thus rescue it from degradation. Rescued and thus
stabilized p53 can mediate apoptosis and/or cell cycle arrest. HAUSP was the first ubiquitin-
specific protease that was shown to specifically target a proapoptotic factor for deubiquitination.
According to Li et al. [Li, 2002]. 
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complex by the IKK kinase complex (Fig. 4.1.2). Inactivation of CYLD by knockdown experiments 
leads to enhanced NF-κB activity and, in consequence, renders cells more resistant to apoptosis 
induction by TNF-α [Brummelkamp, 2003]. Thus, besides HAUSP, CYLD is the second known 
example for a deubiquitinating enzyme that targets a specific substrate with impact on cellular survival 
and apoptosis. CYLD is a paradigm for a deubiquitinating enzyme which, besides having impact on 
survival and cell death signalling, can possess tumor-suppressive properties whose impairment results 
in cancer.   
 
Fig. 4.1.2 
The deubiquitinating enzyme CYLD specifically deubiquitylates the TRAF2 protein. The
NF-κB survival pathway can be activated in response to the ligation of the tumor necrosis
factor receptor (TNFR) with TNF-α. The adaptor protein TRADD is recruited to the activated
TNF receptor, which besides forwarding the signal to proapoptotic signalling components such
as the DISC, also allows the binding of TRAF2, RIP, and the IKK complex. The IKK complex is
phosphorylated and thereby activated by the IKK kinase complex and mediates
phosphorylation and degradation of IκB with consequent activation of NF-κB. The IKK kinase
complex is recruited to the TNFR-TRAF2-IKK complex when TRAF2 is modified by a
multiubiquitin chain in which the ubiquitin units are linked with each other by their internal
Lys63 residue. Lys63 linkage within multiubiquitin chains is unusual because in most
polyubiquitins it is the Lys48 residue that is covalently attached to the C-terminus of another
ubiquitin molecule. Lys48-linked multiubiquitin chains target their corresponding substrate
proteins for recognition and degradation by the proteasome as is the case with e.g. IκB. In
contrast, Lys63-linked multiubiquitin chains were discussed to preferentially play regulatory
roles such as during DNA repair processes [Hoege, 2002]. CYLD physically interacts with the
IKK-γ/NEMO subunit of the IKK complex and causes deubiquitination of TRAF2, thereby
disrupting the interaction of TRAF2 with the IKK kinase complex which consequently is
prevented from activating the IKK complex. 
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4.1.2  The effect of UBP41 overexpression in comparison to 
overexpression of other members of the USP family 
 
In this thesis, it was demonstrated that hUBP41 mediates the induction of apoptosis when 
overexpressed in various transformed human cell lines such as 293T, HeLa, and PC3 (see paragraph 
3.1.2). hUBP41 is the first example for a ubiquitin-specific protease which upon overexpression 
displays proapoptotic activity, because there are no previous reports in the literature that describe 
apoptosis induction by the overexpression of USPs. In one case, cells were reported to undergo cell 
death when an active-site mutant of the ubiquitin-specific protease Ubp-M was overexpressed. The 
wildtype form of Ubp-M, however, did not have any apparent effect on transfected cells. Ubp-M has 
been discussed to selectively act on histones H2A and H2B, thereby contributing to the condensation 
of mitotic chromosomes. An explanation for the apoptosis-inducing effect of the active-site mutant 
form of Ubp-M might be its observed tight association with mitotic chromosomes during all stages of 
cell division, possibly triggerig cell cycle arrest and eventually apoptosis [Cai, 1999].  
 
Overexpression experiments have also been reported with the ubiquitin-specific proteases DUB-1 
[Zhu, 1996], USP21 [Gong, 2000], and UBPY [Naviglio, 1998] but in all three cases no apoptosis has 
been observed. Instead, DUB-1 overexpression was reported to result in growth suppression by 
arresting cells in G1, and overexpression of USP21 and of UBPY also mediated a profound growth 
inhibitory effect. Results of this thesis demonstrate that overexpression of hUSP21-HA but also 
hUSP18-HA do not not result in apoptosis induction in 293T cells (Fig. 3.1.5). It must be mentioned 
that it cannot totally be ruled out that this is explained by the fact that expression levels of hUSP18-
HA and hUSP21-HA could not be obtained as high as was the case with hUBP41-HA overexpression 
(Fig. 3.1.5 C). Indeed, it appears that appropriately high expression levels of hUBP41-HA are 
necessary in order to obtain a reasonable degree of apoptosis induction. Therefore, if hUBP41-
mediated sensitivation for apoptosis induction plays a role under physiological or pathological 
conditions, tissues with strong hUBP41 / hUSP2 expression levels such a kidney or skeletal muscle 
(Fig. 3.1.16) or testis [Miles, 2002] are most likely to be affected.  
In this context, it might be worth noting that in the attempt to generate 293T clone pools stably 
expressing hUBP41-HA, hUSP18-HA, hUSP21-HA, as well as their corresponding enzymatic mutant 
forms, only in case of hUBP41-HA it was not able to recover any surviving cell clone, whereas from 
293T cells transfected with the other constructs many clones could be rescued under selection 
conditions (not shown). In this sort of experiment, the transfection of a pool of cells is expected to 
result in cells with varying amounts of overexpression, from very low to very high levels of hUBP41. 
The fact that not one single hUBP41-transfected 293T cell clone (not even a clone with minor 
overexpression) could be recovered under selection conditions may indicate that not even a slight 
increase of hUBP41 levels is tolerable for a cell to survive over a long term. From this observation one
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also may draw the conclusion that endogenous hUBP41 activity is in balance with other cellular 
events and that a disturbance of this balance by overexpression of hUBP41 will result in cell death. 
 
 
4.1.3  Possible explanations for the apoptotic effect of UBP41 
overexpression 
 
Overexpression of hUBP41-HA resulted in dramatic deubiquitination of a wide range of substrates 
(Fig. 3.1.12), and a severe interference with the ubiquitin-proteasome system should be expected. The 
apoptotic effect of UBP41 overexpression might be explained by various different possible scenarios, 
which will be discussed below and are schematically summarized in Fig. 4.1.3.  
 
Fig. 4.1.3  
Possible explanations for the  apoptosis-inducing effect of UBP41 overexpression. UBP41
overexpression might cause a massive increase in the free mono-ubiquitin pool and thus might
result in cell death either by stimulating inappropriate protein degradation by the proteasome or by
mediating a chaotropic effect in partially unfolding proteins (1). Another possibility would be the
broad range deubiquitination and the consequent stabilization of a vast number of proteins,
possibly being comparable to an inhibition of the proteasome. Inhibition of the protasome is known
to result in apoptosis induction (2). In case that only specific proteins are stabilized as a
consequence of UBP41 overexpression, it would be the accumulation of proapoptotic factors that
might be responsible for apoptosis induction (3).  
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4.1.3.1  Apoptosis induction by the accumulation of monoubiquitin 
 
Increased deubiquitinating activity within the cell, such as caused by UBP41 overexpression, might 
possibly lead to an inappropriate level of free monomeric ubiquitin that might interfere with cellular 
processes, e.g. by its putative chaotropic action towards other proteins. This chaotropic effect of 
ubiquitin is characterized by a partial unfolding of proteins due to the interference of ubiquitin with 
intramolecular non-covalent binding forces of proteins [Wenzel, 1993]. But this scenario appears not 
to be likely since when wildtype ubiquitin was overexpressed in HeLa cells and 293T cells, no effect 
concerning cell death induction could be observed (data not shown) and, moreover, anti-ubiquitin 
immunoblots already demonstrated very high basal levels of monoubiquitin in untreated 293T and 
HeLa cells which did not recognizably change in hUBP41-HA transfected cells (see the prominent 
protein band at < 10 kDa in Fig. 3.1.12).  
 
4.1.3.2  Apoptosis by a general disturbance of the cellular ubiquitination status 
 
Overexpression of UBP41 resulted in the deubiquitination of a broad range of proteins (Fig. 3.1.12), 
suggesting that the ubiquitination status of the cell is severely disturbed. Interestingly, the capacity to 
cause broad range deubiquitination upon overexpression has been previously observed with USP21 
[Gong, 2000] and UBPY [Naviglio, 1998], but in both cases not apoptosis but a strong growth 
inhibitory effect was observed. It certainly cannot be excluded that the growth inhibition observed in 
those studies is a consequence of slow and gradual cell death induction that had not been recognized 
by the corresponding investigators. Furthermore, a similar decrease of overall ubiquitination levels and 
concurrent apoptosis induction has been reported for cells rendered deficient in the ubiquitin-
activating enzyme E1 [Monney, 1998]. E1 deficiency resulted in broad range protein deubiquitination 
and apoptosis, but in contrast to hUBP41-mediated apoptosis, this type of cell death was caspase-
independent. The broad range deubiquitylating effect of E1 deficiency was accompanied by the 
accumulation of p21, p27, cyclin D1 and p53, but not Bax. The authors proposed that as yet 
unidentified short-lived proteins might be stabilized, accumulate and act as death effectors in the 
induction of apoptosis. 
Therefore, broad range deubiquitination has previously been observed in other cell systems either in 
response to USP overexpression or by impairment of the ubiquitination system in E1-deficient cells. In 
the latter case, the broad range deubiquitination effect eventually resulted in apoptosis, but also in this 
study it remained elusive whether apoptosis induction was caused by the accumulation of distinct 
proapoptotic protein factors or by the general defect in the ubiquitination system.   
 
A general disturbance of the cellular ubiquitination status by UBP41 overexpression may correspond 
to an interference with the proteasomal degradation system as a whole, i.e. might be analogous to the
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inhibition of the proteasome. Indeed, treatment of cells with proteasome inhibitors has been 
recognized to induce apoptosis under certain conditions [Shah, 2001; Adams, 2002]. For this reason, 
the response of HeLa cells to the proteasome inhibitor MG132 was examined and compared to the 
overexpression of hUBP41-HA in the same cell system. It became apparent that MG132 primarily 
leads to a cell cycle arrest in G2/M and presumably only subsequently results in moderate apoptosis 
induction (Fig. 3.1.15) which is in line with previous reports [Chen, 2000; Shah, 2001]. In contrast, 
overexpression of hUBP41-HA did not arrest cells in the cell cycle but apparently was driving cells 
directly into apoptosis (Fig. 3.1.15). Thus, even though a strong interference with the ubiquitin-
proteasome system must be assumed upon hUBP41-HA overexpression, the resulting cellular changes 
are clearly distinct from a general inhibition of proteasome activity by the common drug MG132. 
Proteasome inhibitors have recently been introduced into clinical studies due to their potential 
capability to enhance the proapoptotic effect of chemotherapeutical drugs towards otherwise resistant 
tumor cells [Adams, 1999]. Since overexpression of Ubp41 induces apoptosis with distinct differences 
to a common proteasome inhibitor (MG132), it might be rewarding to identify and characterize drugs 
that act on the level of protein ubiquitination in addition to the development of drugs that directly 
target the proteasome for the therapeutic induction of cell death in tumor cells. Interfering with the 
ubiquitination status might present an additional approach to target cancer cells for destruction and 
might be of advantage under certain conditions in certain cell or tissue systems. 
 
In the attempt to interfere with the ubiquitination status in an alternative way, the ubiquitin double 
mutant Ub K48R, G76A was expressed in 293T.  Overexpression of Ub K48R, G76A did not result in 
apoptosis induction (Fig. 3.1.13). The ubiquitin double mutant is certainly not expected to confer 
deubiquitination comparable to that observed for hUBP41 HA (Fig. 3.1.12) but rather to influence the 
dynamics of polyubiquitin chain formation with a bias toward shorter chain length [Finley, 1994]. 
 
4.1.3.3  Apoptosis induction as a cause of specific protein stabilization  
 
Since hUBP41 overexpression apparently causes deubiquitination of a majority of cellular proteins 
(Fig. 3.1.12), it consequently can be expected that many proteins, which normally are regulated by the 
ubiquitin-proteasome system, will be rescued from degradation and therefore will accumulate within 
the cell. The arbitrary accumulation of a broad range of cellular proteins would correspond to a 
general disturbance of the ubiquitin/proteasome system as discussed in paragraph 4.1.3.2. However, at 
least within the scope of this thesis work, it could not be demonstrated that broad range 
deubiquitination directly corresponds to broad range stabilization of protein substrates. The cell cycle 
proteins p21, p27 and cyclin B1 have been well described to be ubiquitylated and to be degraded by 
the proteasome. Consistently, protein levels of p21, p27, and cyclin B1 accumulated in the presence of 
the drug inhibitor of the proteasome, MG132. In contrast, overexpression of hUBP41-HA did not 
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stabilize those proteins (Fig. 3.1.14 B). Moreover, 2-dimensional gel electrophoresis of protein 
extracts from hUBP41- or control-transfected cells did not reveal any striking differences in the 
overall protein expression pattern (data not shown).  
 
While no endogenous proteins could be demonstrated to be stabilized by hUBP41-HA overexpression, 
the artifical test substrate Ub-G76V-GFP [Dantuma, 2000] was stabilized when co-expressed with 
hUBP41-HA. (Fig 3.1.14 A). This result at least leaves the possibility that despite the apparent broad 
range deubiquitination effect of hUBP41-HA, only distinct, usually short-lived substrates are actually 
stabilized, leading to the observed cell death effect. It should be noted, that the significance of the 
results obtained with the test substrate Ub-G76V-GFP is somewhat questionable since not only co-
expression of hUBP41-HA but also of the active site mutant hUBP41-C24A-HA resulted in 
stabilization of the GFP test substrate, almost as efficient as with hUBP41-HA itself (Fig 3.1.14 A). 
Possibly, the mutant enzyme hUBP41-C24A-HA can still bind to Ub-G76V-GFP, however it is not 
able to deubiquitinate this substrate. Therefore, it might be speculated that hUBP41-C24A-HA keeps 
Ub-G76V-GFP bound in a complex in which the ubiquitin moiety is shielded from recognition by the 
proteasome and in this way Ub-G76V-GFP is rescued from degradation (Fig. 4.1.4).  
 
Fig. 4.1.4 
Effect of hUBP41 and hUBP41-C24A on the test substrate Ub-G76V-GFP. Ub-G76V-GFP is a
GFP protein artificially fused at its N-terminus to the C-terminus of a ubiquitin-monomer. The C-
terminus of the ubiquitin was changed from Gly to Val in order to make the fusion more stable
towards deubiquitination. A. When Ub-G76V-GFP is overexpressed alone, it is multiubiquitylated
and efficiently degraded by the proteasome: the cells are GFP-negative. B. When coexpressed with
UBP41, Ub-G76V-GFP still can be ubiquitylated, but this is reversed by the action of UBP41. The
monoubiquitylated Ub-G76V-GFP cannot be targeted by the proteasome and therefore is not
degraded: the cells are GFP-positive. C.When coexpressed with UBP41-C24A, this enzymatic
mutant form of UBP41 may still bind to, but cannot deubiquititinate Ub-G76V-GFP. UBP41-C24A
therefore possibly remains bound to Ub-G76V-GFP in a complex and shields it from the
proteasome: the cells are GFP-positive.  
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In support of this possibility, when EYFP fusions of hUBP41 and its active-site mutant were observed 
under the fluorescence microscope (Fig. 3.1.9) it could be seen that in contrast to wildtype hUBP41, 
the mutant enzyme obviously forms prominent aggregates within the cell, i.e. it might associate with 
certain targets within the cell in an inappropritately tight manner. If this is the case, it may explain the 
significant cell-death effect of the active-site mutant hUBP41-C24A-HA in the HeLa cell system 
(Fig.3.1.7 and Fig. 3.1.8). In this context, it should be noted that the already mentioned enzymatically 
inactive mutant of Ubp-M was described to tightly associate with mitotic chromosomes, thereby 
possibly mediating its apoptotic effect upon overexpression [Cai, 1999].  
 
 
4.1.4  The possible role of UBP41 as a modulator of apoptosis under 
physiological and pathological conditions 
 
The data presented in this study mainly describe the response of human cancer cell lines to high level 
overexpression of genes, in this case of UBP41. It is questionable whether the protein levels obtained 
in transient transfection experiments will ever be reached under physiological conditions. 
Nevertheless, it cannot be ruled out that UBP41 expression might be strongly deregulated under 
pathological conditions, thereby causing or at least contributing to inappropriate or premature cell 
death induction in certain settings.  
Under physiological conditions, UBP41 possibly should not predominantly be regarded as a dominant 
apoptosis-inducing factor as it is under conditions of high level overexpression but rather as a factor 
that modulates the sensitivity of cells to death stimuli. While UBP41 is obviously capable of 
influencing the ubiquitination status of a broad range of proteins (Fig 3.1.12), it realistically must be 
assumed that not only proapoptotic factors are among the proteins stabilized but antiapoptotic proteins 
as well. Instead of specifically stabilizing distinct proapoptotic proteins, it therefore might be more 
likely that hUBP41 overexpression interferes with the well balanced ratio between pro- and
antiapoptotic mediators. Whereas in a normal, viable cell proapoptotic signalling is counteracted by 
the presence and action of an equivalent or more than equivalent number of antiapoptotic factors, the 
situation might be inversed after hUBP41 overexpression so that in total the proapoptotic signalling 
machine can overpower the antiapoptotic mechanisms (Fig. 4.1.5). 
Thus, the status of UBP41 expression might influence the balance between pro- and antiapoptotic 
factors. Consequently, a minor change in the UBP41 level not necessarily will lead to apoptosis 
induction by itself but would contribute to the cellular status that determines whether a cell is more or 
less sensitive to the induction of apoptosis in the context of survival or death signals from within or 
outside the cell (Fig. 4.1.5). 
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4.1.5  Genomic sequence analysis of the USP2 gene locus 
 
In this study, a cDNA clone named UI-64 was isolated in the screen for apoptosis-inducing genes. By 
sequence analysis using BLAST [Altschul, 1997] this clone was identified as the mouse orthologue of 
the ubiquitin-specific protease UBP41 which originally was isolated and characterized in chick 
skeletal muscle [Baek, 1997]. The sequence alignment in Fig. 3.1.2 reveals that the coding sequence 
of the original cDNA clone (UI64) from the screen lacks the first five aminoterminal amino acids 
when compared to the published mouse UBP41 sequence (mUBP41, NCBI gi:7949157). At that time, 
when sequence analysis was done for the clone UI64, the mUBP41 sequence was the only mouse 
sequence hit in the database. In the meantime, several isoforms of UBP41 were discovered and 
according to a unifying nomenclature [Baker, 1999] are now known as USP2 isoforms. Recently (Oct 
2003), the sequences of  three murine USP2 (mUSP2) isoforms were published in Genbank. The 
mUSP2 transcript variant 1 (Accession NM_016808, gi:7949157) corresponds to the former mUBP41 
entry, whereas mUSP2 transcript variant 2 (NM_198091, gi:37674278) and mUSP2 transcript variant 
3 (NM_198092 , gi:37674280) possess N-terminal extensions when compared to variant 1 (Fig. 4.1.6). 
pro-apoptotic factor
anti-apoptotic factor
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anti-apoptotic factors keep in 
check pro-apoptotic signalling
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Fig. 4.1.5   
A hypothetical mode of action of hUBP41 overexpression. hUBP41 overexpression may interfere
with the well balanced ratio between pro- and antiapoptotic mediators. Whereas in a normal, viable
cell proapoptotic signalling is counteracted by the presence and action of an equivalent or more than
equivalent number of antiapoptotic factors, the situation might be inversed after hUBP41
overexpression so that in total the proapoptotic signalling machine can overpower the antiapoptotic
mechanisms. 
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The sequence of the cDNA clone UI64 starts with a methionine that presumably corresponds to an 
internal methionine of the mUSP2 transcript variant 3 (see Fig. 4.1.6). Therefore, taking into account 
this recent sequence information, the cDNA clone UI64 is most likely a fragment of the mUSP2 
transcript variant 3. This explains why UI64 lacks the first five aminoterminal amino acid residues 
when compared to the transcript variant 1. 
 mUSP2_var3    (1) MSQLSSTLKRYTESSRYTDAPYAKPGYGTYTPSSYGANLAASFLEKEKLG 
      _var3   (51) FKPVSPTSFLPRPRTYGPSSILDCDRGRPLLRSDIIGSSKRSESQTRGNE 
      _var3  (101) RPSGSGLNGGSGFSYGVSSNSLSYLPMNARDQGVTLSQKKSNSQSDLARD 
      _var3  (151) FSSLRTSDGYRTSEGFRIDPGNLGRSPMLARTRKELCALQGLYQAASRSE 
 
 mUSP2_var1    (1) -------------------------------------------------- 
 mUSP2-var2    (1) ------------------MRTSYTVTLPEEPPAAHFPALAKELRPRSPLS 
 mUSP2_var3  (201) YLTDYLENYGRKGSAPQVLTQAPPPS-RVPEVLSPTYRPSGRYTLWEKSK 
 UI64              -------------------------------------------------- 
  
 mUSP2_var1    (1) -----------MLNKAKNSKSAQGLAGLRNLGNTCFMNSILQCLSNTREL 
 mUSP2-var2   (33) PSLLLSTFVGLLLNKAKNSKSAQGLAGLRNLGNTCFMNSILQCLSNTREL 
 mUSP2_var3  (250) GQASGPSRSSSPGRDTMNSKSAQGLAGLRNLGNTCFMNSILQCLSNTREL 
 UI64          (1) ----------------MNSKSAQGLAGLRNLGNTCFMNSILQCLSNTREL 
 
 mUSP2_var1   (40) RDYCLQRLYMRDLGHTSSAHTALMEEFAKLIQTIWTSSPNDVVSPSEFKT 
 mUSP2-var2   (83) RDYCLQRLYMRDLGHTSSAHTALMEEFAKLIQTIWTSSPNDVVSPSEFKT 
 mUSP2_var3  (300) RDYCLQRLYMRDLGHTSSAHTALMEEFAKLIQTIWTSSPNDVVSPSEFKT 
 UI64         (35) RDYCLQRLYMRDLGHTSSAHTALMEEFAKLIQTIWTSSPNDVVSPSEFKT 
 
 mUSP2_var1   (90) QIQRYAPRFMGYNQQDAQEFLRFLLDGLHNEVNRVAARPKASPETLDHLP 
 mUSP2-var2  (133) QIQRYAPRFMGYNQQDAQEFLRFLLDGLHNEVNRVAARPKASPETLDHLP 
 mUSP2_var3  (350) QIQRYAPRFMGYNQQDAQEFLRFLLDGLHNEVNRVAARPKASPETLDHLP 
 UI64         (85) QIQRYAPRFMGYNQQDAQEFLRFLLDGLHNEVNRVAARPKASPETLDHLP 
 
 mUSP2_var1  (140) DEEKGRQMWRKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDL 
 mUSP2-var2  (183) DEEKGRQMWRKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDL 
 mUSP2_var3  (400) DEEKGRQMWRKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDL 
 UI64        (135) DEEKGRQMWRKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDX 
 
 mUSP2_var1  (190) SLPIAKRGYPEVTLMDCMRLFTKEDILDGDEKPTCCRCRARKRCIKKFSV 
 mUSP2-var2  (233) SLPIAKRGYPEVTLMDCMRLFTKEDILDGDEKPTCCRCRARKRCIKKFSV 
 mUSP2_var3  (450) SLPIAKRGYPEVTLMDCMRLFTKEDILDGDEKPTCCRCRARKRCIKKFSV 
 UI64        (185) SLPIAKRGYPEVTLMDCMRLFTKXDILDGDEKPTCCRCRARKRCIKKFSV 
 
 mUSP2_var1  (240) QRFPKILVLHLKRFSESRIRTSKLTTFVNFPLRDLDLREFASENTNHAVY 
 mUSP2-var2  (283) QRFPKILVLHLKRFSESRIRTSKLTTFVNFPLRDLDLREFASENTNHAVY 
 mUSP2_var3  (500) QRFPKILVLHLKRFSESRIRTSKLTTFVNFPLRDLDLREFASENTNHAVY 
 UI64        (235) QRFPKILVLHLKRFSESRIRTSKLXTFVNFXLRDLDLREFASENXNHAVY 
 
 mUSP2_var1  (290) NLYAVSNHSGTTMGGHYTAYCRSPVTGEWHTFNDSSVTPMSSSQVRTSDA 
 mUSP2-var2  (333) NLYAVSNHSGTTMGGHYTAYCRSPVTGEWHTFNDSSVTPMSSSQVRTSDA 
 mUSP2_var3  (550) NLYAVSNHSGTTMGGHYTAYCRSPVTGEWHTFNDSSVTPMSSSQVRTSDA 
 UI64        (285) NLYAVSNHSGTXMGGXYTAYCRSPVTGEWHTFNDSSVTPMSSSQVRTSDA 
 
 mUSP2_var1  (340) YLLFYELASPPSRM 
 mUSP2-var2  (383) YLLFYELASPPSRM 
 mUSP2_var3  (600) YLLFYELASPPSRM 
 UI64        (335) YLLFYELASPPSRM 
 
Fig. 4.1.6 
Amino acid alignment of the three mouse USP2 isoforms together with the sequence derived
from the cDNA clone UI64 from the screen. Recently, the sequences of three murine USP2
sequences were released in Genbank, here designated mUSP2_var1-3. The three isoforms are
identical in their last 340 amino acids with mUSP2 transcript variants 2 and 3 possessing N-terminal
extensions. By length, the translated UI64 cDNA clone sequence is most closely related to mUSP2
variant 1. However, the N-terminus of UI64 corresponds to an internal methionine of the mUSP2
variant 3. This explains why UI64 lacks the first five aminoterminal amino acid residues when
compared to the transcript variant 1. The X residues in the UI64 sequence are due to inaccuracies
during sequencing. 
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At the time when the UBP41 project was started (in the year 2000), the NCBI Genbank contained one 
single entry for a human form of UBP41 (NM_004205.1, gi:4759291). According to this sequence, 
hUBP41 was isolated by RT PCR and was used for all further studies. In the meantime, NCBI 
databank entries were revised several times for hUBP41 as can be seen in the revision history for the 
NCBI Genbank accession number NM_004205. As is the case with mouse UBP41, more sequence 
information about hUBP41 has been released recently. The protein that was originally named human 
UBP41 (consisting of 353 amino acid residues) is now designated human USP2 (hUSP2) of which two 
isoforms are described: the long transcript variant 1 (Accession NM_004205, gi:21361711) and the 
short transcript variant 2 (Accession NM_171997, gi:28565284). The originally published human 
UBP41 sequence is a perfect match of the last 352 C-terminal amino acids of the shorter hUSP2 
variant 2 which consists of 396 amino acids and thus possesses a N-terminal 43 amino acid extension 
when compared to hUBP41 (Fig. 4.1.7).  
It remained elusive whether hUBP41 is just a fragment of hUSP2 variant 2 or exists independently as 
a third hUSP2 variant. Recent information provided by the Human Genome Sequence server at NCBI 
(second release of the finished human reference genome from Oct 7, 2003) for the first time allowed 
the identification of the complete hUSP2 coding sequence with its corresponding genomic 
counterparts (exon sequences) on chromosome 11q23.3 (Fig 4.1.8). Previous genomic sequence 
releases did not contain matching sequences for the extreme N-terminal part of hUBP41, hUSP2 
variant 1, and hUSP2 variant 2. 
Genomic sequence analysis, using this revised sequence release, suggests that hUBP41 might be a 
fragment of the human USP2 transcript variant 2 (Fig. 4.1.8) because hUBP41 is identical in sequence 
as well as in  exon/ intron organisation when compared to hUSP2 variant 2 but it is missing the first 
129 bp. Importantly, at the putative start position of the UBP41 coding sequence the expected ATG 
codon is missing: instead, a CTG codon is found. This raises doubts whether the hUBP41 sequence 
investigated within the scope of this thesis does exist on its own or indeed is only a fragment of the 
USP2 variant 2. Notably, the same situation is found when the mus musculus mUBP41 sequence is 
analysed: as indicated above, three mUSP2 isoforms have been published in Genbank of which the 
mUSP2 transcript variant 1 corresponds exactly to the previously published mUBP41 sequence and 
therefore would be the mouse orthologue of the putative human UBP41. 
The mouse USP2 locus is found on chromosome 9, and sequence analysis indicates that also for 
mUBP41 (alias mUSP2 transcript variant 1) no start ATG but instead a CTG codon is present. 
Consequently, with respect to those data, also the existence of the mUBP41 transcript would appear 
questionable and mUBP41 could be suspected to represent only a fragment of the longer mUSP2 
transcript variant 2. However, the mUBP41 transcript has been identified in several independent 
cDNA sequencing projects and has been annotated as a putative full-length cDNA [Strausberg, 2002; 
Kawai, 2001]. This leaves open the possibility, that mUBP41 and also hUBP41 exist as USP2 
isoforms on their own, and that translation can be initiated at a putative alternative CTG start
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codon. At least there exist examples for the capacity of CTG codons as a start for translation [Arnaud, 
1999]. 
 
hUSP2-L    MSQLSSTLKRYTESARYTDAHYAKSGYGAYTPSSYGANLAASLLEKEKLG 
hUSP2-S    -------------------------------------------------- 
hUBP41     -------------------------------------------------- 
                  
hUSP2-L    FKPVPTSSFLTRPRTYGPSSLLDYDRGRPLLRPDITGGGKRAESQTRGTE 
hUSP2-S    -------------------------------------------------- 
hUBP41     -------------------------------------------------- 
 
hUSP2-L    RPLGSGLSGGSGFPYGVTNNCLSYLPINAYDQGVTLTQKLDSQSDLARDF 
hUSP2-S    -------------------------------------------------- 
hUBP41     -------------------------------------------------- 
 
hUSP2-L    SSLRTSDSYRIDPRNLGRSPMLARTRKELCTLQGLYQTASCPEYLVDYLE 
hUSP2-S    -------------------------------------------------- 
hUBP41     -------------------------------------------------- 
 
hUSP2-L    NYGRKGSASQVPSQAPPSRVPEIISPTYRPIGRYTLWETGKGQAPGPSRS 
hUSP2-S    -------- MRTSYTVTLPEDPPAAPFPALAKELRPRSPLSPSLLLSTFV 
hUBP41     -------------------------------------------------- 
 
hUSP2-L    SSPGRDGMNSKSAQGLAGLRNLGNTCFMNSILQCLSNTRELRDYCLQRLY 
hUSP2-S    GLLLNKAKNSKSAQGLAGLRNLGNTCFMNSILQCLSNTRELRDYCLQRLY 
hUBP41     --MLNKAKNSKSAQGLAGLRNLGNTCFMNSILQCLSNTRELRDYCLQRLY 
 
hUSP2-L    MRDLHHGSNAHTALVEEFAKLIQTIWTSSPNDVVSPSEFKTQIQRYAPRF 
hUSP2-S    MRDLHHGSNAHTALVEEFAKLIQTIWTSSPNDVVSPSEFKTQIQRYAPRF 
hUBP41     MRDLHHGSNAHTALVEEFAKLIQTIWTSSPNDVVSPSEFKTQIQRYAPRF 
 
hUSP2-L    VGYNQQDAQEFLRFLLDGLHNEVNRVTLRPKSNPENLDHLPDDEKGRQMW 
hUSP2-S    VGYNQQDAQEFLRFLLDGLHNEVNRVTLRPKSNPENLDHLPDDEKGRQMW 
hUBP41     VGYNQQDAQEFLRFLLDGLHNEVNRVTLRPKSNPENLDHLPDDEKGRQMW 
 
hUSP2-L    RKYLEREDSRIGDLFVGQLKGSLTCTDCGYCSTVFDPFWDLSLPIAKRGY 
hUSP2-S    RKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDLSLPIAKRGY 
hUBP41     RKYLEREDSRIGDLFVGQLKSSLTCTDCGYCSTVFDPFWDLSLPIAKRGY 
 
hUSP2-L    PEVTLMDCMRLFTKEDVLDGDEKPTCCRCRGRKRCIKKFSIQRFPKILVL 
hUSP2-S    PEVTLMDCMRLFTKEDVLDGDEKPTCCRCRGRKRCIKKFSIQRFPKILVL 
hUBP41     PEVTLMDCMRLFTKEDVLDGDEKPTCCRCRGRKRCIKKFSIQRFPKILVL 
 
hUSP2-L    RLKRFSESRIRTSKLTTFVNFPLRDLDLREFASENTNHAVYNLYAVSNHS 
hUSP2-S    HLKRFSESRIRTSKLTTFVNFPLRDLDLREFASENTNHAVYNLYAVSNHS 
hUBP41     HLKRFSESRIRTSKLTTFVNFPLRDLDLREFASENTNHAVYNLYAVSNHS 
 
hUSP2-L    GTTMGGHYTAYCRSPGTGEWHTFNDSSVTPMSSSQVRTSDAYLLFYELAS 
hUSP2-S    GTTMGGHYTAYCRSPGTGEWHTFNDSSVTPMSSSQVRTSDAYLLFYELAS 
hUBP41     GTTMGGHYTAYCRSPGTGEWHTFNDSSVTPMSSSQVRTSDAYLLFYELAS 
 
hUSP2-L    PPSRM 
hUSP2-S    PPSRM 
hUBP41     PPSRM 
Fig. 4.1.7 
Alignment of hUBP41 with the two published hUSP2 variants. The hUBP41
sequence (essentially as published in Genbank gi:4759291) was aligned with the two
hUSP2 variants: hUSP2 variant 1, here designated hUSP-L (gi:21361711), and
hUSP2 variant 2, here designated hUSP-S (gi:28565284 ). The C-terminal part of
hUSP variant 2 is identical to the complete hUBP41 sequence whereas there are a
few differences to variant 1, possibly due to polymorphisms. 
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As a conclusion, sequence analysis of the human USP2 locus raises doubts about the existence of 
hUBP41 as a transcript on its own. Strongest doubts arise from the fact, that the putative hUBP41 
coding sequence does not possess a start ATG but instead displays a CTG. From this one should 
assume that hUBP41 is only a fragment of the longer hUSP2 transcript variant 2. On the other hand, 
the cDNA of mouse USP2 transcript variant 1 – which is almost identical to human UBP41 -  has been 
identified in several independent EST sequencing programs, even though according to analysis of the 
mouse genome also the mUBP41 coding sequence is not expected to possess a start ATG but also the 
CTG codon. Therefore, it remains elusive whether or not UBP41 exists as a USP2 isoform on its own. 
 
4.1.6  Characterization of the rabbit anti-hUSP2 polyclonal antibody 
 
To characterize the endogenous hUSP2 expression and as a means to investigate the existence of 
USP2 isoforms on the protein level, an anti-hUBP41 polyclonal antibody was raised in rabbit and the 
obtained serum was affinity purified (see paragraph 3.1.4). The purified antibodies recognized the 
immunopeptide GST-IP-B that was used for immunization and overexpressed hUBP41 was 
recognized as well (Fig. 3.1.16). However, the antibody is also expected to be immunogenic against 
hUSP2 transcript variants 1 and -2 because the immunopeptide taken for immunization corresponds to 
Fig. 4.1.8 
Genomic organization of the USP2 locus on chromosome 11q23.3. This sequence analysis is
based on the second release of the finished human reference genome from Oct 7, 2003. The
human USP2 variant 1 (here designated hUSP2-L) consists of 12 exons distributed over a total
length of 16646 bp. Exon 1a  (773 bp) is unique to hUSP2-L whereas exons 2 to 12 (as well as the
corresponding intron sequences) are identical to the human USP2 variant 2 (here designated
hUSP2-S). The coding sequence of hUSP2-S starts with the unique exon 1b which is located in a
region between exon 1a and exon 2. Therefore, hUSP2-L and hUSP2-S are very likely to be splice
isoforms. The difference in two amino acid positions as shown in Fig. 4.1.6 are presumably due to
single nucleotide polymorphisms. The hUBP41 sequence is identical to that of USP2-S but the
first exon of hUBP41 possesses only the last 15 bp of exon 1b. At the putative start position of
hUBP41, the genomic sequence does not contain a start ATG but instead displays a CTG codon,
thus the start adenosine is missing.This strongly suggests that the formerly published sequence of
human hUBP41 (Genbank gi: 4759291) is only a fragment of the USP2 transcript variant 2 with
the first 43 N-terminal amino acids missing. However, it cannot be excluded that CTG serves as
an alternative start codon. 
hUSP2-L
hUSP2-S
hUBP41
Exon 1a 2 3 4 5 6 7 8 9 10 11 12
Exon 1b
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amino acids 119-150 of hUBP41 which are identical to both hUSP2 variants. Therefore the anti-
hUBP41 polyclonal antibody is actually an anti-hUSP2 polyclonal antibody.  
When these antibodies were used for detection of endogenous hUSP2, a pattern of five bands was 
detected (Fig. 3.1.17). Three bands corresponded to proteins larger than hUBP41, two smaller bands 
also appeared. Most likely would be that the band somewhat below the 47 kDa marker band would be 
USP2 variant 2 (which has a predicted molecular mass of 45 kDa) and the band higher than the 47 
kDa band possibly USP2 variant 1 (predicted molecular mass 68 kDa). Unfortunately, no band was 
detected that was of the size expected for hUBP41, indicating that no hUSP2 variant of this kind is 
expressed at a high enough level in the cell lines tested.  
 
4.1.7  Remaining questions and perspectives for future research 
 
With respect to the previous two paragraphs (4.1.5 and 4.1.6), it remains to be elucidated what is the 
identity of the proteins that are recognized by the polyclonal anti-hUSP2 antibody (Fig. 3.1.17). It 
should be assumed that the two hUSP2 transcript variants 1 and –2 are among the proteins detected. It 
also is an open question whether hUBP41 is expressed in endogenous form or if it is merely a 
fragment of hUSP2 transcript variant 2. It remains to be tested whether overexpression of the hUSP2 
transcript variant 2  also triggers apoptosis in human cell lines as efficiently as does hUBP41 
overexpression.  
In case that hUBP41 or its hUSP2 variants were detectable by the polyclonal antibody on the protein 
level, it might be rewarding to optimize RNAi conditions (as described in paragraph 3.1.4) to 
successfully downregulate the endogenous UBP41 / USP2 proteins. Then the sensitivity to apoptosis-
inducing reagents could be compared between wildtype cells and cells with downregulated hUBP41 / 
hUSP2. If hUBP41 or its related hUSP2 variants play a role in determining the cellular balance 
between pro- and antiapoptotic factors, thereby influencing the sensitivity of tumor cells to apoptosis 
(as hypothesized in Fig. 4.1.3), then one might expect that cells with downregulated UBP41 / USP2 
are possibly less sensitive to cell death induction. 
Also depending on the successful detection and identification of the hUSP proteins by the anti-hUSP2 
antibody, it could be investigated on the protein level whether USP2 levels are decreased in tumors of 
the kidney compared to normal kidney tissue as was observed on the mRNA level using the 
Tumor/Normal Profiling Array (Figs. 3.1.20 and 3.1.21). If the data from this Tumor/Normal Profiling 
Array can be varified, UBP41 itself or its USP2 variants might be candidate tumor suppressors which, 
when downregulated, allow neoplastic cells to be less sensitive to apoptosis. This hypothesis is 
certainly highly speculative but it should be noted that the deubiquitinating enzyme CYLD has been 
presented as an example for a USP whose downregulation results in increased resistance of cells to 
apoptosis and which has been identified as a tumor-suppressor that is frequently inactivated in tumor 
disease (see paragraph 4.1.1). In addition it shall be mentioned, that the hUSP2 gene is localized to the 
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chromosomal region 11q23.3 which has been reported to be lost in various cases of cancer and for 
which the existence of tumor-suppressors has been predicted [O’Sullivan, 2001; Monni, 1999, Herbst, 
1999]. 
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4.2  Cathepsins and their possible involvement in 
proapoptotic signalling 
 
Caspases are thought to build the central proteolytic network involved in the execution of apoptotic 
signalling pathways induced by virtually all kinds of death stimuli [Earnshaw, 1999; Nagata, 1999; 
Robertson, 2000]. In recent years it has been recognized that besides caspases also other proteases 
such as cathepsins, calpains, and the proteasome may play a role as cofactors in mediating several cell 
death pathways, e.g. Cath-B in TNF-α-induced apoptosis [Leist, 2001a; Leist, 2001b]. Cath-B has 
been reported to be released from the lysosomes to the cytosol in response to TNF-α [Foghsgaard, 
2001; Guicciardi, 2000] and to contribute to apoptotic downstream events such as cytochrome c 
release and the activation of executioner caspases [Guicciardi, 2000; Stoka, 2001]. Those observations 
suggest a possible role for cathepsins as positive effectors of cell death pathways (see paragraph 1.3), 
and the fact that tumors frequently contain high levels of cysteine proteases led to the hypothesis that 
Cath-B-like proteases may prove useful in selectively targeting tumor cells for apoptosis induction 
(Fig. 4.2.1).  
 
Normal cell
cathepsin 
level
Cancer cell
cathepsin 
level
Apoptosis-inducing stimulus
(TNF-a, Fas, Interferon-gamma, Etoposide, H2O2 ...)
Moderate Level of Apoptosis Enhanced Apoptosis
Fig. 4.2.1 
Hypothesis: do elevated cathepsin expression levels sensitize cancer cells to apoptosis
induction? Whereas elevated cathepsin expression is frequently observed in tumors and is
commonly regarded as a tumor marker correlated with poor prognosis, cathepsins on the other
hand have recently been proposed to be involved in proapoptotic signalling (see also Fig. 1.12). If
this were true, cells with elevated cathepsin expression levels would be expected to be more
sensitive to certain death-inducing stimuli. It therefore has been hypothesized that this property
might be exploited to selectively target tumor cells with high cathepsin expression levels for
enhanced cell death induction in response to cytotoxic agents [Foghsgaard, 2001]. 
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4.2.1  Inhibition of cathepsin-B and -L appears to influence TNF-α- 
mediated apoptosis 
 
The central objective of this study was to test the hypothesis, whether increased expression levels of 
Cath-L or Cath-B would enhance the sensitivity of HeLa cells to TNF-mediated apoptosis. The results 
obtained do not support this hypothesis, although at the same time inhibitor studies provided evidence 
for an influence of cathepsins in the TNF signalling pathway: apoptotic DNA fragmentation induced 
by cotreatment of HeLa cells with TNF-α and CHX could be significantly suppressed by various 
cathepsin inhibitors in a dose dependent manner (Figs. 3.2.3 A,B). This effect could be confirmed in 
PC3 cells (Fig. 3.2.4) and is also in line with observations in other cell systems shown in previous 
reports [Foghsgaard, 2001; Guicciardi, 2000]. Interestingly, apoptosis induced by irradiating the cells 
with UV light could not be diminished in presence of E64d (Fig. 3.2.3 C). Thus, in HeLa cells, 
cathepsins appear to contribute to the extrinsic receptor-mediated TNF cell death pathway, but not to 
the intrinsic apoptosis signalling pathways induced by UV.  
 
 
4.2.2  Commonly used cathepsin inhibitors lack specificity 
 
The inhibitor CA074Me is usually regarded to be highly selective for Cath-B, and therefore the results 
shown in Fig. 3.2.3 and Fig. 3.2.4 would suggest that Cath-B is a non-caspase cysteine protease 
contributing to TNF-mediated apoptosis in the HeLa cell system. In the attempt to verify the specific 
inhibitory activity of CA074Me, it turned out that CA074Me not only completely blocked hCath-B 
enzymatic activity but also hCath-L activity to almost the same extent (Fig. 3.2.5). This observation 
was confirmed by a recent publication, also demonstrating that CA074Me is not a selective inhibitor 
of Cath-B [Montaser, 2002]. Therefore, it cannot be ruled out that, besides Cath-B, CA074Me also 
inhibits other cysteine proteases such as Cath-L and by this exerts its inhibitory effect. The possibility 
that E64d might even be able to unspecifically inhibit caspases was excluded by the observation that 
E64d is not able to significantly inhibit caspase activity in a cell-free system (data not shown). From 
the inhibitor studies (see paragraph 3.2.3) it therefore can be concluded, that Cath-B itself or Cath-B-
like proteases, such as Cath-L, contribute to TNF-mediated DNA fragmentation. 
 
Discussion 
 113
4.2.3  No influence of elevated cathepsin expression levels on sensitivity 
of HeLa cells to TNF-mediated apoptosis  
 
There are several reports about an involvement of lysosomal cysteine proteases such as Cath-L and 
Cath-B in cancer progression and metastasis either by direct degradation of the extracellular matrix or 
by activation of other proteases such as urokinase-type plasminogen activator [Turk, 2000]. In many 
cases, strongly increased expression levels of Cath-L and Cath-B were detected in tumor cells and 
tumor tissues when compared to normal counterparts, and frequently the increase in cathepsin 
expression and activity correlated with malignant progression and metastasis. Consequently, 
cathepsins are regarded to be tumor markers with increased expression levels correlating with poor 
prognosis [Chauhan, 1991; Duffy, 1996; Kirschke, 1997; Lah, 1998; Sivaparvathi, 1996a; 
Sivaparvathi, 1996b; Sivaparvathi, 1996c; Sloane, 1990; Yan, 1998]. The tumor-promoting effect of 
cathepsins is obviously in contrast with the observation that cathepsins such as Cath-B can mediate 
proapoptotic signals triggered by TNF-α [Foghsgaard, 2001; Guicciardi, 2001; Mathiasen, 2001], but 
also bile-salts [Roberts, 1999], sphingosine [Kagedal, 2001b], B cell antigen receptor [Katz, 2001], 
and L-2,5-dihydrophenylalanine [Kiso, 2001]. But exactly this contrast might prove useful in 
developing a cancer therapy selectively targeting tumor cells for cell death with high level expression 
of cathepsins [Foghsgaard, 2001]. Even though this hypothesis appears attractive, up to now, no 
studies have been presented investigating a possible correlation between elevated cellular cathepsin 
levels and sensitivity to apoptotic stimuli such as TNF-α. 
Since the inhibitor studies presented in this study indicate a contribution of Cath-B-like cysteine 
proteases in TNF-α/CHX-induced apoptosis in HeLa cells (Fig. 3.2.3 and Fig. 3.2.4), it was further 
investigated whether sensitivity of HeLa cells to the TNF-α/CHX signal is enhanced by increased 
hCath-L or hCath-B levels. High level overexpression of hCath-L or hCath-B by itself did not result in 
apoptosis induction in HeLa cells (Fig. 3.2.2) whereas overexpression of hCath-D resulted in moderate 
but significant apoptosis as could be expected from a previous report [Deiss, 1996]. It also was not 
possible to detect a significant increase in sensitivity to TNF-α/CHX-induced apoptosis in HeLa cells 
transiently transfected with hCath-L or hCath-B (Fig. 3.2.6 A). In those transient transfection 
experiments transfection efficiencies between 40% and 60% were usually obtained as judged be GFP 
cotransfection, and overall cathepsin activities were increased by at least 6- to 10-fold for hCath-L and 
10- to 20-fold in case of hCath-B what presumably is comparable to what is frequently detected in 
tumor tissues [Chauhan, 1991; Lah, 1998; Yan, 1998]. Under those experimental conditions it should 
be possible to detect any significant increase in sensitivity that might have been correlated with 
cathepsin overexpression. Additionally, HeLa cell pools were generated that stably overexpress hCath-
L or hCath-B, respectively. In this case it was assumed that the majority of stable transfected cells 
overexpress the corresponding cathepsin, although at at a lower level than in transient expression
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experiments. Also those stable transfected pool clones did not show any increased sensitivity to the 
TNF-α death signal (Fig. 3.2.6 B).  
 
Additionally, the rat hepatoma cell line McA RH 7777 was used for another transient expression 
experiment, which also did not indicate any change in sensitivity to TNF-α/CHX upon cathepsin 
overexpression (Fig. 3.2.6 C). This additional cell line was chosen because hepatocyte apoptosis has 
been discussed in particular to be influenced by Cath-B proapoptotic activity [Guicciardi, 2000; 
Guicciardi, 2001; Roberts, 1999]. 
 
 
4.2.4  Inhibition but not overexpression of cathepsins influences TNF-
mediated apoptosis – possible explanations   
 
As shown in Fig. 3.2.7, lysosomal integrity is apparently disturbed when HeLa cells are treated with 
TNF-α/CHX as indicated by the partial redistribution of Cath-L from a lysosomal spot-like pattern to 
a more diffuse staining. Thus, increased expression levels of cathepsins are expected to result in 
correspondingly higher amounts of cathepsin activity in the cytoplasm in response to TNF-α/CHX. 
How then can be explained that TNF-α/CHX-induced apoptosis is inhibited in presence of the 
cathepsin inhibitors E64d and CA074Me (Fig. 3.2.3 and Fig. 3.2.4) but that cathepsin overexpression 
does not enhance TNF/CHX-induced cell death (Fig.3.2.6)?  
Possibly, endogenous basal levels of lysosomal Cath-L or Cath-B activity are sufficient to provide the 
lysosomal stimulus contributing to the proapoptotic signalling cascade for cell death execution. In this 
case, other factors than Cath-L or Cath-B levels would be rate limiting in the execution process of 
apoptosis, and an increase in Cath-L or Cath-B levels would not further accelerate or enhance the 
signal coming from the TNF receptor. It also cannot be excluded that other cathepsin-like proteases 
than Cath-L or Cath-B are mainly responsible for the contribution to TNF-α apoptotic pathways, since 
the inhibitors E64d and apparently also CA074Me are not specific inhibitors of distinct cathepsins 
(Fig.2 and [Montaser, 2002]). 
Both explanations would be in line with the observation, that overexpression of hCath-L or hCath-B 
not even shows any death-enhancing effect on NDI-HCl-induced cell death (Fig. 3.2.8), even though 
in this case it can be assumed that upon treatment with NDI-HCl the overexpressed cathepsins are 
almost completely released from the lysosomal compartments to the cytosol (Fig. 3.2.7). It should be 
pointed out, that NDI-HCl-induced death behaves different than TNF-α/CHX-mediated death because 
NDI-HCl results in cell death that cannot be suppressed by E64d at all, and zVAD-fmk can only 
partially block this cell death (Fig. 3.2.8), presumably due to the extreme extent of lysosomal rupture
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caused by this lysosomotropic detergent (Fig. 3.2.7) leading to both, a caspase-dependent apoptotic 
mode and caspase-independent mode of cell death.  
 
 
4.2.5  Conclusions and perspectives for future research 
 
In conclusion, there is evidence that Cath-B-like cysteine proteases contribute to certain aspects of 
apoptotic signalling pathways. Whereas the possibility appears attractive to exploit the proapoptotic 
features of cathepsins in specifically targeting tumor cells with elevated cathepsin expression levels 
for cell death induction, overexpression experiments presented in this study do not support such an 
hypothesis. Since this is the first report directly investigating a possible correlation between cathepsin 
expression levels and sensitivity to an apoptotic stimulus, further studies are certainly necessary to 
confirm and extend the here presented data for other cell systems and additional death stimuli besides 
TNF-α. Moreover, downregulation of cathepsin expression levels via the RNAi methodology (instead 
of using cathepsin inhibitors with limited specificity) should prove extremely useful in further 
determining the possible role of cathepsins in the mediation of cell death signals such as those 
triggered at the TNF receptor complex. 
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Abbreviations 
 
AICD   Activation-induced cell death 
AIDS   Acquired immunodeficiency syndrome 
AIF   Apoptosis-inducing factor 
AMC   Aminomethylcoumarine 
ANT-1   Adenine nucleotide translocator 1 
Apaf-1   Apoptotic protease activating factor 1 
APC   Anaphase-promoting complex 
ARF   Alternative reading frame within the Ink4a/ARF gene locus 
ATP   adenosine triphosphate  
 
Bad   Bcl-2 agonist of cell death 
Bak   Bcl-2 agonist/killer 
Bax   Bcl-2 associated X-factor 
Bcl-2   B cell lymphoma gene 2 
Bcl-XL   Bcl-2 related gene x, large splice isoform 
BH domain  Bcl-2 homology domain 
Bid   BH3-interacting DD agonist 
Bim   Bcl-2 interacting mediator of cell death 
Bmf   Bcl-2-modifying factor 
BIR   Baculovirus inhibitor repeat 
BLAST  Basic local alignment search tool 
 
CA074Me  Inhibitor of cathepsin-B-like cysteine proteases 
CAD   Caspase-activated DNase 
CARD   Caspase recruitment domain 
Caspase  Cysteine-dependent aspartate-specific protease 
Cath-B   cathepsin B 
Cath-D   cathepsin D 
Cath-L   cathepsin L 
cDNA   complementary DNA 
CDK   Cyclin-dependent kinase 
C. elegans  Caenorhabditis elegans – a nematode worm 
ced-3   Caenorhabditis elegans death gene 3 – homologue of mammalian caspase-1 
ced-4   Caenorhabditis elegans death gene 4 – homologue of mammalian Apaf-1 
ced-9   Caenorhabditis elegans death gene 9 – homologue of mammalian Bcl-2 
c-FLIP   cellular FLICE inhibitory protein 
CHX   Cycloheximide 
CIDE-A  Cell death-inducing DFF45-like effector A 
 
DAPI   Diamidino-2-phenylindole 
DR5   Death receptor 5 
 
∆Ψ   inner mitochondrial transmembrane potential 
dATP   deoxyadenosine triphosphate 
DD   Death domain 
DED   Death effector domain 
DISC   Death-inducing signalling complex 
DNA   Deoxyribonucleic acid 
DUB   Deubiquitinating enzyme 
 
E1   ubiquitin-activating enzyme 
E2   ubiquitin-conjugating enzyme 
Abbreviations 
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E3   ubiquitin ligase 
E4   accessory factor for multiubiquitylation 
E64d   broad range cathepsin inhibitor 
E6-AP   E6-associated protein 
EGFP   Enhanced green fluorescent protein 
Egl-1   Egg-laying defective gene 1 in C. elegans 
endoG   Endonuclease G 
EPO   Erythropoietin 
ER   Endoplasmic Reticulum 
EYFP   Enhanced yellow fluorescent protein 
 
faf   Fat facets gene in Drosophila 
FACS   Fluorescence aided cell sorting, flow cytometric analysis 
Fam   Fat facets in mouse 
FLICE   former name for caspase-8 
 
GSH   Glutathione 
GST   Glutathione S-transferase 
 
HA   Haemagglutinin-derived peptide tag sequence (YPYDVPDYA) 
HAUSP  Herpes virus associated USP 
hCath-B  human cathepsin B 
hCath-D  human cathepsin D 
hCath-L  human cathepsin L 
HECT   Homologous to E6-AP carboxyl terminus, ubiquitin ligase motif 
HIF-α   Heat shock inducible factor α 
HIV   Human Immunodeficiency Virus 
 
IAP   Inhibitor of apoptosis protein 
ICAD   Inhibitor of CAD 
ICE   Interleukin-1β-converting enzyme 
IκB   Inhibitor of NF-κB 
IL-3   Interleukin-3 
 
lqf   Liquid facets gene in Drosophila 
 
Mdm2   Murine double minute 2 gene 
MG132   Cbz-leu-leu-leucinal, aldehyde inhibitor of the proteasome 
 
NADH   Nicotinamide adenine dinucleoti de, reduced form 
NADPH  Nicotinamide adenine dinucleotide phosphate, reduced form 
NCBI   National Center for Biotechnology Information 
NDI-HCl 
NF-κB   Nuclear factor κB 
 
PAGE   Polyacrylamide gel electrophoresis 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PI   Propidium iodide 
PI FACS  Flow cytometric analysis using PI for determining DNA content 
PKB   Protein kinase B 
pro-IL-1β  pro-Interleukin-1β 
pro-IL-18  pro-Interleukin-18  
PT   Permeability transition 
PTP   Permeability transition pore 
 
Rb   Retinoblastoma protein 
Abbreviations 
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RING domain  Really interesting new gene domain with ubiquitin ligase activity  
RNAi   RNA interference 
ROS   Reactive oxygen species 
RT PCR  Reverse transcription PCR 
 
SAIP   Small apoptosis-inducing protein 
SCF   Skp1/Cullin/F-Box complex 
siRNA   small inhibitory RNA 
Smac   Second mitochondrial activator of apoptosis 
Spike   Small protein with inherent killing effect 
SUMO   Small ubiquitin-like modifier 
 
tBid   truncated Bid 
TBS   Tris buffered saline 
TNF   sometimes used as a short form of TNF-α 
TNF-α   Tumor necrosis factor α 
TNFR   Tumor necrosis factor receptor 
TRADD  Tumor necrosis factor receptor associated death domain protein 
TRAF2   TNF receptor associated factor 2 
TRAIL   Tumor necrosis factor related apoptosis-inducing ligand 
 
Ub   Ubiquitin 
UBP   Ubiquitin-processing protease 
UCH   Ubiquitin carboxy terminal hydrolase 
USP   Ubiquitin-specific protease 
UV   Ultraviolet 
 
VDAC   Voltage-dependent anion channel 
VEGF   Vascular endothelial growth factor 
VHL   Von Hippel-Lindau, a tumor syndrome 
 
WT   wild type 
 
XIAP   X-chromosome linked IAP 
 
zDEVD-AMC  Benzoxy-Asp-Glu-Val-Asp-aminomethylcoumarine 
zFR-AMC  Benzoxy-Phe-Arg-aminomethylcoumarine 
zVAD-fmk  Benzoxy-Val-Ala-Asp-fluoromethylketone 
 
